<SEC-DOCUMENT>0001193125-19-109100.txt : 20190417
<SEC-HEADER>0001193125-19-109100.hdr.sgml : 20190417
<ACCEPTANCE-DATETIME>20190417161557
ACCESSION NUMBER:		0001193125-19-109100
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190522
FILED AS OF DATE:		20190417
DATE AS OF CHANGE:		20190417
EFFECTIVENESS DATE:		20190417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		19753206

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d695930ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to &#167;240.14a-12</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Neurocrine
Biosciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12780 El Camino Real </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San&nbsp;Diego, CA 92130 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice of
Annual Meeting of Stockholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held on May&nbsp;22, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE STOCKHOLDERS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN
that the 2019 Annual Meeting of Stockholders of Neurocrine Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;), will be held on May&nbsp;22, 2019, at 10:30&nbsp;a.m., local time, at the Company&#146;s corporate headquarters located
at 12780 El Camino Real, San&nbsp;Diego, California 92130, for the following purposes as more fully described in the Proxy Statement accompanying this Notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The election of the two nominees for Class&nbsp;II Director named herein to the Board of Directors to serve for
a term of three years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An advisory vote on the compensation paid to the Company&#146;s named executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve an amendment to the Company&#146;s 2011 Equity Incentive Plan to increase the number of shares of
common stock reserved for issuance thereunder from 19,000,000 to 21,000,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The ratification of the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered
public accounting firm for the fiscal year ending December&nbsp;31, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the Annual Meeting of Stockholders or any
continuation, adjournment or postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on
March&nbsp;29, 2019 are entitled to receive notice of and to vote at the Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stockholders are cordially
invited to attend the Annual Meeting of Stockholders in person. Your vote is important. Whether or not you plan to attend the Annual Meeting, we hope you will vote as soon as possible. You may vote over the Internet, as well as by telephone or by
mailing a proxy or voting instruction form. Please review the instructions on each of your voting options described in these proxy materials. Stockholders attending the Annual Meeting may vote in person even if they have returned a proxy. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By&nbsp;Order&nbsp;of&nbsp;the&nbsp;Board&nbsp;of&nbsp;Directors,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g695930g59p42.jpg" ALT="LOGO">
</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Darin Lippoldt</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief&nbsp;Legal&nbsp;Officer&nbsp;and&nbsp;Corporate&nbsp;Secretary</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San&nbsp;Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;17, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Meeting to be Held on May&nbsp;22, 2019 at 10:30 a.m. Local Time at </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12780 El Camino Real, San Diego, California 92130. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The proxy statement and annual report to stockholders are available at </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>www.proxyvote.com</U>. Please have the control number on your proxy card available. </B></P></div>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12780 El Camino Real </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San&nbsp;Diego, California 92130 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proxy is solicited on behalf of Neurocrine Biosciences, Inc., a Delaware corporation (the &#147;Company&#148; or &#147;Neurocrine&#148;),
for use at its 2019 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held on May&nbsp;22, 2019 beginning at 10:30&nbsp;a.m., local time, or at any continuations, postponements or adjournments thereof for the purposes set forth
in this proxy statement and the accompanying Notice of Annual Meeting of Stockholders. The Annual Meeting will be held at the Company&#146;s corporate headquarters, located at 12780 El Camino Real, San&nbsp;Diego, California 92130. The
Company&#146;s phone number is <FONT STYLE="white-space:nowrap">(858)&nbsp;617-7600.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THE ANNUAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Why did I receive these proxy materials? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has sent you these proxy materials because the Board of Directors of the Company is soliciting your proxy to vote at the Annual
Meeting, including at any adjournments or postponements of the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote
your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions on the enclosed proxy card to submit your proxy over the telephone or Internet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to mail these proxy materials on or about April&nbsp;22, 2019 to all shareholders of record entitled to vote at the Annual Meeting.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is the purpose of the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, stockholders will act upon the matters outlined in these proxy materials, including the election of the two nominees for
Class&nbsp;II Director named herein, an advisory vote on the compensation paid to the Company&#146;s named executive officers, approval of an amendment increasing the number of shares of common stock reserved for issuance under the Company&#146;s
2011 Equity Incentive Plan from 19,000,000 to 21,000,000, and ratification of the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019. In
addition, following the Annual Meeting, management will report on the performance of the Company and respond to questions from stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who
can attend the Annual Meeting? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stockholders of record at the close of business on March&nbsp;29, 2019 (the &#147;Record
Date&#148;), or their duly appointed proxies, may attend the Annual Meeting. If you attend, please note that you may be asked to present valid picture identification, such as a driver&#146;s license or passport. Cameras, recording devices and other
electronic devices will not be permitted at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please also note that if you hold your&nbsp;shares in &#147;street
name&#148; (that is, through a broker or other nominee), you will need to bring a copy of a brokerage statement reflecting your stock ownership as of the record date and check in at the registration desk at the Annual Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who is entitled to vote at the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of record at the close of business on the Record Date are entitled to receive notice of and to participate in the Annual Meeting.
At the close of business on the Record Date, 91,284,279 shares of the Company&#146;s common stock, $0.001&nbsp;par value per&nbsp;share, were issued and outstanding. If you were a stockholder of record on that date, you will be entitled to vote all
of the&nbsp;shares that you held on that date at the Annual Meeting, or any continuations, postponements or adjournments of the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding&nbsp;share of the Company&#146;s common stock will be entitled to one vote on each proposal considered at the Annual Meeting.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What constitutes a quorum? What are broker <FONT STYLE="white-space:nowrap">non-votes?</FONT> What are advisory votes? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence at the Annual Meeting, in person or by proxy, of the holders of a majority of the aggregate voting power of the common stock
outstanding on the Record Date will constitute a quorum, permitting the Company to conduct its business at the Annual Meeting. As of the Record Date, 91,284,279 shares of common stock, representing the same number of votes, were outstanding. Thus,
the presence of the holders of common stock representing at least 45,642,140 shares will be required to establish a quorum. The presence of a quorum will be determined by the Inspector of Elections (the &#147;Inspector&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proxies received but marked as abstentions, as well as &#147;broker <FONT STYLE="white-space:nowrap">non-votes,&#148;</FONT> will be included
in the calculation of the number of&nbsp;shares considered to be present at the Annual Meeting. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when a holder of&nbsp;shares in &#147;street name&#148; does not give instructions to the
broker or nominee holding the&nbsp;shares as to how to vote on <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Under the rules and interpretations of the New York Stock Exchange (the &#147;NYSE&#148;), <FONT
STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters are matters that may substantively affect the rights or privileges of stockholders, such as mergers, stockholder proposals and elections of directors, even if not contested. In
addition, as required by Section&nbsp;957 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, advisory votes on executive compensation are <FONT STYLE="white-space:nowrap">non-routine</FONT> matters for which brokers do not
have discretionary authority to vote&nbsp;shares held by account holders. Only ratification of our independent registered public accounting firm under Proposal Four is considered a routine matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote on Proposal Two is advisory. The approval or the disapproval of Proposal Two will not be binding on the Company or the Board of
Directors and will not create or imply any change to the fiduciary duties of the Board of Directors. However, the Company and the Board of Directors will consider the results of the advisory vote on Proposal Two in making future decisions about
compensation of the Company&#146;s named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How do I vote my shares in person at the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may vote your shares held in your name as the stockholder of record in person at the Annual Meeting. You may vote your shares held
beneficially in street name in person at the Annual Meeting only if you obtain a legal proxy from the broker, bank, trustee, or nominee that holds your shares giving you the right to vote the shares. Even if you plan to attend the Annual Meeting, we
recommend that you also submit your proxy or voting instructions as described below so that your vote will be counted if you later decide not to attend the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How can I vote my shares without attending the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct how your shares are voted without
attending the Annual Meeting. If you are a stockholder of record, you may vote by proxy. You can vote by proxy over the Internet, by mail or by telephone pursuant to instructions provided on the enclosed proxy card. If you hold shares beneficially
in street name, you may also vote by proxy over the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Internet or you can also vote by telephone or mail by following the voting instruction form provided to you by your broker, bank, trustee, or nominee. The deadline for voting by telephone or
electronically is 11:59&nbsp;p.m., Eastern Time, on May&nbsp;21, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who will bear the cost of soliciting votes for the Annual Meeting?
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent such costs are incurred, the cost of solicitation of proxies will be borne by the Company. The Company will
reimburse expenses incurred by brokerage firms and other persons representing beneficial owners of&nbsp;shares in forwarding solicitation material to beneficial owners. To assist in soliciting proxies (votes), the Company may retain a professional
proxy solicitation firm, at an approximate cost of $10,000. Proxies also may be solicited by certain of the Company&#146;s directors, officers and regular employees, without additional compensation, personally, by telephone or by other appropriate
means. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Can I change my vote after I return my proxy? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yes. Even after you have submitted your proxy, you may change your vote at any time before the proxy is exercised by filing with the Corporate
Secretary of the Company either a notice of revocation or a duly executed proxy bearing a later date. Your proxy will also be revoked if you attend the Annual Meeting and vote in person. Attendance at the Annual Meeting will not by itself revoke a
previously granted proxy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What does it mean if I receive more than one set of proxy materials? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you receive more than one set of proxy materials, your common stock is registered in more than one name or are registered in different
accounts. Please complete a proxy for each separate set of proxy materials that you receive to ensure that all of your&nbsp;shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What
are the Board of Directors&#146; recommendations? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless you give other instructions on your proxy, the persons named as proxy
holders on the proxy will vote in accordance with the recommendations of the Board of Directors. The Board of Directors&#146; recommendation is set forth together with the description of each item in this proxy statement. In summary, the Board of
Directors recommends a vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>for</I> election of the two nominees for Class&nbsp;II Director named herein (see Proposal&nbsp;One);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>for</I> an advisory vote on the compensation paid to the Company&#146;s named executive officers (see Proposal
Two); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>for</I> approval of the amendment to the Company&#146;s 2011 Equity Incentive Plan to increase the number of
shares of common stock reserved for issuance thereunder from 19,000,000 to 21,000,000 (see Proposal Three); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>for</I> ratification of the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent
registered public accounting firm for the fiscal year ending December&nbsp;31, 2019 (see Proposal&nbsp;Four). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With
respect to any other matter that properly comes before the meeting, the proxy holders will vote as recommended by the Board of Directors or, if no recommendation is given, in their own discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What vote is required to approve each item? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Election of Directors.</B> The affirmative vote of a plurality of the votes cast at the Annual Meeting is required for the election of
directors. A properly executed proxy marked &#147;WITHHOLD AUTHORITY&#148; with respect to the election of one or more directors will not be voted with respect to the director or directors indicated, although it will be counted for purposes of
determining whether there is a quorum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Other Items.</B> For each other item, the affirmative vote of the holders of a majority
of the&nbsp;shares represented in person or by proxy and entitled to vote on the item will be required for approval. A properly executed proxy marked &#147;ABSTAIN&#148; with respect to any such matter will not be voted, although it will be counted
for purposes of determining the number of&nbsp;shares represented in person or by proxy at the Annual Meeting. Accordingly, an abstention will have the effect of a negative vote for each item. If you hold your&nbsp;shares in &#147;street name&#148;
through a broker or other nominee, your broker or nominee will not be permitted to exercise voting discretion with respect to each of the matters to be acted upon, other than Proposal Four. Thus, if you do not give your broker or nominee specific
instructions, your&nbsp;shares will not be voted on and will not be counted for any other matter to be acted upon, other than Proposal Four. Shares represented by such &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> will,
however, be counted in determining whether there is a quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who counts the votes? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes cast by proxy or in person at the Annual Meeting will be tabulated by the Inspector. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How can I find out the results of the voting at the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form
<FONT STYLE="white-space:nowrap">8-K</FONT> within four business days after the meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within four business days after the final results are
known to us, file an amended Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What proxy materials are available on
the internet? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy statement and annual report to stockholders are available at www.proxyvote.com. Please have the control
number on your proxy card available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OWNERSHIP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who are the principal stockholders, and how much stock does management own? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of the Company&#146;s common stock as of March&nbsp;15, 2019 by (i)&nbsp;each of the
executive officers named in the table under the heading &#147;Summary Compensation Table,&#148; (ii)&nbsp;each current director, (iii)&nbsp;all current directors and executive officers as a group and (iv)&nbsp;all persons known to the Company to be
the beneficial owners of more than 5% of the Company&#146;s common stock. The table is based upon information supplied by our executive officers, directors and principal stockholders and a review of Schedules&nbsp;13D and 13G, if any, filed with the
SEC. A total of 91,266,478 shares of the Company&#146;s common stock were issued and outstanding as of March&nbsp;15, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common&nbsp;Stock<BR>Owned&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Acquirable<BR>Within<BR>60&nbsp;Days&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number<BR>of&nbsp;Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,097,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,097,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">245 Summer Street, Boston, MA 02210</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Group plc (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,120,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,120,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">201 Bishopsgate EC2M 3AE, United Kingdom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,079,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,079,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Vanguard Blvd., Malvern, PA&nbsp;19355</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc. (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,978,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,978,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street, New York, NY
10055</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Advisors LLC (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,608,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 Astor Place, 10th Floor, New York, NY 10003</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">951,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. Lyons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr., M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin,&nbsp;M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (15&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,734,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,913,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of the Company&#146;s
common stock as of March&nbsp;15, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of each beneficial owner named is c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San
Diego, CA 92130, unless otherwise indicated. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares of common stock owned, excluding shares of common stock subject to stock options that are
listed under the heading &#147;Number of Shares of Common Stock Acquirable Within 60 Days,&#148; by the named parties as of March&nbsp;15, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares of common stock subject to stock options currently exercisable or exercisable within 60 days of
March&nbsp;15, 2019, regardless of exercise price, are deemed to be outstanding for computing the percentage ownership of the person holding such options and the percentage ownership of any group of which the holder is a member, but are not deemed
outstanding for computing the percentage of any other person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or
investment power with respect to securities. Except as indicated by footnote, and subject to community property laws where applicable, the Company believes that the persons named in the table have sole voting and investment power with respect to all
shares of common stock shown as beneficially owned by them. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Amendment No.&nbsp;9 to Schedule 13G filed by FMR LLC (&#147;FMR&#148;) on February&nbsp;13, 2019,
reporting ownership as of December&nbsp;31, 2018. According to such filing, FMR beneficially owns 13,097,329 shares of common stock and has sole voting power as to 1,805,400 shares of common stock. Various persons have the right to receive or the
power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock held by FMR. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Amendment No.&nbsp;1 to Schedule 13G filed by Janus Henderson Group plc (&#147;Janus&#148;) on
February&nbsp;8, 2019, reporting ownership as of December&nbsp;31, 2018. According to such filing, Janus beneficially owns 9,120,212 shares of common stock and sole voting power as to 0 shares of common stock. These securities are owned by various
institutional investors for which Janus has a controlling ownership interest. As a result of its role as an investment adviser or <FONT STYLE="white-space:nowrap">sub-adviser</FONT> to such institutional investors, for the purposes of the reporting
requirements of the Exchange Act, Janus is deemed to be a beneficial owner of such securities; however, Janus expressly disclaims that it is, in fact, the beneficial owner of such securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Amendment No.&nbsp;3 to Schedule 13G filed by The Vanguard Group, Inc. (&#147;Vanguard Group&#148;) on
February&nbsp;11, 2019, reporting ownership as of December&nbsp;31, 2018. According to such filing, Vanguard Group beneficially owns 8,079,818 shares of common stock and sole voting power as to 49,601 shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Amendment No.&nbsp;6 to Schedule 13G filed by BlackRock, Inc. (&#147;BlackRock&#148;) on
February&nbsp;11, 2019, reporting ownership as of December&nbsp;31, 2018. According to such filing, BlackRock beneficially owns 4,978,917 shares of common stock and sole voting power as to 4,617,444 shares of common stock. Various persons have the
right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of shares of the common stock held by BlackRock. No one person&#146;s interest in the common stock held by BlackRock is more than five percent of
the Company&#146;s total outstanding common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on Amendment No.&nbsp;2 to Schedule 13G filed by Perceptive Advisors LLC (&#147;Perceptive&#148;) on
February&nbsp;14, 2019, reporting ownership as of December&nbsp;31, 2018. According to such filing, Perceptive beneficially owns 4,608,554 shares of common stock and sole voting power as to 0 shares of common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s officers and directors, and persons who beneficially own 10% or greater of a
registered class of the Company&#146;s equity securities, to file reports of ownership on Form&nbsp;3 and reports of changes in ownership on Form&nbsp;4 or Form&nbsp;5 with the SEC. Such officers, directors and 10% or greater stockholders are also
required by SEC rules to furnish the Company with copies of all Section&nbsp;16(a) forms they file. Based solely on its review of the copies of such forms received by it, and written representations from certain reporting persons, the Company
believes that its officers, directors and 10% or greater stockholders complied with all Section&nbsp;16(a) filing requirements applicable to them during the fiscal year ended December&nbsp;31, 2017, except that: (i)&nbsp;one report covering one
transaction was inadvertently filed late by the Company on behalf of each of Mr.&nbsp;Lyons, Mr.&nbsp;Mollica, Mr.&nbsp;Morrow, Ms.&nbsp;Nevinny, Mr.&nbsp;Pops, Dr.&nbsp;Rastetter, Dr.&nbsp;Sandrock and Dr.&nbsp;Sherwin; (ii)&nbsp;one report
covering three transactions was inadvertently filed late by the Company on behalf of each of Dr.&nbsp;Gano and Dimitri Grigoriadis, Ph.D., our Chief Research Officer; (iii)&nbsp;one report covering seven transactions was inadvertently filed late by
the Company on behalf of Christopher O&#146;Brien, M.D., our former Chief Medical Officer; (iv)&nbsp;one report covering six transactions was inadvertently filed late by the Company on behalf of Malcolm Lloyd-Smith, our Chief Regulatory Officer; and
(v)&nbsp;two reports covering six transactions were inadvertently filed late by the Company on behalf of Darin Lippoldt, our Chief Legal Officer. Based solely on its review of the copies of such forms received by it, and written representations from
certain reporting persons, the Company believes that its officers, directors and 10% or greater stockholders complied with all Section&nbsp;16(a) filing requirements applicable to them during the fiscal year ended December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOARD OF DIRECTORS AND COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s bylaws, as
amended, provide that the Board of Directors is comprised of seven directors. The Company&#146;s Certificate of Incorporation provides that the Board of Directors is divided into three classes. There are currently two directors in Class&nbsp;I
(William H. Rastetter, Ph.D. and George J. Morrow), two directors in Class&nbsp;II (Richard F. Pops and Stephen A. Sherwin,&nbsp;M.D.), and three directors in Class&nbsp;III (Kevin C. Gorman,&nbsp;Ph.D., Gary A. Lyons and Alfred W. Sandrock, Jr.,
M.D., Ph.D.). With the exception of Kevin C. Gorman,&nbsp;Ph.D., who is the Chief Executive Officer of the Company, all current members of the Board of Directors meet the definition of &#147;independent director&#148; under the Nasdaq Stock Market
qualification standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors in Class&nbsp;I hold office until the 2021 Annual Meeting of Stockholders, the directors in
Class&nbsp;II hold office until the 2019 Annual Meeting of Stockholders, and the directors in Class&nbsp;III hold office until the 2020 Annual Meeting of Stockholders (or, in each case, until their earlier resignation, removal from office, or
death). After each such election, the directors in each such case will then serve in succeeding terms of three years and until a successor is duly elected and qualified. Officers of the Company serve at the discretion of the Board of Directors.
There are no family relationships among the Company&#146;s directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of office for directors Richard F.
Pops and Stephen A. Sherwin,&nbsp;M.D. will expire at the 2019 Annual Meeting of Stockholders. At the 2019 Annual Meeting of Stockholders, the stockholders will elect two Class&nbsp;II directors for a term of three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Biographies of Class&nbsp;I and Class&nbsp;III Directors not Nominated for Reelection at the 2019 Annual Meeting of Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kevin C. Gorman,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B>&nbsp;has been employed with the Company since 1993. He was appointed
President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice
President of Business Development. He currently serves as Chief Executive Officer and has served on the Board of Directors since January 2008. From 1990 until 1993, Dr.&nbsp;Gorman was a principal of Avalon Medical Partners, L.P. where he was
responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr.&nbsp;Gorman received his
Ph.D. in immunology and M.B.A. in Finance from the University of California, Los&nbsp;Angeles and did further post-doctoral training at The Rockefeller University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of<I> </I>Dr.&nbsp;Gorman<I> </I>on the Company&#146;s Board of Directors is based on the fact that as Chief Executive
Officer of the Company, Dr.&nbsp;Gorman has extensive knowledge of our product candidates, our employees and the industry in which we operate. Dr.&nbsp;Gorman has also demonstrated exceptional leadership skills, sound business judgment and a strong
commitment to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>William H. Rastetter, Ph.D.</I></B> has served on the Board of Directors since February 2010 and as
Chairman of the Board of Directors since May 2011. Currently, he serves as the Chairman of the Board of Directors for Fate Therapeutics, a publicly traded company focused on cellular therapies. Dr.&nbsp;Rastetter also serves on the Board of
Directors for each of Regulus Therapeutics, a publicly traded company focused on RNA based therapeutics, and Dar&eacute; Bioscience, Inc. (previously known as Cerulean Pharma Inc.), a publicly traded company focused on women&#146;s health care and
Grail, Inc., a private company developing deep sequencing approaches for disease diagnosis, with an initial focus on the early diagnosis of cancer. Dr.&nbsp;Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013
and was Executive Chairman of Biogen Idec, Inc. from 2003 to 2005. Earlier, he served as Chairman and Chief Executive Officer of IDEC Pharmaceuticals Corporation until its merger with Biogen in 2003; he joined IDEC Corporation as its Chief Executive
Officer at the company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
founding in 1986. From 1984 to 1986, Dr.&nbsp;Rastetter was Director of Corporate Ventures at Genentech, where from 1982 to 1984 he held scientific positions. He held a series of faculty
positions including Associate Professor at the Massachusetts Institute of Technology (&#147;MIT&#148;) from 1975 to 1982. Dr.&nbsp;Rastetter has a Bachelor of Science degree in chemistry from MIT, and received Master of Art and doctorate degrees in
chemistry from Harvard University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of Dr.&nbsp;Rastetter on the Company&#146;s Board of Directors is based on
Dr.&nbsp;Rastetter&#146;s scientific and technical expertise combined with his business experience in leading rapidly growing companies in the life science industry. The Company&#146;s continued growth is dependent on scientific and technical
advances, and the Board of Directors believes that Dr.&nbsp;Rastetter offers both strategic and technical insight into the risks and opportunities associated with our business. In addition, Dr.&nbsp;Rastetter&#146;s board and executive leadership
experience at other life science companies provides valuable strategic and governance insight to the Board of Directors as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gary A. Lyons</I></B> has served on the Board of Directors since joining Neurocrine in February 1993. Mr.&nbsp;Lyons served as the
President and Chief Executive Officer of the Company from February 1993 through January 2008. Prior to joining the Company, Mr.&nbsp;Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business
Development and Vice President of Sales. Mr.&nbsp;Lyons is currently the Chairman of the Board of Directors for each of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and
metabolic diseases, and Retrophin, an ultra-orphan disease commercial stage company. Mr.&nbsp;Lyons is a member of the Board of Directors of Vical Incorporated, a biotechnology company focused on the prevention and treatment of serious or
life-threatening diseases, and Novus Therapeutics, Inc., a biotechnology company focused on ear, nose and throat therapies. Mr.&nbsp;Lyons was previously a director of Neurogesx, Cytori Therapeutics, and Facet Biotech Corporation. Mr.&nbsp;Lyons
holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University&#146;s J.L. Kellogg Graduate School of Management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of Mr.&nbsp;Lyons on the Company&#146;s Board of Directors is based on Mr.&nbsp;Lyons&#146; extensive business
development and corporate governance experience and, as the Company&#146;s former Chief Executive Officer, his <FONT STYLE="white-space:nowrap">in-depth</FONT> understanding of the Company&#146;s product candidates, management and culture. With this
history with the Company and management, Mr.&nbsp;Lyons brings a unique perspective and point of view to the Company&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>George J. Morrow </I></B>has served on the Board of Directors since October 2015. Mr.&nbsp;Morrow served as Executive Vice President,
Global Commercial Operations at Amgen Inc., a global biotechnology company, from 2003 until his retirement in 2011. He joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing. His responsibilities included oversight of all
commercial functions for Amgen&#146;s broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr.&nbsp;Morrow held executive management and commercial
positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.).
Mr.&nbsp;Morrow currently serves on the board of directors of Vical, Inc., a biotechnology company and Align Technology, Inc., a global medical device company. He has previously served on the boards of Glaxo Wellcome, Inc., Human Genome Sciences,
Inc., Safeway, Inc., National Commerce Bank, the John Hopkins School of Public Health, and the Duke University Fuqua School of Business. Mr.&nbsp;Morrow holds a B.S. in chemistry from Southampton College, Long Island University, an M.S. in
biochemistry from Bryn Mawr College and an M.B.A. from Duke University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of Mr.&nbsp;Morrow on the Company&#146;s
Board of Directors is based on his extensive commercialization experience at Amgen, his broad executive experience at GlaxoSmithKline Inc., and his years of experience in corporate governance as a board member of several publicly traded
companies.&nbsp;Mr.&nbsp;Morrow&#146;s board, leadership experience and commercialization expertise prove valuable strategic insights to the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Alfred W. Sandrock, Jr., M.D., Ph.D.</I></B> has served on our Board of Directors
since September 2015. Dr.&nbsp;Sandrock is the Executive Vice President and Chief Medical Officer at Biogen, Inc., and has served in this role since November 2015. Since joining Biogen in 1998, Dr.&nbsp;Sandrock has held several senior executive
positions including Group Senior Vice President of Development Sciences, Senior vice President of Neurology research and Development, and Vice President of clinical Development, Neurology. Prior to joining Biogen, Dr.&nbsp;Sandrock was Assistant
Professor of Neurology at Harvard Medical School and Assistant in Neurology at Massachusetts General Hospital. Dr.&nbsp;Sandrock currently serves on the Boards of Directors of Praxis Precision Medicines, Inc. and Disarm Therapeutics Inc., and is a
member of the Partners Healthcare Innovation Advisory Board. Dr.&nbsp;Sandrock also serves as Chairman of the Board of the PhRMA Foundation. Dr.&nbsp;Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical
School and a Ph.D. in neurobiology from Harvard University. Dr.&nbsp;Sandrock completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology
(electromyography) at Massachusetts General Hospital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of Dr.&nbsp;Sandrock on the Company&#146;s Board of Directors
is based on his extensive experience and credentials in the biotechnology industry as an Executive Vice President of Biogen and his extensive experience in successfully leading development teams. In addition, Dr.&nbsp;Sandrock&#146;s medical
expertise in neurology and his scientific background provide a unique contribution to the Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Director Biographies of
Class&nbsp;II Directors Nominated for Reelection at the 2019 Annual Meeting of Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Richard F. Pops</I></B> has served
on the Board of Directors since April 1998. Mr.&nbsp;Pops is the Chairman and Chief Executive Officer of Alkermes, Inc. He joined Alkermes as Chief Executive Officer in February 1991. Under his leadership, Alkermes has grown from a privately held
research-based company with 25 employees to an international, publicly traded pharmaceutical company with more than 1,200 employees. In addition to Alkermes, he currently serves on the Board of Directors of: Acceleron Pharma, Inc., a biotechnology
company focused on musculoskeletal and metabolic therapeutics; Epizyme Corporation, a biotechnology company focused on epigenetics; the Biotechnology Industry Organization; and the Pharmaceutical Research and Manufacturers of America (PhRMA). He
holds a B.A. in economics from Stanford University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nomination of Mr.&nbsp;Pops for election to the Company&#146;s Board of Directors
is based on his leadership experience and track record for growing companies, his strength in business strategy and his financial acumen and capital markets experience. In addition, Mr.&nbsp;Pops is recognized for his service to the
biopharmaceutical industry as a member of the Boards of the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. His breadth and range of industry experience from operations and strategy is a significant
contribution to the Board of Directors. The Nominating and Governance Committee also considers whether each nominee has the time available, in light of other business and personal commitments. Among the criteria considered is whether any incumbent
director nominee demonstrates preparedness and engagement required for effective service to the Board and its Committees. In connection with the nomination of Mr.&nbsp;Pops, the Nominating and Governance Committee considered Mr.&nbsp;Pops&#146;
consistently demonstrated preparedness, attendance, engagement, and vigorous leadership of the Compensation Committee and his contributions to both the Audit Committee and the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stephen A. Sherwin, M.D.</I></B> has served on the Board of Directors since April 1999. Dr.&nbsp;Sherwin currently divides his time
between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in
Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr.&nbsp;Sherwin currently serves on the Board of Directors of Aduro Biotech, Biogen and Neon Therapetics. He is a Venture Partner with Third Rock Ventures and a member of the
Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy. Previously Dr.&nbsp;Sherwin was chairman and chief executive officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company&#146;s merger in 2009
with BioSante </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharmaceuticals (now ANI Pharmaceuticals). He was also a <FONT STYLE="white-space:nowrap">co-founder</FONT> and chairman of Abgenix, an antibody company which was acquired by Amgen in 2006, and <FONT
STYLE="white-space:nowrap">co-founder</FONT> and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr.&nbsp;Sherwin held various positions in clinical research at Genentech, most
recently that of Vice President. Prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr.&nbsp;Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its
chairman from 2009 to 2011, and was a member of the President&#146;s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development from 2011 to 2013. Dr.&nbsp;Sherwin holds a B.A. in biology summa cum laude from Yale
University and an M.D. from Harvard Medical School, is board-certified in internal medicine and medical oncology, and is a fellow of the American College of Physicians. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nomination of Dr.&nbsp;Sherwin for election to the Company&#146;s Board of Directors is based on his experience and credentials in the
biotechnology industry as the former Chief Executive Officer of Cell Genesys, Inc., the former chairman and <FONT STYLE="white-space:nowrap">co-founder</FONT> of Abgenix, Inc., the chairman and <FONT STYLE="white-space:nowrap">co-founder</FONT> of
Ceregene, Inc., and his positions at Genentech, Inc. and the National Cancer Institute. Dr.&nbsp;Sherwin is also currently Chairman Emeritus of the Biotechnology Industry Organization. In addition to his biotechnology credentials,
Dr.&nbsp;Sherwin&#146;s medical expertise in internal medicine and medical oncology provides a unique contribution to the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>We have long believed that
good corporate governance is important to ensure that Neurocrine is managed for the long-term benefit of its&nbsp;stockholders. We periodically review our corporate governance policies and practices. The Board of Directors has adopted Corporate
Governance Guidelines which describe our corporate governance practices and address corporate governance issues such as Board composition, responsibilities and director qualifications. These guidelines are available at <U>www.neurocrine.com.</U>
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is the Board&#146;s leadership structure? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is the Company&#146;s policy to separate the roles of Chief Executive Officer and Chairman of the Board. This separation recognizes the
independent roles of the Board of Directors, Chairman of the Board and Chief Executive Officer. The Board of Directors sets Company strategy and provides oversight and accountability for the Chief Executive Officer and Company management. The
Chairman of the Board presides over the Board of Directors and provides guidance to the Chief Executive Officer. The Chief Executive Officer and the balance of the Board of Directors set Company goals with the Chief Executive Officer providing
leadership and day to day oversight in furtherance of those goals. The Company believes that separation of the Board of Directors and Company leadership reinforces the independence of the Board of Directors in its oversight of the business and
affairs of the Company, and creates an environment that is more conducive to objective evaluation and oversight of management&#146;s performance, increasing management accountability and improving the ability of the Board of Directors to monitor
whether management&#146;s actions are in the best interests of the Company and its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Are the members of the Board independent?
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors annually reviews the independence of each of the directors. With the exception of Kevin C.
Gorman,&nbsp;Ph.D., who is the Chief Executive Officer of Neurocrine, all current members of the Board of Directors meet the definition of &#147;independent director&#148; under the Nasdaq Stock Market qualification standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How often did the Board meet during fiscal 2018? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors held a total of five meetings during 2018. For 2018, the Board of Directors had an Audit Committee, a Compensation
Committee, a Nominating/Corporate Governance Committee, and a Science and Medical Technology Committee. Charters for each of these committees have been established and approved by the Board of Directors and current copies of the charters for each of
the committees have been posted on the Company&#146;s website at<I></I><I>&nbsp;www.neurocrine.com.</I>&nbsp;During 2018, no director attended fewer than 75% of the aggregate of the total meetings of the Board of Directors and no director attended
fewer than 75% of the total number of meetings held by all committees of the Board of Directors on which such director served. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What are the various
committees of the Board and which directors are on those committees? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Audit Committee is comprised entirely of
directors who meet the independence requirements set forth in Nasdaq Stock Market Rule&nbsp;5605(c)(2)(A). Information regarding the functions performed by the committee, its membership, and the number of meetings held during the fiscal year is set
forth in the &#147;Report of the Audit Committee,&#148; included in this proxy statement. The members of the Audit Committee are Richard F. Pops, George J. Morrow and Stephen A. Sherwin, M.D. The Board of Directors has determined that Richard F.
Pops, George J. Morrow and Stephen A. Sherwin, M.D. are &#147;audit committee financial experts&#148; within the meaning of item&nbsp;407(d)(5) of SEC <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> This committee met five times during
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Compensation Committee consists of directors Richard F. Pops, George J. Morrow and Alfred W. Sandrock, Jr.,
M.D., Ph.D. The Compensation Committee reviews and recommends to the Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors the compensation of executive officers and other employees of the Company. Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees as
appropriate. Each of the current members of the Compensation Committee is an &#147;independent director&#148; as defined by Nasdaq Stock Market Rule&nbsp;5605(a)(2). This committee met seven times during 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., George J. Morrow and Alfred W.
Sandrock, Jr. M.D., Ph.D., all of whom are &#147;independent directors&#148; as defined by Nasdaq Stock Market Rule&nbsp;5605(a)(2). The Nominating/Corporate Governance Committee is responsible for developing and implementing policies and practices
relating to corporate governance, including administration of the Company&#146;s Code of Business Conduct and Ethics, which applies to all of the Company&#146;s officers, directors and employees, and is available on the Company&#146;s website
at<I></I><I>&nbsp;www.neurocrine.com.</I> The functions of this committee also include consideration of the composition of the Board of Directors and recommendation of individuals for election as directors of the Company. The Nominating/Corporate
Governance Committee will consider nominees recommended by stockholders, provided such nominations are made pursuant to the Company&#146;s bylaws and applicable law. This committee met four times during 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Science and Medical Technology Committee consists of directors Gary&nbsp;A. Lyons, William&nbsp;H. Rastetter, Ph.D. and
Alfred W. Sandrock, Jr. M.D., Ph.D.&nbsp;The purpose of the Science and Medical Technology Committee is to assist the Board of Directors in its oversight of management&#146;s exercise of its responsibility to make significant scientific judgments
relating to the Company&#146;s research and development activities and portfolio. This committee met two times during 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee
interlocks and insider participation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2018, the Compensation Committee consisted of George J. Morrow, Richard F. Pops,
Corinne H. Nevinny and Alfred W. Sandrock, Jr., M.D., Ph.D. Ms.&nbsp;Nevinny served on the Compensation Committee until she resigned from the Board of Directors on September&nbsp;18, 2018. Dr.&nbsp;Sandrock joined the Compensation Committee in
September 2018 after Ms.&nbsp;Nevinny&#146;s resignation. No interlocking relationship existed between any member of the Compensation Committee and any member of any other company&#146;s Board of Directors or compensation committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is our director nomination process? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In selecting <FONT STYLE="white-space:nowrap">non-incumbent</FONT> candidates and reviewing the qualifications of incumbent candidates for the
Board of Directors, the Nominating/Corporate Governance Committee considers the Company&#146;s corporate governance principles, which include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Directors should possess the highest ethics, integrity and values, and be committed to representing the long-term
interest of the stockholders. They also must have experience they can draw upon to help direct the business strategies of the Company together with sound judgment. They must be actively engaged in the pursuit of information relevant to the
Company&#146;s business and must constructively engage their fellow Board members and management in dialogue and the decision-making process. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Directors must be willing to devote sufficient time to carrying out their duties and responsibilities
effectively, and should be committed to serve on the Board of Directors for an extended period of time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Directors should notify the Chairman of the Board and Chairman of the Nominating/Corporate Governance Committee
in the event of any significant change in their employment responsibilities or affiliations. Director nominees should meet the Director Qualification requirements set forth in the Company&#146;s Corporate Governance Guidelines.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In evaluating director nominees, the Nominating/Corporate Governance Committee considers the following factors:
personal and professional integrity, ethics and values including any potential conflicts of interest; experience in corporate management and the biopharmaceutical industry, such as serving as an officer or former officer of a publicly held company;
experience as a board member of another publicly held company; and additionally, for nominees seeking <FONT STYLE="white-space:nowrap">re-election,</FONT> meeting attendance and participation and compliance with Company policies.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is the Company&#146;s policy to have a diversity of skills, professional experience,
education, associations, achievements, training, points of view and individual qualities and attributes represented on the Board of Directors. The Nominating/Corporate Governance Committee considers the diversity of the Board of Directors when
evaluating candidates for election or <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Nominating/Corporate Governance Committee&#146;s goal is to assemble a Board of Directors that brings to the Company a variety of perspectives and skills derived from high quality business and professional experience. In doing so, the
Nominating/Corporate Governance Committee also considers candidates with appropriate <FONT STYLE="white-space:nowrap">non-business</FONT> backgrounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, the Nominating/Corporate Governance Committee Charter and Corporate Governance Guidelines set forth minimum
criteria for director nominees. The Nominating/Corporate Governance Committee may also consider such other facts as it may deem are in the best interests of the Company and its stockholders. The Nominating/Corporate Governance Committee does,
however, believe that at least one, and preferably several members of the Board of Directors, meet the criteria for an &#147;audit committee financial expert&#148; as defined by SEC rules. We believe that all of our directors should have a
reputation for honesty, integrity and highest ethical standards, and should demonstrate business acumen, an ability to exercise sound judgment and a commitment to serve the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Self-Assessment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Nominating/Corporate Governance Committee ensures that each member of the Board, the Committees, and the Chair of the Board are annually assessed annually aimed at enhancing effectiveness. Directors complete a number of different evaluations in
order to provide performance feedback and suggestions for improved effectiveness or contributions. The assessments are done by way of a questionnaire conducted by our external legal counsel, Cooley, LLP. The assessments are treated on a confidential
basis, with the results tallied on an anonymous basis for review. The results of the evaluation are analyzed by our Chief Legal Officer, the Nomination/Corporate Governance Committee and the Board, who decide whether any changes are needed to the
Board&#146;s processes, procedures, composition or Committee structure. The evaluation carried out in 2018 indicated that all individuals and groups were effectively fulfilling their responsibilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Education </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board recognizes the
importance of ongoing director education. In order to facilitate member of the Board of Directors&#146; educational development, the members of the Board of Directors regularly meet with management and are given periodic presentations on our
business and recent business developments. Members of the Board of Directors also attend dinners on the evening before regularly scheduled Board meetings. Generally, at these dinners the Board meets with senior decision-makers within the Company or
outside experts in order to enhance the Board&#146;s understanding of our business and affairs. In addition, on an annual basis an external expert meets with the Board to discuss new developments relating to corporate governance and the operation of
public company boards. The Company also provides funding for members of the Board of Directors to attend outside director continuing education programs sponsored by educational and other institutions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Identification and Evaluation of Nominees for Director </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating/Corporate Governance Committee identifies nominees for director by first evaluating the current members of the Board of
Directors willing to continue in service. Current members with qualifications and skills that are consistent with the Nominating/Corporate Governance Committee&#146;s criteria for service and who are willing to continue are considered for <FONT
STYLE="white-space:nowrap">re-nomination,</FONT> balancing the value of continuity of service by existing members of the Board of Directors with that of obtaining members who would offer a new perspective. If any member of the Board of Directors
does not wish to continue in service, or if the Board of Directors decides not to <FONT STYLE="white-space:nowrap">re-nominate</FONT> a member for <FONT STYLE="white-space:nowrap">re-election,</FONT> the Nominating/Corporate Governance Committee
identifies the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
desired skills and experience of a new nominee in light of the criteria above. The Nominating/Corporate Governance Committee generally polls the Board of Directors and members of management for
their recommendations and may also seek input from third-party search firms. The Nominating/Corporate Governance Committee may also seek input from industry experts or analysts. The Nominating/Corporate Governance Committee reviews the
qualifications, experience and background of the candidates. Final candidates are then interviewed by the Company&#146;s independent directors and executive management. In making its determinations, the Nominating/Corporate Governance Committee
evaluates each individual in the context of the Company&#146;s Board of Directors as a whole, with the objective of assembling a group that can best perpetuate the success of the Company and represent stockholder interests through the exercise of
sound judgment. After review and deliberation of all feedback and data, the Nominating/Corporate Governance Committee makes its recommendation to the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not received director candidate recommendations from the Company&#146;s stockholders and do not have a formal policy regarding
consideration of such recommendations. However, any recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by members of our Board of Directors, management or other parties are evaluated.
Accordingly, our Board of Directors believes a formal policy regarding consideration of such recommendations is unnecessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is our process
for stockholder communications with the Board of Directors? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of the Company wishing to communicate with the
Company&#146;s Board of Directors or an individual director may send a written communication to the Board of Directors or such director c/o&nbsp;Neurocrine Biosciences, Inc., 12780 El Camino Real, San&nbsp;Diego, CA 92130, Attn: Corporate Secretary.
Each communication must set forth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name and address of the Company stockholder on whose behalf the communication is sent;&nbsp;and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of Company&nbsp;shares that are beneficially owned by such stockholder as of the date of the
communication. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder communication will be reviewed by the Company&#146;s Corporate Secretary to determine
whether it is appropriate for presentation to the Board or such director. Examples of inappropriate communications include advertisements, solicitations or hostile communications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Communications determined by the Corporate Secretary to be appropriate for presentation to the Board or such director will be submitted to the
Board or such director on a periodic basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is the Board&#146;s role in risk oversight? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Board of Directors has ultimate oversight responsibility for the risk management process, it has delegated portions of this
responsibility to various committees. The Board of Directors and its committees oversee risk throughout the business with focus on financial risk, legal/compliance risk, scientific/clinical development risk, and strategic risk. The Audit Committee
focuses on financial risk and internal controls. The Nominating/Corporate Governance Committee and Audit Committee each focus on legal/compliance risk with the Nominating/Corporate Governance Committee taking the lead on the governance and
management process and the Audit Committee taking the lead on SEC reporting and compliance. The Compensation Committee addresses compensation policies and practices as they relate to risk management practices and risk-taking incentives. The Science
and Medical Technology Committee reviews the scientific risk associated with the Company&#146;s research and development activities and any related legal/compliance risk. The participation of the full Board of Directors in setting the Company&#146;s
business strategy incorporates assessment of strategic risk for the Company overall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How do the Company&#146;s compensation policies and practices relate to risk management practices and
risk-taking incentives? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2018, the Compensation Committee, in conjunction with the Board of Directors, conducted an
assessment of how the Company&#146;s compensation policies and practices relate to risk management practices and risk-taking incentives. As part of the process, the Compensation Committee engaged the services of an external, independent compensation
consulting firm to conduct an independent risk assessment. Based on this assessment, the Compensation Committee concluded that the Company&#146;s compensation policies and practices do not create risks that are reasonably likely to have a material
adverse effect on the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is our policy regarding Board member attendance at the Company&#146;s Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not have a formal policy regarding attendance by members of the Board of Directors at the Annual Meeting. Directors
Dr.&nbsp;Rastetter and Dr.&nbsp;Gorman attended the 2018 Annual Meeting of Stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following Report of the Audit Committee does not constitute soliciting material and should not be deemed filed or incorporated by
reference into any other Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent the Company specifically incorporates this Report by reference therein. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee is currently comprised of directors George J. Morrow, Richard F. Pops and Stephen A. Sherwin, M.D. All current committee
members satisfy the definition of &#147;independent director&#148; as established in the Nasdaq Stock Market qualification requirements. The Audit Committee met five times during the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the Company&#146;s financial reporting process on behalf of the Board of Directors. Management has the primary
responsibility for the Company&#146;s financial statements and the reporting process, including the Company&#146;s systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee has reviewed and discussed with
management the Company&#146;s audited financial statements as of and for the year ended December&nbsp;31, 2018, including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant
judgments and the clarity of disclosures in the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee also has reviewed and discussed the
Company&#146;s audited financial statements as of and for the year ended December&nbsp;31, 2018 with the Company&#146;s independent registered public accounting firm, who are responsible for expressing an opinion on the conformity of those audited
financial statements with accounting principles generally accepted in the United States, as well as their judgments as to the quality, not just the acceptability, of the Company&#146;s accounting principles and such other matters as are required to
be discussed with the Audit Committee under Auditing Standard No.&nbsp;16, <I>Communications with Audit Committees</I>, as adopted by the Public Company Accounting Oversight Board (United States) (the &#147;PCAOB&#148;). The independent registered
public accounting firm also is responsible for performing an independent audit of the Company&#146;s internal control over financial reporting in accordance with the auditing standards of the PCAOB. In addition, the Audit Committee has discussed the
independent registered public accounting firm&#146;s independence from management and the Company, including the matters in the written disclosures and the letter from the independent registered public accounting firm required by applicable
requirements of the PCAOB and considered the compatibility of <FONT STYLE="white-space:nowrap">non-audit</FONT> services with the auditors&#146; independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee discussed with the Company&#146;s independent registered public accounting firm the overall scope and plans for their
audits. The Audit Committee meets with the independent registered public accounting firm, with and without management present, to discuss the results of their examinations, their evaluations of the Company&#146;s internal controls, and the overall
quality of the Company&#146;s financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In reliance on the reviews and discussions referred to above, the Audit Committee
recommended to the Board of Directors that the audited financial statements be included in the Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2018, for filing with the
Securities and Exchange Commission. The Audit Committee and the Board of Directors are also seeking stockholder ratification of the selection of the Company&#146;s independent registered public accounting firm for the year ending December&nbsp;31,
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Respectfully submitted by: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">AUDIT COMMITTEE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">George J. Morrow </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Richard F. Pops </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin, M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> fees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fees billed to the Company by Ernst&nbsp;&amp; Young LLP, the Company&#146;s independent registered public accounting firm, for
the indicated services for each of the last two fiscal years were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,123,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit related fees (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,139,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,213,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees consist of fees for professional services performed by Ernst&nbsp;&amp; Young LLP for the integrated
audit of the Company&#146;s annual financial statements and internal control over financial reporting and review of financial statements included in the Company&#146;s <FONT STYLE="white-space:nowrap">10-Q</FONT> filings, review of registration
statements on Form <FONT STYLE="white-space:nowrap">S-8,</FONT> and services that are normally provided in connection with statutory and regulatory filings or engagements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit related fees consist of fees for assurance and related services performed by Ernst&nbsp;&amp; Young LLP
that are reasonably related to the performance of the audit or review of the Company&#146;s financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax fees consist of fees for professional services performed by Ernst&nbsp;&amp; Young LLP with respect to tax
compliance, tax advice and tax planning. For 2018, these fees included $78,950 for tax preparation services, $15,450 for services related to Section&nbsp;382 studies for net operating loss utilization and $45,900 for state tax planning. For 2017,
these fees included $74,970 for tax preparation services and $15,000 for services related to Section&nbsp;382 studies for net operating loss utilization. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All other fees consist of fees for other permissible work performed by Ernst&nbsp;&amp; Young LLP that does not
meet with the above category descriptions </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has considered whether the provision of <FONT
STYLE="white-space:nowrap">non-audit</FONT> services is compatible with maintaining the independence of Ernst&nbsp;&amp; Young LLP, and has concluded that the provision of such services is compatible with maintaining the independence of that firm.
All of the services rendered by Ernst&nbsp;&amp; Young LLP were <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee in accordance with the Audit Committee <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee policy regarding <FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services of our independent registered public accounting firm </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Audit
Committee has established a policy that all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the Company&#146;s independent registered public accounting firm will be
<FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee. These services may include audit services, audit related services, tax services and other services. The Audit Committee considers whether the provision of each <FONT
STYLE="white-space:nowrap">non-audit</FONT> service is compatible with maintaining the independence of the Company&#146;s registered public accounting firm. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> is detailed as to the particular
service or category of services and is generally subject to a specific budget. The Company&#146;s independent registered public accounting firm and management are required to periodically (at least quarterly) report to the Audit Committee regarding
the extent of services provided by the independent registered public accounting firm in accordance with this <FONT STYLE="white-space:nowrap">pre-approval,</FONT> and the fees for the services performed to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following Report of the Committee does not constitute soliciting material and should not be deemed filed or incorporated by reference
into any other Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent the Company specifically incorporates this Report by reference therein. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Company has reviewed and discussed the Compensation Discussion and Analysis required by Item&nbsp;402(b) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Respectfully submitted by: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">COMPENSATION COMMITTEE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">George J. Morrow </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Richard F. Pops </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr., M.D., Ph.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL&nbsp;ONE: ELECTION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s bylaws, as amended, provide that the Board of Directors is comprised of seven directors. The Company&#146;s Certificate of
Incorporation provides that the Board of Directors is divided into three classes. There are currently two directors in Class&nbsp;I (William&nbsp;H. Rastetter, Ph.D. and George J. Morrow), two directors in Class&nbsp;II (Richard F. Pops and
Stephen&nbsp;A. Sherwin,&nbsp;M.D.), and three directors in Class&nbsp;III (Kevin C. Gorman,&nbsp;Ph.D., Gary A. Lyons and Alfred&nbsp;W. Sandrock, M.D., Ph.D.). With the exception of Kevin C. Gorman,&nbsp;Ph.D., who is the Chief Executive Officer
of Neurocrine, all current members of the Board of Directors meet the definition of &#147;independent director&#148; under the Nasdaq Stock Market qualification standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors in Class&nbsp;I hold office until the 2021 Annual Meeting of Stockholders, the directors in Class&nbsp;II hold office until the
2019 Annual Meeting of Stockholders and the directors in Class&nbsp;III hold office until the 2020 Annual Meeting of Stockholders (or, in each case, until their earlier resignation, removal from office, or death). After each such election, the
elected directors will then serve in succeeding terms of three years and until a successor is duly elected and qualified. Officers of the Company serve at the discretion of the Board of Directors. There are no family relationships among the
Company&#146;s directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of office for directors Richard F. Pops and Stephen&nbsp;A. Sherwin,&nbsp;M.D.,
will expire at the 2019 Annual Meeting of Stockholders. At the 2019 Annual Meeting of Stockholders, the stockholders will elect two Class&nbsp;II directors for a term of three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees for Election at the Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the nominees (Richard F. Pops and Stephen&nbsp;A. Sherwin,&nbsp;M.D.) are currently Class&nbsp;II directors of the Company. All of the
nominees were previously elected to the Board of Directors by the Company&#146;s stockholders. Information about the nominees is set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position&nbsp;in&nbsp;the&nbsp;Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops (1) (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen&nbsp;A. Sherwin,&nbsp;M.D. (1) (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who are the remaining Directors that are not up for election this year? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;I and&nbsp;III directors will remain in office after the 2019 Annual Meeting of Stockholders. The names and certain other
current information about the directors whose terms of office continue after the Annual Meeting are set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position&nbsp;in&nbsp;the&nbsp;Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chief&nbsp;Executive&nbsp;Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. Lyons (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow (1) (2) (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr. M.D., Ph.D. (2) (3) (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating/Corporate Governance Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Science and Medical Technology Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominees receiving the
highest number of affirmative votes of the&nbsp;shares present in person or represented by proxy at the 2019 Annual Meeting of Stockholders and entitled to vote on the election of directors will be elected to the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes withheld from any director are counted for purposes of determining the presence or
absence of a quorum, but have no other legal effect under Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, the proxy holders will vote the
proxies received by them for the Company&#146;s Class&nbsp;II nominees named above. If any of the Company&#146;s nominees is unable or declines to serve as a director at the time of the Annual Meeting, the proxies will be voted for any nominee who
is designated by the present Board of Directors to fill the vacancy. It is not expected that any of the Company&#146;s nominees will be unable or will decline to serve as a director.<B> The Board of Directors unanimously recommends that stockholders
vote &#147;FOR&#148; the Class</B><B></B><B>&nbsp;II nominees named above.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL TWO: ADVISORY VOTE ON </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION PAID TO THE COMPANY&#146;S NAMED EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the 2017 Annual Meeting of
Stockholders, the Board of Directors, as a matter of good corporate governance, recommended that the stockholders approve an advisory vote on Named Executive Officer compensation
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;say-on-pay&#148;)</FONT></FONT> on an annual basis. Approximately 94% of the&nbsp;stockholder votes cast at the 2017 Annual Meeting of Stockholders were for the Company&#146;s
recommendation, and in response the Company holds an annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote. This annual vote is not intended to address any specific compensation item, but rather the
overall compensation of the Company&#146;s Named Executive Officers and the philosophy, policies and practices described in this proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Company&#146;s Executive Compensation Philosophy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Board of Directors (the &#147;Committee&#148;) bases its executive compensation decisions on a number of
objectives which include aligning management incentives with interests of stockholders, providing competitive compensation, appropriately balancing compensation risk in the context of the Company&#146;s business strategy and meeting evolving
compensation governance standards. The philosophy of the Committee in establishing the Company&#146;s compensation policy for executive officers as well as all other employees is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">align compensation plans with both short-term and long-term goals and objectives of the Company and stockholder
interests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain highly skilled individuals by offering compensation that compares favorably to other employers
who are competing for available employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incentivize employees through a mix of base salary, bonus amounts based on achievement of defined corporate and
personal goals and long-term equity awards to generate returns for stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay for performance by ensuring that an ever-increasing percentage of an individual&#146;s compensation is
performance-based as they progress to higher levels within the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed below in the Compensation
Discussion and Analysis, we believe we have adopted a compensation philosophy that provides strong alignment between executive pay and performance based on strategic goals designed to provide both near-term and long-term growth in stockholder value.
The historical approval rates, on an advisory basis, for the Company&#146;s executive compensation program have been over 98% for each of the 2016, 2017 and 2018 Annual Meetings of Stockholders. The Committee and our Board of Directors believe that
this level of approval of our executive compensation program is indicative of our stockholders&#146; strong support of our compensation philosophy and goals as well as the overall administration of executive compensation by the Committee and the
Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are being asked to approve on an advisory basis, the compensation paid to the Company&#146;s Named Executive
Officers as set forth in the Compensation Discussion and Analysis, Summary Compensation Table and related notes and narrative set forth herein. This vote is not intended to address any specific compensation item, but rather the overall compensation
of the Company&#146;s Named Executive Officers and the philosophy, policies and practices described in this proxy statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#145;say-on-pay&#146;</FONT></FONT> vote is advisory and therefore not
binding on the Company, the Committee or the Board of Directors. However, we value the opinions of our stockholders and will review and will continue to consider the outcome of this advisory vote when making future compensation decisions for our
Named Executive Officers and will evaluate whether any actions are necessary to address the stockholders&#146; concerns. Approval of this advisory vote requires the affirmative vote of the majority of&nbsp;shares represented in person or by proxy
and entitled to vote on the item.<B> The Board of Directors unanimously recommends voting &#147;FOR&#148; approval of the Company&#146;s Named Executive Officers compensation.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL THREE: APPROVAL OF AN AMENDMENT TO THE 2011 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Neurocrine Biosciences, Inc.
2011 Equity Incentive Plan was originally approved by the Board of Directors and the stockholders of the Company in 2011, and was subsequently amended by the Board of Directors and our stockholders most recently in 2018 (the &#147;2011 Plan&#148;).
Subject to stockholder approval, our Board of Directors approved an amendment of the 2011 Plan on February&nbsp;8, 2019 (the 2011 Plan, as amended, the &#147;Amended 2011 Plan&#148;). The Board of Directors is requesting stockholder approval of the
Amended 2011 Plan, which includes the following material changes to the 2011 Plan, as described in more detail under &#147;Summary of the Amended 2011 Plan&#148; below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to increase in the maximum number of shares of common stock that may be issued under the 2011 Plan from
19,000,000 to 21,000,000 shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors believes that the proposed increase in the number of shares of
common stock reserved for issuance under the Amended 2011 Plan will allow the Company to attract and retain valuable employees and continue to provide its employees, consultants and directors with a proprietary interest in the Company. In
particular, the Company anticipates a material increase in its number of employees in 2019 in connection with: (i)&nbsp;the continued commercialization of the Company&#146;s first approved product, INGREZZA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (valbenazine) capsules, which began in May 2017; and (ii)&nbsp;development activities related to the Company&#146;s other development programs. Within the Company, equity awards foster an
ownership culture and are a critical tool for driving stockholder value and for recruiting, retaining and motivating employees. The Company grants annual equity awards to employees as an incentive to retain its work force and remain competitive. The
terms of the Company&#146;s annual equity awards and the Company&#146;s employee policies are designed to align employee and stockholder interests. The Company grants equity awards to a broad group of employees and such awards constitute a
significant component of the Company&#146;s employees&#146; total compensation. The Company&#146;s equity awards contain long-term vesting, performance-based vesting, and provisions designed to encourage employees to focus on the Company&#146;s
long-term goals and success. If our stockholders do not approve the Amended 2011 Plan, the Company strongly believes that it will be unable to successfully continue to use equity as part of its compensation program, as most of its competitors in the
industry do, putting the Company at a significant disadvantage and compromising its ability to enhance stockholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
2011 Plan authorizes the grant to our employees of options that qualify as incentive stock options under Section&nbsp;422 of the Code. The 2011 Plan also authorizes the grant of nonstatutory stock options, stock appreciation rights, restricted stock
awards, restricted stock units, performance stock awards and other stock awards (collectively &#147;stock awards&#148;) to our employees, directors and consultants. The 2011 Plan also provides that certain nonstatutory stock options will be
automatically granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and the Chairman of the Board of Directors of the Company, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;15, 2019, under the 2011 Plan there were 6,675,604 options outstanding to purchase shares of common stock, and 4,998,075
shares were available for future stock awards; 1,690,001 shares were subject to outstanding restricted stock units; and 3,400,386 shares previously issued upon exercise of options granted and 2,242,069 shares previously issued upon vesting of
restricted stock units under the 2011 Plan are now outstanding shares of common stock. As of March&nbsp;29, 2019, there were approximately 630 employees and directors eligible to receive grants under the 2011 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, whether granted under the 2011 Plan or otherwise, an aggregate of 6,873,590 shares are issuable upon exercise of
outstanding options with a weighted average exercise price of $48.69 and a weighted average remaining contractual term of 7.1 years; and 1,714,376 shares are subject to unvested restricted stock units. The closing price of the Company&#146;s common
stock on March&nbsp;29, 2019 was $88.10 with 91,284,279 shares outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, the stockholders are being asked to approve the Amended 2011 Plan. The affirmative vote of the holders of a majority of
the shares represented in person or by proxy at the Annual Meeting and entitled to vote on the item will be required to approve the Amended 2011 Plan. <B>The Board of Directors recommends voting &#147;FOR&#148; the approval of the Amended 2011
Plan.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Amended 2011 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The essential features of the Amended 2011 Plan are summarized below. This summary does not purport to be complete and is subject to, and
qualified by reference to, all provisions of the Amended 2011 Plan. The Amended 2011 Plan, which reflects all of the changes proposed to be made to the 2011 Plan, is attached as Appendix A&nbsp;to this proxy statement and is incorporated herein by
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Purpose</I></B>. The purpose of the Amended 2011 Plan is to enable the Company to attract and retain the best available
personnel, to provide additional incentives to the employees, directors and consultants of the Company and to promote the success of the Company&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Administration</I></B>. Our Board of Directors has the authority to administer the Amended 2011 Plan. Our Board of Directors also has
the authority to delegate some or all of the administration of the Amended 2011 Plan (except the <FONT STYLE="white-space:nowrap">Non-Discretionary</FONT> Grant Program summarized below) to a committee or committees composed of one or more members
of the Board of Directors or Company officers (the Board of Directors or any such committee, the &#147;Administrator&#148;). The Amended 2011 Plan may be administered by different committees with respect to different groups of employees and
consultants. The Administrator may make any determinations deemed necessary or advisable for the Amended 2011 Plan. The Administrator, in its discretion, selects the employees, directors and consultants to whom stock awards may be granted, the time
or times at which such awards shall be granted, the number of shares subject to each such grant, and other terms of the stock awards. All decisions, determinations and interpretations of the Administrator shall be final and binding on all holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility</I></B>. Incentive stock options may be granted only to our employees. Nonstatutory stock options, stock appreciation
rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards may be granted under the Amended 2011 Plan to our employees, directors and consultants. Participation in the <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> grant program is limited to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors (see <FONT STYLE="white-space:nowrap">&#147;Non-Discretionary</FONT> Grant Program&#148; below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Subject to the Amended 2011 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to stockholder approval of this Proposal Three and adjustments for changes in our capitalization, an aggregate of 21,000,000 shares of
common stock will be reserved for issuance under the Amended 2011 Plan. Shares may be issued in connection with a merger or acquisition as permitted by the rules of the applicable national securities exchange, and such issuance shall not reduce the
number of shares available for issuance under the Amended 2011 Plan. If a stock award granted under the Amended 2011 Plan expires or otherwise terminates without all of the shares having been issued, or if any shares of common stock issued pursuant
to a stock award are forfeited to us because of the failure to meet a contingency or condition required for the vesting of such shares, then the shares of common stock not issued under such stock award, or forfeited to us, shall revert to and again
become available for issuance under the Amended 2011 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any shares subject to a stock award are not delivered to a participant
because such shares are withheld for the payment of taxes or the stock award is exercised through a reduction of shares subject to the stock award (i.e. &#147;net exercised&#148;), or an appreciation distribution in respect of a stock appreciation
right is paid in shares of common stock, the number of shares that are not delivered will not again become available for issuance under the Amended 2011 Plan. If the exercise price of any stock award is satisfied by tendering shares of common stock
held by the participant, then the number of shares so tendered will not become available for issuance under the Amended 2011 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate maximum number of shares of common stock that may be issued under the Amended
2011 Plan pursuant to the exercise of incentive stock options, subject to stockholder approval of this Proposal Three, is 21,000,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Per-Person</FONT> Award Limitations</I></B>. The Amended 2011 Plan provides that no employee may be
granted, in any fiscal year of the Company, stock options, stock appreciation rights (and any other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least the fair market value on the date of
grant) (all such options, stock appreciation rights and other stock awards &#147;appreciation awards&#148;) covering more than 500,000 shares of common stock. Notwithstanding this limit, however, in connection with an employee&#146;s initial
employment, he or she may be granted appreciation awards covering up to an additional 500,000 shares of common stock. Additional <FONT STYLE="white-space:nowrap">per-person</FONT> limitations apply to performance stock awards, as described below in
the section entitled &#147;Terms of Performance Awards&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Full Value Stock Award Limitations</I></B>. In addition, subject to
adjustments upon changes in our capitalization or in connection with a merger or other similar event, the maximum number of shares of common stock that may be issued pursuant to the grant of &#147;full value stock awards&#148; (i.e., restricted
stock, restricted stock units, performance stock and other stock awards, but not including stock options or stock appreciation rights) is 50% of the total number of shares of common stock issuable under the Amended 2011 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Minimum Vesting</I></B>. Generally, no full value stock award that vests on the basis of the participant&#146;s continuous service with
the Company shall vest at a rate that is any more rapid than ratably over a three-year period, and no full value stock award that vests based on the satisfaction of performance goals shall have a performance period of less than twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limited Exception to Minimum Vesting Restrictions</I></B><I>. </I>Up to five percent (5%)&nbsp;of the total number of shares of common
stock available for issuance under the Amended 2011 Plan may in the aggregate be issued as full value stock awards that are not subject to the minimum vesting requirements set forth in the Amended 2011 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limit on <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation</I></B><I>. </I>The aggregate value of all
compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any period commencing on the date of the Company&#146;s annual meeting of stockholders for
a particular year and ending on the date of the Company&#146;s annual meeting of stockholders for the next subsequent year, including stock awards granted under the Amended 2011 Plan and cash fees paid to such
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $1,250,000 in total value. In addition, the aggregate value of the initial option grant or other similar stock award(s) granted under the Plan or otherwise to any
individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon or in connection with his or her initial election or appointment to the Board of Directors will not exceed $2,000,000 in total value. For purposes of
these limitations, the value of stock awards is calculated based on the grant date fair value of such stock awards for financial reporting purposes.&nbsp;The Board of Directors has the authority to make exceptions to these limits in extraordinary
circumstances, in its discretion, provided that any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is granted or paid such additional compensation may not participate in the decision to grant or pay such additional compensation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Section</I></B><B><I></I></B><B><I>&nbsp;162(m) Transition Relief for Performance-Based Compensation</I></B>. Under
Section&nbsp;162(m) of the Code, compensation paid to any publicly held corporation&#146;s &#147;covered employees&#148; (as defined under Section&nbsp;162(m) of the Code) that exceeds $1&nbsp;million per taxable year for any covered employee is
generally <FONT STYLE="white-space:nowrap">non-deductible.</FONT> Certain provisions in the Amended 2011 Plan refer to the &#147;performance-based compensation&#148; exception to the $1&nbsp;million deduction limit under Section&nbsp;162(m) of the
Code. Pursuant to the Tax Cuts and Jobs Act, this exception was repealed with respect to taxable years beginning after December&nbsp;31, 2017. However, an award may still be eligible for this exception if, among other requirements, it is intended to
qualify, and is eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act for remuneration provided pursuant to a written binding
contract which was in effect on November&nbsp;2, 2017 and which was not modified in any material respect on or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after such date. For purposes of this Proposal Three, the term &#147;Section&nbsp;162(m) Transition Relief&#148; refers to such transition relief. Accordingly, the provisions in the Amended 2011
Plan which refer to the &#147;performance-based compensation&#148; exception under Section&nbsp;162(m) of the Code will only apply to any award that is intended to qualify, and is eligible to qualify, as &#147;performance-based compensation&#148;
under Section&nbsp;162(m) of the Code pursuant to the Section&nbsp;162(m) Transition Relief and, therefore, such provisions are not applicable to any other awards granted under the Amended 2011 Plan. Because of certain ambiguities and uncertainties
as to the application and interpretation of Section&nbsp;162(m) of the Code, as well as other factors beyond the control of the Compensation Committee, no assurance can be given that any award granted under the Amended 2011 Plan will be eligible for
such transition relief and be deductible by the Company in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms and Conditions of Options and Stock Appreciation Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options and stock appreciation rights may be granted under the Amended 2011 Plan pursuant to stock option agreements and stock appreciation
right agreements. The following is a description of the permissible terms of options and stock appreciation rights under the Amended 2011 Plan. Individual grants may be more restrictive as to any or all of the permissible terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise Price</I></B>. The Administrator determines the exercise price of options and strike price of stock appreciation rights at the
time the options or stock appreciation rights are granted as set forth in the applicable stock award agreement. The exercise price of a stock option and strike price of a stock appreciation right may not be less than 100% of the fair market value of
the common stock on the date such award is granted. In the case of an incentive stock option granted to an optionee who owns more than 10% of all classes of stock of the Company or any parent or subsidiary of the Company, the exercise price may not
be less than 110% of the fair market value of the common stock on the date such option is granted. The fair market value of the common stock is generally determined with reference to the closing sale price for the common stock on the date the option
or stock appreciation right is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation Rights</I></B>. Each stock appreciation right is denominated in shares
of common stock equivalents. Upon exercise of a stock appreciation right, we will pay the participant an amount equal to the excess of (i)&nbsp;the aggregate fair market value of our common stock on the date of exercise over (ii)&nbsp;the strike
price determined by the Administrator on the date of grant. The appreciation distribution upon exercise of a stock appreciation right will be paid in shares of our common stock, in cash, any combination of the two or any other form of consideration
determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Repricing; Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock
Awards</I></B>. Under the Amended 2011 Plan, the Administrator does not have the authority to reprice any outstanding stock awards by reducing the exercise price of the stock award or to cancel any outstanding stock awards in exchange for cash or
other stock awards without obtaining the approval of our stockholders within 12 months prior to the repricing or cancellation and <FONT STYLE="white-space:nowrap">re-grant</FONT> event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise; Form of Consideration</I></B>. The Administrator determines when options and stock appreciation rights become exercisable as
set forth in the applicable stock award agreement. The means of payment for shares issued upon exercise of an option is specified in each option agreement. The Amended 2011 Plan permits payment to be made to the extent permitted under applicable
laws by cash, check, other shares of common stock of the Company (with some restrictions), net exercise, cashless exercise, any other form of consideration permitted by applicable law, or any combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term</I></B>. The Administrator determines the term of options and stock appreciation rights granted under the Amended 2011 Plan as set
forth in the applicable stock award agreement. The term of options and stock appreciation rights granted under the Amended 2011 Plan may be no more than 10 years from the date of grant. In the case of an incentive stock option granted to an optionee
who owns more than 10% of all classes of stock of the Company or any parent or subsidiary of the Company, the term of the option may be no more than five years from the date of grant. No option or stock appreciation right may be exercised after the
expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Continuous Service</I></B>. Options and stock appreciation rights
granted under the Amended 2011 Plan generally terminate three months after termination of the participant&#146;s service unless (i)&nbsp;such termination is due to the participant&#146;s disability, in which case the stock award may, but need not,
provide that it may be exercised (to the extent the stock award was exercisable at the time of the termination of service) at any time within 12 months of such termination; (ii)&nbsp;the participant dies before the participant&#146;s service has
terminated, or within the period specified in the stock award agreement after termination of such service, in which case the stock award may, but need not, provide that it may be exercised (to the extent the stock award was exercisable at the time
of the participant&#146;s death) within 18 months of the participant&#146;s death by the person or persons to whom the rights to exercise such stock award pass by will or by the laws of descent and distribution; (iii)&nbsp;the stock award by its
terms specifically provides otherwise, or (iv)&nbsp;the termination is for cause. Except as provided otherwise in a participant&#146;s stock award agreement, or otherwise set forth in an employment agreement, upon termination of a participant&#146;s
service for cause, the stock award shall immediately terminate and may not thereafter be exercised. A participant may designate a beneficiary who may exercise the stock award following the participant&#146;s death. Individual grants by their terms
may provide for exercise within a longer or shorter period of time following termination of service. In no event, however, may an option or stock appreciation right be exercised beyond the expiration of its maximum term. The option or stock
appreciation right term generally is extended in the event that exercise of the stock award within the foregoing periods is prohibited. A participant&#146;s stock award agreement may provide that if the exercise of the stock award following the
termination of the participant&#146;s service would be prohibited because the issuance of stock would violate the registration requirements under the Securities Act of 1933, as amended, then the stock award will terminate on the earlier of
(i)&nbsp;the expiration of the term of the stock award or (ii)&nbsp;three months after the termination of the participant&#146;s service during which the exercise of the stock award would not be in violation of such registration requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Provisions</I></B>. The stock option agreement may contain other terms, provisions and conditions not inconsistent with the
Amended 2011 Plan as may be determined by the Administrator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Restricted Stock Awards and Restricted Stock Unit Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards and restricted stock unit awards may be granted under the Amended 2011 Plan pursuant to restricted stock award and
restricted stock unit award agreements. The following is a description of the permissible terms of restricted stock awards and restricted stock unit awards under the Amended 2011 Plan. Individual grants may be more restrictive as to any or all of
the permissible terms described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consideration</I></B>.&nbsp;The Administrator may grant restricted stock awards and
restricted stock unit awards in consideration for past services rendered to the Company or in exchange for any other form of legal consideration acceptable to the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Vesting</I></B>. Shares of stock issued under a restricted stock award agreement may, but need not, be subject to forfeiture to the
Company in accordance with a vesting schedule as determined by the Administrator. Restricted stock unit awards vest and are issued at the rate specified in the restricted stock unit award agreement as determined by the Administrator. However, at the
time of grant, the Administrator may impose additional restrictions or conditions that delay the delivery of stock to be issued in respect of the restricted stock unit award after vesting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Service</I></B>. Unless the Administrator determines otherwise, the restricted stock purchase agreement shall give the
Company a repurchase option exercisable upon the voluntary or involuntary termination of the purchaser&#146;s employment or consulting relationship with the Company for any reason (including death and disability). The purchase price for any issued
shares repurchased by the Company shall be the original price paid by the purchaser, if any. The repurchase option lapses at a rate determined by the Administrator. Except as otherwise provided in the applicable award agreement, restricted stock
unit awards that have not vested will be automatically forfeited upon the participant&#146;s termination of service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Equivalents</I></B>. Dividend equivalent rights may be credited with respect
to shares covered by a restricted stock unit award. However, we do not anticipate paying cash dividends on our common stock for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Performance Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
2011 Plan allows the Administrator to issue performance stock awards. Performance stock awards may be granted, vest or be exercised based upon the attainment during a certain period of time of certain performance goals and will be issued in shares
of our common stock, or if determined by the Administrator, cash. All of our employees, consultants and directors are eligible to receive performance stock awards under the Amended 2011 Plan. The length of any performance period, the performance
goals to be achieved during the performance period and the measure of whether and to what degree such performance goals have been attained shall be determined by the Administrator. The maximum amount to be granted to any individual in any calendar
year attributable to such performance stock awards may not exceed 500,000 shares of our common stock. Notwithstanding this limit, however, in connection with an employee&#146;s initial employment, he or she may be granted performance stock awards
covering up to an additional 500,000 shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In granting a performance stock award, the Administrator will set a period
of time, or a performance period, over which the attainment of one or more goals, or performance goals, will be measured for the purpose of determining whether the stock award recipient has a vested right in or to such performance stock award. With
respect to stock awards that are intended to qualify as performance based compensation for purposes of Section&nbsp;162(m) of the Code, within the time period prescribed by Section&nbsp;162(m) of the Code, the Administrator will establish the
performance goals, based upon one or more <FONT STYLE="white-space:nowrap">pre-established</FONT> criteria, or performance criteria, enumerated in the Amended 2011 Plan and described below. However, in order to qualify as &#147;performance-based
compensation&#148; under Section&nbsp;162(m) of the Code, among other requirements, such awards must be eligible to qualify for the Section&nbsp;162(m) Transition Relief (as described in &#147;Section&nbsp;162(m) Transition Relief for
Performance-Based Compensation&#148; above). As soon as administratively practicable following the end of the performance period, the Administrator will certify (in writing) whether the performance goals have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Performance goals under the Amended 2011 Plan shall be established by the Administrator, based on one or more of the following performance
criteria: (i)&nbsp;earnings (including earnings per share and net earnings, in either case before or after any or all of: interest, taxes, depreciation and amortization, legal settlements or other income (expense), or stock-based compensation, other
<FONT STYLE="white-space:nowrap">non-cash</FONT> expenses and changes in deferred revenue); (ii)&nbsp;total stockholder return; (iii)&nbsp;return on equity or average stockholder&#146;s equity; (iv)&nbsp;return on assets, investment, or capital
employed; (v)&nbsp;stock price; (vi)&nbsp;margin (including gross margin); (vii)&nbsp;income (before or after taxes); (viii)&nbsp;operating income; (ix)&nbsp;operating income after taxes; <FONT STYLE="white-space:nowrap">(x)&nbsp;pre-tax</FONT>
profit; (xi)&nbsp;operating cash flow; (xii)&nbsp;sales or revenue targets; (xiii)&nbsp;increases in revenue or product revenue; (xiv)&nbsp;expenses and cost reduction goals; (xv)&nbsp;improvement in or attainment of working capital levels;
(xvi)&nbsp;economic value added (or an equivalent metric); (xvii)&nbsp;market share; (xviii)&nbsp;cash flow; (xix)&nbsp;cash flow per share; (xx)&nbsp;cash burn; (xxi)&nbsp;share price performance; (xxii)&nbsp;debt reduction;
(xxiii)&nbsp;implementation or completion of projects or processes (including, without limitation, discovery of a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> drug candidate, recommendation of a drug candidate to enter a clinical trial,
clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, presentation of studies and
launch of commercial plans, compliance programs or education campaigns); (xxiv)&nbsp;customer satisfaction; (xxv)&nbsp;stockholders&#146; equity; (xxvi)&nbsp;capital expenditures; (xxvii)&nbsp;debt levels; (xxviii)&nbsp;financings;
(xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii)&nbsp;employee hiring; (xxxiv)&nbsp;funds from operations; (xxxv)&nbsp;budget
management; (xxxvi)&nbsp;strategic partnerships or transactions (including acquisitions, joint ventures or licensing transactions); (xxxvii)&nbsp;engagement of thought leaders and patient advocacy groups; (xxxviii)&nbsp;enhancement of intellectual
property portfolio, filing of patent applications and granting of patents; (xxxix)&nbsp;litigation preparation and management; and (xl)&nbsp;to the extent that an award is not intended to comply with Section&nbsp;162(m) of the Code, other measures
of performance selected by the Administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by the Administrator, the attainment of performance goals for a
performance period will be calculated: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated net sales
and operating earnings; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv)&nbsp;to exclude the effects of any statutory adjustments to corporate tax
rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (vi)&nbsp;to exclude the dilutive effects of acquisitions or joint
ventures; (vii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&nbsp;to exclude the effect of any change in the
outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of
shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans;
(x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (xi)&nbsp;to exclude the goodwill and intangible asset impairment charges
that are required to be recorded under generally accepted accounting principles; and (xii)&nbsp;to exclude the effects of the timing of acceptance for review and/or approval of submissions to the FDA or any other regulatory body. In addition, the
Administrator retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-Discretionary</FONT> Grant Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant
program under the Amended 2011 Plan provides for the grant of stock options to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors over their period of service on the Board of Directors. These stock options will be granted as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Initial Option Grant</I></B>. Each new <FONT STYLE="white-space:nowrap">non-employee</FONT> director will, at the time of his or
her initial election or appointment to the Board of Directors, receive an option to purchase a number of shares of the Company&#146;s common stock determined by the Board of Directors (the &#147;initial option grant&#148;). The initial option grant
shall vest monthly with respect to 1/36th of the shares over the three-year period following the date of grant, subject to the director&#146;s continuous service through the applicable vesting dates, so that the initial option grant will be fully
vested on the third anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Option Grant</I></B>. On each annual meeting, each continuing <FONT
STYLE="white-space:nowrap">non-employee</FONT> director will automatically be granted a stock option to purchase a number of shares of our common stock determined by the Board of Directors (the &#147;annual option grant&#148;). The annual option
grant shall vest monthly with respect to 1/12th of the shares over the one year period following the date of grant, subject to the director&#146;s continuous service through the applicable vesting dates, so that the annual option grant will be fully
vested on the first anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General Terms</I></B>. The exercise price of each option granted under the <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> grant program is 100% of the fair market value of the common stock subject to the option on the date of grant. The maximum term of options granted under the
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program is ten years. All other terms of each option granted under the <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program shall be consistent with the terms of the
Amended 2011 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Transaction</I></B>. Each option granted under the
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program shall automatically fully accelerate vesting upon a corporate transaction, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service
through the date of the corporate transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Other Stock Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may grant other stock awards that are valued in whole or in part by reference to our common stock. Subject to the provisions
of the Amended 2011 Plan, the Administrator has the authority to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determine the persons to whom, and the dates on which, such other stock awards will be granted, the number of shares of common stock (or cash equivalents) to be subject to each award, and other
terms and conditions of such awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tax Withholding</I></B>. To the extent provided by the terms of any stock award agreement, a participant may satisfy any federal, state
or local tax withholding obligation relating to such stock award by a cash payment, by authorizing the Company to withhold a portion of the stock otherwise issuable to the participant, by withholding from any amounts otherwise payable to the
participant, by a combination of these means, or by such other method as set forth in the stock award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Transferability</I></B>. Stock awards may not be sold, pledged, transferred, or disposed of in any manner other than by will or by the
laws of descent and distribution, pursuant to a domestic relations order, or with respect to stock awards other than options or stock appreciation rights, with the Administrator&#146;s consent, and may be exercised, during the lifetime of the
holder, only by the holder or such transferees as have been transferred a stock award with the Administrator&#146;s consent. If the Administrator makes a stock award transferable, such stock award shall contain such additional terms and conditions
as the Administrator deems appropriate and such award will not otherwise be transferred for consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adjustments Upon Changes
in Capitalization</I></B>. In the event any change is made to the outstanding shares of the Company&#146;s common stock without the receipt of consideration (whether through a stock split or other specified change in our capital structure), the
Administrator shall appropriately adjust the number and kind of shares of stock (or other securities or property) subject to the Amended 2011 Plan, the maximum number of shares that may be issued pursuant to the exercise of incentive stock options,
the maximum numbers and/or class of securities for which any one person may be granted appreciation awards, full value stock awards and performance stock awards per calendar year, the number and kind of shares of stock (or other securities or
property) subject to any stock award outstanding under the Amended 2011 Plan, and the exercise or purchase price of any such outstanding stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Corporate Events</I></B>. In the event of a dissolution or liquidation of the Company, all outstanding stock awards
under the Amended 2011 Plan shall terminate immediately prior to such dissolution or liquidation. The Amended 2011 Plan further provides that, in the event of a sale, or other disposition of all or substantially all of the Company&#146;s assets or
specified types of mergers or consolidations (each, a &#147;corporate transaction&#148;), any surviving or acquiring corporation shall either assume stock awards outstanding under the Amended 2011 Plan or substitute similar stock awards for those
outstanding under the Amended 2011 Plan. If any surviving corporation declines to assume stock awards outstanding under the Amended 2011 Plan or to substitute similar stock awards, then, with respect to participants whose service with the Company
has not terminated prior to the time of such corporate transaction, the vesting and the time during which such stock awards may be exercised will be accelerated in full, and all outstanding stock awards will terminate if the participant does not
exercise such stock awards at or prior to the corporate transaction. With respect to any stock awards that are held by other participants that terminated service with the Company prior to the corporate transaction, the vesting and exercisability
provisions of such stock awards will not be accelerated and such stock awards will terminate if not exercised prior to the corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment and Termination of the Amended 2011 Plan</I></B>. The Board of Directors may amend, alter, suspend or terminate the Amended
2011 Plan, or any part thereof, at any time and for any reason. Unless sooner terminated, the Amended 2011 Plan will terminate on February&nbsp;20, 2021.&nbsp;However, the Amended 2011 Plan requires stockholder approval for any amendment to the
Amended 2011 Plan to the extent necessary to comply with applicable laws, rules and regulations. No action by the Board of Directors or stockholders may impair any award previously granted under the Amended 2011 Plan without the consent of the
holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Stock Options</I></B>. An optionee who is granted an incentive stock option does not recognize taxable income at the time the
option is granted or upon its exercise, although the exercise is an adjustment item for alternative minimum tax purposes and may subject the optionee to the alternative minimum tax. Upon a disposition of the shares more than two years after grant of
the option and one year after exercise of the option, any gain or loss is treated as long-term capital gain or loss. If these holding periods are not satisfied, the optionee recognizes ordinary income at the time of disposition equal to the
difference between the exercise price and the lesser of (i)&nbsp;the excess of the stock&#146;s fair market value on the date of exercise over the exercise price, or (ii)&nbsp;the participant&#146;s actual gain, if any, on the purchase and sale. Any
gain or loss recognized on such a premature disposition of the shares in excess of the amount treated as ordinary income is treated as long-term or short-term capital gain or loss, depending on the holding period. A different rule for measuring
ordinary income upon such a premature disposition may apply if the optionee is also an officer, director or 10% stockholder of the Company. Unless limited by Section&nbsp;162(m) of the Code, the Company is entitled to a deduction in the same amount
as the ordinary income recognized by the optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nonstatutory Stock Options</I></B>. An optionee does not recognize any taxable
income at the time he or she is granted a nonstatutory stock option. Upon exercise, the optionee recognizes taxable income generally measured by the excess of the then fair market value of the shares over the exercise price. Any taxable income
recognized in connection with an option exercise by an employee of the Company is subject to tax withholding by the Company. Unless limited by Section&nbsp;162(m) of the Code, the Company is entitled to a deduction in the same amount as the ordinary
income recognized by the optionee. Upon a disposition of such shares by the optionee, any difference between the sale price and the optionee&#146;s exercise price, to the extent not recognized as taxable income as provided above, is treated as
long-term or short-term capital gain or loss, depending on the holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation Rights</I></B>. No taxable income
is realized upon the receipt of a stock appreciation right. Upon exercise of the stock appreciation right, the fair market value of the shares (or cash in lieu of shares) received is recognized as ordinary income to the participant in the year of
such exercise. Generally, with respect to employees, we are required to withhold from the payment made on exercise of the stock appreciation right or from regular wages or supplemental wage payments an amount based on the ordinary income recognized.
Subject to the requirement of reasonableness, Section&nbsp;162(m) of the Code and the satisfaction of a reporting obligation, we will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards</I></B>. For federal income tax purposes, if an individual is granted a restricted stock award, the recipient
generally will recognize taxable ordinary income equal to the excess of the common stock&#146;s fair market value over the purchase price, if any. However, to the extent the common stock is subject to certain types of restrictions, such as a
repurchase right in favor of the Company, the taxable event will be delayed until the vesting restrictions lapse unless the recipient makes a valid election under Section&nbsp;83(b) of the Code. If the recipient makes a valid election under
Section&nbsp;83(b) of the Code with respect to restricted stock, the recipient generally will recognize ordinary income at the date of acquisition of the restricted stock in an amount equal to the difference, if any, between the fair market value of
the shares at that date over the purchase price for the restricted stock. If, however, a valid Section&nbsp;83(b) election is not made by the recipient, the recipient will generally recognize ordinary income when the restrictions on the shares of
restricted stock lapse, in an amount equal to the difference between the fair market value of the shares at the date such restrictions lapse over the purchase price for the restricted stock. With respect to employees, the Company is generally
required to withhold from regular wages or supplemental wage payments an amount based on the ordinary income recognized. Generally, the Company will be entitled (subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of
the Code and the satisfaction of a tax reporting obligation) to a business expense deduction equal to the taxable ordinary income realized by the recipient. Upon disposition of the common stock, the recipient will recognize a capital gain or loss
equal to the difference between the selling price and the sum of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount paid for such common stock, if any, plus any amount recognized as ordinary income upon acquisition (or the lapse of restrictions) of the common stock. Such gain or loss will be long-term
or short-term depending on how long the common stock was held. Slightly different rules may apply to recipients who are subject to Section&nbsp;16(b) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Unit Awards</I></B>. No taxable income is recognized upon receipt of a restricted stock unit award. The participant
will recognize ordinary income in the year in which the shares subject to that unit are actually issued to the participant in an amount equal to the fair market value of the shares on the date of issuance. The participant and the Company will be
required to satisfy certain tax withholding requirements applicable to such income. Subject to the requirement of reasonableness, Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, we will be entitled to an income
tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued. In general, the deduction will be allowed for the taxable year in which such ordinary income is recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential Limitation on Company Deductions</I></B>. Under Section&nbsp;162(m) of the Code, compensation paid to any publicly held
corporation&#146;s &#147;covered employees&#148; (as defined under Section&nbsp;162(m) of the Code) that exceeds $1&nbsp;million per taxable year for any covered employee is generally <FONT STYLE="white-space:nowrap">non-deductible.</FONT> Prior to
the enactment of the Tax Cuts and Jobs Act, Section&nbsp;162(m) of the Code provided a performance-based compensation exception, pursuant to which the deduction limit under Section&nbsp;162(m) of the Code did not apply to any compensation that
qualified as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code. Pursuant to the Tax Cuts and Jobs Act, the performance-based compensation exception under Section&nbsp;162(m) of the Code was repealed with respect to
taxable years beginning after December&nbsp;31, 2017, except that certain transition relief is provided for compensation paid pursuant to a written binding contract which was in effect on November&nbsp;2, 2017 and which is not modified in any
material respect on or after such date. Compensation paid to each of the Company&#146;s &#147;covered employees&#148; in excess of $1&nbsp;million per taxable year generally will not be deductible unless it qualifies for the performance-based
compensation exception under Section&nbsp;162(m) of the Code pursuant to the transition relief described above. Because of certain ambiguities and uncertainties as to the application and interpretation of Section&nbsp;162(m) of the Code, as well as
other factors beyond the control of the Compensation Committee, no assurance can be given that any compensation paid by the Company (including any award granted under the Amended 2011 Plan) will be eligible for such transition relief and be
deductible by the Company in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The foregoing is only a summary of the effect of federal income taxation upon holders of
stock awards and the Company with respect to the grant and exercise of stock awards under the Amended 2011 Plan. It does not purport to be complete, and does not discuss the tax consequences of the holder&#146;s death or the provisions of the income
tax laws of any municipality, state or foreign country in which the holder may reside. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended 2011 Plan </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Business Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group (nine persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group&nbsp;(six
persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees, including all current officers who are not executive officers, as a group
(approximately 690 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Awards granted under the Amended 2011 Plan to our executive officers and other employees are discretionary and
are not subject to set benefits or amounts under the terms of the Amended 2011 Plan, and our Board of Directors and our Compensation Committee have not granted any awards under the Amended 2011 Plan subject to stockholder approval of this Proposal
Three. Accordingly, the benefits or amounts that will be received by or allocated to our executive officers and other employees under the Amended 2011 Plan are not determinable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Amended 2011 Plan, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
are entitled to receive options as described in <FONT STYLE="white-space:nowrap">&#147;Non-Discretionary</FONT> Grant Program&#148; above. Under our compensation arrangements for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and the
Amended 2011 Plan, in 2018 each of our six current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was granted a nonstatutory stock option to purchase 12,500 (15,000 in the case of our Chairman) shares at the 2018 Annual Meeting and
such options were granted under the Amended 2011 Plan. For additional information regarding our current compensation arrangements for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, please see &#147;Director Compensation&#148; below.
The actual value realized upon exercise of an option will depend on the excess, if any, of the stock price over the exercise prices on the date of exercise. Only <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of the Company are
eligible to receive <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grants under the Amended 2011 Plan. All other grants under the Amended 2011 Plan are within the discretion of the Administrator. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, for each of the individuals and groups indicated, the total number of shares of our common stock subject to
options and stock awards that have been granted (even if not currently outstanding) under the 2011 Plan through the Record Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2011
Plan </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;shares&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,882,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Business Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group (nine persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,396,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors who are not executive officers as a group (six&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each nominee for election as a director: (two persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees, including all current officers who are not executive officers, as a group
<BR>(approximately 690 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,448,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY COMPENSATION PLANS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding all of the Company&#146;s equity compensation plans as of March&nbsp;1, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities&nbsp;to&nbsp;be<BR>Issued upon<BR>Exercise of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Exercise Price of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Remaining&nbsp;Available<BR>for Future Issuance<BR>Under Equity<BR>Compensation Plans<BR>(Excluding<BR>Securities
Reflected<BR>in Column a)<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,406,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,002,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,646,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,057,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of securities remaining available for future issuance under equity compensation plans as of
March&nbsp;1, 2019 are from the 2011 Plan. The shares available for issuance under the 2011 Plan may be issued in the form of option awards, restricted stock awards, restricted stock unit awards or stock bonus awards subject to limitations set forth
in the 2011 Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of shares of common stock issuable pursuant to employment commencement nonstatutory stock option
awards and restricted stock unit awards. </P></TD></TR></TABLE> <P STYLE="margin-top:322pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A VOTE &#147;FOR&#148; PROPOSAL THREE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL&nbsp;FOUR: RATIFICATION OF APPOINTMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has selected
Ernst&nbsp;&amp; Young LLP to audit the financial statements of the Company for the current fiscal year ending December&nbsp;31, 2019. Ernst&nbsp;&amp; Young LLP has audited the Company&#146;s financial statements since 1992. Representatives of
Ernst&nbsp;&amp; Young LLP are expected to be present at the Annual Meeting, will have the opportunity to make a statement if they so desire, and are expected to be available to respond to appropriate questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders are not required to ratify the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public
accounting firm. However, the Audit Committee is submitting the selection of Ernst&nbsp;&amp; Young LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit
Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in their discretion may direct the selection of a different independent registered public accounting firm at any time during the
year if they determine that such a change would be in the best interests of the Company and its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the&nbsp;shares represented in person or by proxy at the Annual Meeting and entitled to
vote on the item will be required to approve and ratify the Audit Committee&#146;s selection of Ernst&nbsp;&amp; Young LLP.<B> The Board of Directors unanimously recommends voting &#147;FOR&#148; approval and ratification of such
selection.</B>&nbsp;In the event of a negative vote on such ratification, the Audit Committee will reconsider its selection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, our executive officers were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dimitri E. Grigoriadis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Research Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darin M. Lippoldt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief&nbsp;Legal&nbsp;Officer&nbsp;and&nbsp;Corporate&nbsp;Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malcolm C. Lloyd-Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Regulatory Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See above for biographical information concerning Kevin C. Gorman,&nbsp;Ph.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew C. Abernethy</I></B><B> </B>was appointed Chief Financial Officer in November 2017 and is responsible for leading corporate
finance activities and commercial supply chain operations, as well as information technology and investor relations functions at Neurocrine. Mr.&nbsp;Abernethy has nearly 15 years of experience in the financial sector and investor relations with
expertise in the healthcare industry. He joined Neurocrine from Zimmer Biomet, where he held various positions from February 2009 to November 2017, including most recently, Vice President, Investor Relations and Treasurer and Vice President of
Finance for the Americas and Global Product Engines. He began his career with KPMG LLP and is a certified public accountant. Mr.&nbsp;Abernethy earned his B.S. in Accounting and Business Administration from Grace College and an MBA from the
University of Chicago. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eric Benevich </I></B>was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects
of commercial development, marketing and sales of the Neurocrine product portfolio.&nbsp;Previously, Mr.&nbsp;Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015, serving most recently as Vice President of Marketing where he was
responsible for NUEDEXTA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and commercialization of their CNS pipeline. Mr.&nbsp;Benevich has over 20&nbsp;years of experience in the pharmaceutical industry and previously served in various
positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Epogen<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Prilosec<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Mr.&nbsp;Benevich has a BBA in International Business from Washington State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Haig P. Bozigian,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B> was appointed Chief Development Officer in 2013 after having served as
Senior Vice President of Pharmaceutical and Preclinical Development. Dr.&nbsp;Bozigian is responsible for all preclinical development, chemistry manufacturing and controls (CMC) and clinical pharmacology, and has led such functions since 2006.
Dr.&nbsp;Bozigian joined Neurocrine in 1997. With extensive expertise in CNS related new product development, Dr.&nbsp;Bozigian has participated in research and development for approximately 30&nbsp;years. Prior to joining Neurocrine,
Dr.&nbsp;Bozigian served as Director of Pharmaceutical Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals Corporation and as a Clinical Pharmacokineticist at GlaxoSmithKline.
Dr.&nbsp;Bozigian earned his B.S. in Microbiology from the University of Massachusetts, his M.S. in Pharmacodynamics and Toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in Pharmaceutical Sciences from the University
of Arizona. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kyle W. Gano, Ph.D.</I></B> was appointed Chief Business Development Officer in 2011 and is responsible for all
business and corporate development activities, including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma, BIAL, Jnana Therapeutics and Voyager Therapeutics. From 2001 to 2011, Dr.&nbsp;Gano held several positions of
increasing responsibility at Neurocrine spanning marketing analytics to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business development. Dr.&nbsp;Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and
M.B.A in Finance from the University of California, Los Angeles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dimitri E. Grigoriadis, Ph.D. </I></B>was appointed Chief Research
Officer in 2013. Dr.&nbsp;Grigoriadis oversees all research functions, including drug discovery, biology and chemistry, and has led such functions since 2006. Dr.&nbsp;Grigoriadis joined Neurocrine in 1993, established the pharmacology and drug
screening groups and was most recently a Neurocrine Fellow and Vice President of Discovery Biology. Prior to joining Neurocrine, he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993.
Dr.&nbsp;Grigoriadis received his B.Sc. from the University of Guelph in Ontario, Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on
Drug Abuse from 1987 to 1990. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Darin M. Lippoldt</I></B> was appointed Chief Legal Officer and Corporate Secretary in October 2014
and has oversight of all corporate legal matters, intellectual property, compliance, and government relations. Prior to joining Neurocrine, Mr.&nbsp;Lippoldt served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate
Secretary of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr.&nbsp;Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law
firms of Fulbright&nbsp;&amp; Jaworski LLP and Matthews and Branscomb, P.C. Mr.&nbsp;Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary&#146;s University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Malcolm C. Lloyd-Smith</I></B> was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and
quality assurance. Prior to joining Neurocrine, Mr.&nbsp;Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice
President, Regulatory Affairs and Quality Assurance from August 2008. Mr.&nbsp;Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the
United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr.&nbsp;Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA
and UK. Mr.&nbsp;Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eiry W. Roberts, M.D.,</I></B> was appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and
medical affairs activities at Neurocrine. Dr.&nbsp;Roberts has over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic
areas, including neuroscience, inflammation, oncology and metabolic diseases. She joined Neurocrine from Eli Lilly and Company where she had worked since May 1991. During her tenure at Eli Lily and Company Dr.&nbsp;Roberts held various positions of
increasing responsibility, including Vice President, Clinical Pharmacology/Managing Director of Chorus a position she held from October 2014 until December 2017 and Vice President of R&amp;D, BioMedicines Business Unit. At Eli Lilly Dr.&nbsp;Roberts
was the Chair of the Medical Review Committee, where she was responsible for review and approval of all the integrated clinical plans for molecules in the Lilly portfolio. Dr.&nbsp;Roberts was accountable for early clinical development programs
across all therapeutic areas within Lilly, as well as registration for new chemical entities and biproducts in Phase III development. During her time at Lilly, Dr.&nbsp;Roberts established a new therapeutic area, which resulted in the development of
five potential novel medicines from Phase I through to approval, with two of them successfully receiving regulatory approval. Dr.&nbsp;Roberts also has extensive leadership and business development experience, including the management of strategic
alliances, business partnerships and venture capital collaborations. Dr.&nbsp;Roberts is a physician who trained in pharmacology and medicine in the UK, qualifying from the University of London in 1987. Her post-graduate clinical training was in
clinical pharmacology and cardiology at St. Bartholomew&#146;s Hospital and the Royal London Hospital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Compensation Discussion and Analysis describes Neurocrine&#146;s executive officer compensation program for 2018 and certain elements of
our 2019 program. It provides qualitative information on the factors relevant to these decisions and the manner in which compensation is awarded to the following individuals who are our Named Executive Officers (&#147;NEOs&#148;) for 2018: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer, Kevin C. Gorman, Ph.D.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Financial Officer, Matthew C. Abernethy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Commercial Officer, Eric Benevich; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Business Development Officer, Kyle W. Gano, Ph.D.; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Medical Officer, Eiry W. Roberts, M.D.(1) </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Roberts joined the Company as our Chief Medical Officer on January&nbsp;8, 2018.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business
Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a company focused on discovering, developing, and commercializing innovative and life-changing pharmaceuticals, in
diseases with high unmet medical needs, through our novel research and development (R&amp;D) platform, focused on neurological and endocrine related diseases and disorders. Utilizing a portfolio approach to drug discovery, we have multiple small
molecule drug candidates at various stages of pharmaceutical development. We develop proprietary pharmaceuticals for our pipeline, as well as collaborate with other pharmaceutical companies on our products and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2017, the United States Food and Drug Administration (FDA) approved
INGREZZA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). We market INGREZZA for TD in the United States (U.S.) through our specialty sales force focused
primarily on physicians who treat TD patients, including psychiatrists and neurologists. The commercial launch of INGREZZA occurred on May&nbsp;1, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;24, 2018, we were notified by AbbVie Inc. (AbbVie) that FDA approval was granted for ORILISSA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (elagolix) for the management of moderate to severe endometriosis pain in women. Discovered and developed through Phase II clinical trials by us, ORILISSA, the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> oral medication for the management of endometriosis with associated moderate to severe pain in over a decade, began to be marketed by AbbVie in August 2018 as part of a collaboration to develop and
commercialize elagolix for women&#146;s health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development programs include opicapone as an adjunctive therapy to
levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#146;s disease patients, elagolix for uterine fibroids partnered with AbbVie, <FONT STYLE="white-space:nowrap">NBI-74788</FONT> for the treatment of congenital adrenal hyperplasia, a
vesicular monoamine transporter 2 inhibitor and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> central nervous system compound each with potential use in the treatment of neurologic and psychiatric
disorders, and two gene therapy programs in which we are partnered with Voyager Therapeutics, Inc. (Voyager) for the treatment of Parkinson&#146;s disease and Friedreich&#146;s ataxia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have several collaborations with other companies. In June 2010, we announced an exclusive worldwide collaboration with AbbVie to
develop and commercialize elagolix and all next-generation gonadotropin-releasing hormone antagonists. In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation for the development and
commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. In February 2017, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology from BIAL&#151;Portela&nbsp;&amp; Ca, S.A. for the development and
commercialization of opicapone for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of human diseases and conditions, including Parkinson&#146;s disease, in the U.S. and Canada. In October 2018, we entered into a research collaboration with Jnana Therapeutics, Inc.
aimed at discovering novel small molecule therapeutics for multiple targets for CNS disorders. In January 2019, we entered into a collaboration and license agreement with a Voyager, clinical-stage gene therapy company. The collaboration is focused
on the development and commercialization of four programs using Voyager&#146;s proprietary gene therapy platforms. The four programs consist of Voyager&#146;s <FONT STYLE="white-space:nowrap">VY-AADC</FONT> program for Parkinson&#146;s disease and <FONT
STYLE="white-space:nowrap">VY-FXN01</FONT> program for Friedreich&#146;s ataxia, as well as rights to two programs to be determined by the parties in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Corporate Performance Highlights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2018 was a year of significant achievement for the Company as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued the successful launch of INGREZZA for the treatment of TD with product revenues of over
$400&nbsp;million in its first full year of commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepared for the submission to the FDA of a New Drug Application for opicapone; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entered into a collaboration with Jnana Therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded early stage pipeline by filing two new Investigational New Drug Applications (INDs) with the FDA; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recorded earnings of $18.1&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pay for Performance/At Risk Pay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officer compensation program is designed to reward achievement of the specific strategic goals that we believe will advance our
business strategy and create long-term value for our stockholders. Consistent with our goal of attracting, motivating and retaining a high-caliber executive team, our executive officer compensation program is designed to pay for performance. We
utilize compensation elements that meaningfully align our NEOs&#146; interests with those of our stockholders to create long-term value. As such, a significant portion of our CEO&#146;s and other executive officers&#146; compensation is <FONT
STYLE="white-space:nowrap">&#147;at-risk,&#148;</FONT> performance-based compensation, in the form of long-term equity awards, and annual cash incentives that are only earned if we achieve multiple corporate metrics. The graphics below illustrate
the elements of our CEO&#146;s compensation mix for 2018 and the aggregate compensation mix for 2018 for the other named executive officers as a group. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g695930g68x09.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Compensation Practices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below are key elements of our compensation program, as well as problematic pay practices that we avoid: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>What We Do</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>What We Don&#146;t Do</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Heavily weight our NEO compensation toward &#147;at risk,&#148;
performance-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B>&#8195;&#8201;Allow for the repricing of stock options without stockholder
approval</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Use multi-year vesting for all executive officer equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B><B>&#8195;&#8201;</B>Pay dividends or dividend equivalents on unearned
shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Have an incentive compensation recoupment or clawback policy</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Structure our executive
officer compensation program to minimize inappropriate risk-taking</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B><B>&#8195;&#8201;</B>Permit hedging or other forms of speculative
transactions by employees or directors, or permit borrowing against our stock by employees or directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;&#8201;</B>Cap annual cash incentives at a maximum payout amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B><B>&#8195;&#8201;&#8201;</B>Provide single-trigger change in control
benefits</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Select peer companies that we compete with for executive officer talent,
have a similar business and are of similar size as us, and review their pay practices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Solicit advice from the Committee&#146;s independent compensation
consultant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Have meaningful stock ownership guidelines for NEOs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B>&#8195;</B>Have three independent <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors serve on the Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in greater detail below, the Compensation Committee of our Board of Directors (the &#147;Committee&#148;) takes into consideration
a peer group, survey data and advice from an independent compensation consultant when setting the compensation philosophy and compensation structure for the Company. The Committee&#146;s complete roles and responsibilities are set forth in a written
charter which was adopted by the Board of Directors and is available at<I></I><I>&nbsp;www.neurocrine.com</I>. Some of the significant roles and responsibilities of the Committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and, if necessary, revising the compensation philosophy of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving corporate goals and objectives relating to the compensation of the Company&#146;s
employees, including executive officers, and evaluating the performance of the Company, and its executive officers, in light of these corporate goals and objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving compensation for all executive officers, including perquisite benefits, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all employment agreements for executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all promotions to executive officer positions and the hiring of all new executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing director compensation by taking into consideration peer group data and advice from an independent
compensation consultant, and making recommendations to the Board of Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving guidelines for salaries, merit salary increases, cash incentive payments, stock-based
grants and performance-based stock grants for all <FONT STYLE="white-space:nowrap">non-executive</FONT> officer employees of the Company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving equity grants to <FONT STYLE="white-space:nowrap">non-employees</FONT> of the Company, if
any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the Board of Directors with regard to amendments or modifications to equity incentive
plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering the Company&#146;s equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and taking into consideration stockholder feedback regarding compensation matters, including our annual
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> vote; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retaining independent compensation consultant and advisors when appropriate to advise the Committee on
compensation policies and plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with requirements established by the SEC, assessing the risks arising from the Company&#146;s
compensation policies and taking any actions required as a result thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing executive officer and director compliance with our Stock Ownership Guidelines; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing and approving the Compensation Discussion and Analysis to be included as part of the Company&#146;s
annual proxy statement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committee Actions in Connection with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT> Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Committee is committed to ensuring
that our executive officer compensation program is effective and aligned with our stockholders&#146; interests and concerns. Accordingly, a critical component of our Committee&#146;s process has been to continue to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review emerging compensation &#147;best practices&#148; in the U.S., with a focus toward companies of similar
size; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit advice from our Committee&#146;s independent compensation consultant. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, we sought an advisory vote from our stockholders regarding our executive officer compensation program and received a 98.2% favorable
vote supporting the program. Each year, the Committee considers the results of the advisory vote as it completes its annual review of each pay element and the compensation provided to our NEOs and other executive officers. Given the significant
level of stockholder support, the Committee concluded that our executive officer compensation program continues to align executive officer pay with stockholder interests and provides competitive pay that encourages retention and effectively
incentivizes performance of talented NEOs and executive officers. Accordingly, the Committee determined not to make any significant changes to our programs as a result of the vote. The Committee will continue to consider the outcome of our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> votes and our stockholders&#146; views when making future compensation decisions for the NEOs and executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Philosophy and Overall Compensation Determination Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that in order to create value for our stockholders, it is critical to attract, motivate and retain key executive officer talent by
providing competitive compensation packages. Accordingly, we design our executive officer compensation programs to attract, motivate and retain executive officers with the skills and expertise to execute our business plans, and reward those
executive officers fairly over time for actions consistent with creating long-term stockholder value. The market for talented individuals in the life sciences industry is highly competitive and becoming more challenging for employers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation philosophy for executive officers provides that cash compensation should be structured such that at least <FONT
STYLE="white-space:nowrap">one-third</FONT> of each executive officer&#146;s total cash compensation, consisting of base salary and target cash incentives, is at risk and dependent upon the Company&#146;s achievement of specific corporate metrics
that drive shareholder value. <FONT STYLE="white-space:nowrap">Non-cash</FONT> long-term equity compensation for executive officers is generally a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination of performance-based and time-based vesting, and is designed to motivate executive officers to increase long-term stockholder value as well as reward and retain key employees. The
Committee believes that this approach provides an appropriate blend of short-term and long-term incentives to maximize stockholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of the compensation philosophy is carried out under the supervision of the Committee. The Committee uses the services of an
independent compensation consultant who is retained by, and reports directly to, the Committee. Management, under guidelines and procedures approved by the Committee, determines the compensation of our
<FONT STYLE="white-space:nowrap">non-executive</FONT> officer employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the early part of each year, the Committee, without the
presence of our Chief Executive Officer, deliberates and makes decisions regarding the base salary, target cash incentives and long-term equity award components of compensation to be awarded to our Chief Executive Officer for the new fiscal year, as
well as performance-based compensation payouts for the prior fiscal year. In setting compensation for our other NEOs, the Committee solicits the input of our Chief Executive Officer, who recommends to the Committee the base salary, target cash
incentives and long-term equity award components of compensation to be awarded to our NEOs for the new fiscal year, as well as performance-based compensation payouts for the prior fiscal year. The Committee remains solely responsible for making the
final decisions on compensation for all of our NEOs. Our NEOs are not present during discussions of their compensation packages nor do they participate in approving any portion of their own or other NEO compensation packages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Executive Officer annually reviews the performance of each NEO (other than himself) and discusses these performance reviews with the
Committee. These recommendations reflect his consideration of the overall performance of the Company, market data prepared by the Committee&#146;s independent compensation consultant, the performance of each NEO, internal pay equity among
individuals (including qualifications and contributions to meeting our corporate objectives), criticality and scope of job function and our Chief Executive Officer&#146;s extensive industry experience. The Committee considers a variety of factors,
as described below, which may vary from year to year, to set the compensation of our NEOs at levels that the Committee considers to be competitive and appropriate for each NEO, using the Committee&#146;s professional experience and judgment: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Market data from the independent compensation consultant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chief Executive Officer&#146;s recommendations (other than for himself) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Independent compensation consultant recommendations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Internal pay equity among individuals and positions </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Criticality and scope of job function </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Retention risk </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Company performance </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Individual performance </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total targeted and historical compensation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other factors the Committee determines appropriate </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of the year, the performance of each executive officer for the prior year and market data are reviewed by the Committee,
and base salary adjustments, cash incentive payouts, following year targets and annual equity grants are discussed and approved. Also, during the first quarter of the year, Company-wide performance goals for the then current year are finalized by
the Committee and the Board of Directors. At <FONT STYLE="white-space:nowrap">mid-year</FONT> meetings, the Committee reviews the Company&#146;s compensation philosophy, policies and procedures. Committee meetings in the fourth quarter of the year
generally focus on Company goal achievement, selection of the peer group for the following year and the structure of executive officer performance reviews. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Consultants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee uses the services of an independent compensation consultant who is retained by, and reports directly to, the Committee to provide
the Committee with an additional external perspective with respect to its evaluation of relevant market and industry practices. The Committee continued to select Radford, an AON Hewitt Company, as a third-party compensation consultant to assist the
Committee in establishing 2018 and 2019 overall compensation levels. Radford conducted analyses and provided advice on, among other things, the appropriate peer group, executive officer compensation for our executive officers and compensation trends
in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In weighing its recommendations for executive officer compensation for the fiscal year 2018, the Committee
directed Radford to advise the Committee on both best practices and peer practices when designing and modifying our compensation program for executive officers in order to achieve our objectives. As part of its duties, Radford provided the Committee
with the following services with respect to 2018 compensation decisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">carried out a comprehensive review of our peer group for use in making 2018 executive officer compensation
decisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provided compensation data for the peer group and relevant executive officer pay survey data and an analysis of
the compensation of the Company&#146;s executive officers as compared to this market data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provided a competitive assessment of, and comparison to, incentive design and executive officer pay program
structure based on peer group data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducted a comprehensive pay for performance assessment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provided recommendations regarding the annual cash incentive and long-term equity incentive program design for
2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisted the Committee with the design of 2018 pay programs consistent with the Company&#146;s business strategy
and pay philosophy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provided background information and data for 2018 adjustments to the Company&#146;s executive officer
compensation program consistent with good governance practices and the Company&#146;s objectives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepared an analysis of the Board&#146;s 2018 compensation program. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee annually assesses whether the work of Radford as a compensation consultant has raised any conflict of interest, taking into
consideration the following factors: (i)&nbsp;the provision of other services, if any, to the Company by Radford; (ii)&nbsp;the amount of fees the Company paid to Radford as a percentage of the firm&#146;s total revenue; (iii)&nbsp;Radford&#146;s
policies and procedures that are designed to prevent conflicts of interest; (iv)&nbsp;any business or personal relationship of Radford or the individual compensation advisors employed by the firm with an executive officer of the Company;
(v)&nbsp;any business or personal relationship of the individual compensation advisors with any member of the Committee and (vi)&nbsp;any stock of the Company owned by Radford or the individual compensation advisors employed by the firm. The
Committee has determined, based on its analysis of the above factors, that the work of Radford and the individual compensation advisors employed by Radford as compensation consultants to the Company have not created any conflict of interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competitive Assessment of Compensation&#151;Peer Group and Market Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2018 Peer Group.</I> When developing a proposed list of our peer group companies to be used in connection with making compensation decisions
for 2018, Radford reexamined our compensation philosophy and peer group and recommended changes to our 2017 peer group company list to reflect our growth, market capitalization and the stage of our commercial development.&nbsp;Radford suggested
biopharmaceutical companies that were primarily recently commercial companies with revenue generally less than $300&nbsp;million, had market values of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately one half (0.5x) to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-and-a-half</FONT></FONT></FONT> (2.5x)&nbsp;our market
capitalization at the time (resulting in a range of between $2&nbsp;billion to $12&nbsp;billion in market capitalization) and had headcounts approximately one half (0.5x) to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">two-and-a-half</FONT></FONT></FONT> (2.5x)&nbsp;our headcount at the time (resulting in a range generally between 200 to 1,000 employees approximately). As a result of the growth in revenue, market capitalization and
headcount that we experienced from when our 2017 peer group was determined, there was a change to the criteria used to determine our 2018 peer group, as compared to the criteria used to determine our 2017 peer group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these criteria, for 2018 Radford recommended, and our Committee approved the following peer group: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">ACADIA Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Agios Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Alnylam Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">bluebird bio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Clovis Oncology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exelixis, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Halozyme Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ionis Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ironwood Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Juno Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nektar Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Portola Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Puma Biotechnology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sarepta Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Seattle Genetics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">TESARO, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Medicines Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ultragenyx Pharmaceutical Inc.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2018 peer group reflects the following changes from our 2017 peer group, all of which were recommended by Radford and
approved by our Committee: (i)&nbsp;the removal of the following company Intercept Pharmaceuticals, Inc., which no longer met the criteria above, (ii)&nbsp;the removal of the following companies due to such companies being acquired since the 2017
peer group had been approved: ARIAD Pharmaceuticals, Inc. and Kite Pharma, Inc., and (iii)&nbsp;the addition of the following companies, which met the criteria above: Clovis Oncology, Inc., Halozyme Therapeutics, Inc. and Portola Pharmaceuticals,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining executive officer compensation for 2018, the Committee reviewed data from this group of peer companies.&nbsp;At the
time of approval of our 2018 peer group, our Company was approximately in the 66<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the peer group for market capitalization, in the
8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the peer group for revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In early 2018, Radford completed an
assessment of executive officer compensation based on the 2018 peer group to inform the Committee&#146;s determinations of executive officer compensation for 2018. The data for this assessment was compiled from multiple sources, including:
(i)&nbsp;the 2018 peer group companies&#146; publicly disclosed information, or public peer data and (ii)&nbsp;data from public biotechnology and pharmaceutical companies in the Radford Global Life Sciences Survey that had market values between
$2&nbsp;billion and $12&nbsp;billion or the general survey data. The components of this data were based on the availability of sufficient comparative data for an executive officer&#146;s position. The general survey data and the public peer data,
collectively referred to in this proxy statement together as market data, were reviewed by the Committee, with the assistance of Radford, and used as one reference point, in addition to other factors, in setting our executive officers&#146;
compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee generally reviews target total direct compensation, comprising both target cash compensation and equity
compensation, against the market data described above primarily to ensure that our executive officer compensation program as a whole is positioned competitively to attract and retain the highest caliber executive officers and that the total direct
compensation opportunity for the executive officer group is aligned with our corporate objectives and strategic needs.&nbsp;The Committee does not have a specific target compensation level for the NEOs; rather, the Committee reviews a range of
market data reference points (generally at the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;percentiles
of the market data) with respect to target total direct compensation, target total cash compensation (including both base salary and the target annual cash incentive) and equity compensation (valued based on an approximation of grant date fair
value). In making compensation determinations, the Committee considers the market data, along with the other factors described above under &#147;Compensation Philosophy and Overall Compensation Determination Process&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2019 Peer Group. </I>In November 2018, when developing a proposed list of our peer group companies to be used in connection with making
compensation decisions for 2019, Radford selected primarily recently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial or commercial biopharmaceutical companies with revenue generally between $200&nbsp;million and $1.5&nbsp;billion, market capitalization between $4&nbsp;billion to $25&nbsp;billion and
employee headcounts up to 2,000, reflecting our growth in revenue, market capitalization and headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these criteria, for 2019
Radford recommended, and our Committee approved the following peer group: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Agios Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Alexion Pharmaceuticals, Inc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Alkermes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Alnylam Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BeiGene</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BioMarin Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">bluebird bio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Exelixis, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Incyte Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Ionis Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Intercept Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jazz Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Nektar Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sage Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sarepta Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Seattle Genetics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ultragenyx Pharmaceutical Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">United Therapeutics Corporation</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2019 peer group reflects the following changes from our 2018 peer group, all of which were recommended by Radford and
approved by our Committee: (i)&nbsp;the removal of the following companies ACADIA Pharmaceuticals, Inc., Clovis Oncology, Inc., Halozyme Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Juno Therapeutics, Inc., Portola Pharmaceuticals, Inc., Puma
Biotechnology, Inc., TESARO, Inc. and The Medicines Company, which no longer meet the criteria above or were acquired since the 2018 peer group had been approved and (ii)&nbsp;the addition of the following companies, which met the criteria above:
Alexion Pharmaceuticals, Inc., Alkermes, BeiGene, BioMarin Pharmaceuticals, Inc., Incyte Corporation, Intercept Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Sage Therapeutics, Inc., and United Therapeutics Corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Executive Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Committee considers each executive officer&#146;s performance, contribution to Company goals, responsibilities, experience, qualifications, and where in the competitive range the executive officer&#146;s compensation compares to the Company&#146;s
identified peer group when determining the appropriate compensation for each executive officer. The Committee considers each component of compensation independently and each component in the context of each executive officer&#146;s total
compensation. Compensation for our NEOs currently consists of three key elements that are designed to reward performance in a simple and straightforward manner: base salaries, annual performance-based cash incentives and long-term equity awards,
which generally include restricted stock unit awards (&#147;RSUs&#148;) and stock options, which both vest based on continued service over time, and in some years include performance restricted stock units (&#147;PRSUs&#148;), which vest upon
achievement of key corporate metrics that we believe will create shareholder value. The purpose and key characteristics of each of these elements are summarized below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Base Salary</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Designed to compensate competitively at levels necessary to attract and retain qualified executive officers in the life sciences industry; generally based on the scope of each executive officer&#146;s responsibilities, as well as
his/her qualifications, breadth of experience, performance record and depth of applicable functional expertise; established and adjusted to be appropriate as compared to the applicable market data, enabling the Company to attract, motivate, reward
and retain</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fixed compensation where <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> adjustments to each executive officer&#146;s base salary are based upon sustained superior performance, changes in
the general level of base salaries of persons in comparable positions within our industry, and any average merit salary increase for such year for all employees of the Company established by the Committee, as well as other factors the Committee
judges to be pertinent during an assessment period.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">highly skilled executive officers; gives executive officers a degree of certainty in light of having a majority of their compensation at risk.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In making base salary decisions, the Committee exercises its judgment
to determine the appropriate weight to be given to each of these factors. Adjustments may also be made during the fiscal year for promotions, highly urgent retention reasons, superior performance in response to changed or challenging circumstances,
and similar special circumstances.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Annual Cash Incentives</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Motivates executive officers to achieve our short-term strategic plan and milestones that are designed to drive long-term growth and performance while providing flexibility to respond to opportunities and changing market
conditions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual cash award opportunity based on corporate performance compared to <FONT STYLE="white-space:nowrap">pre-established</FONT> corporate
goals with <FONT STYLE="white-space:nowrap">pre-established</FONT> target and maximum payout opportunities for each executive officer.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The cash incentive program, including corporate goals and target payouts, are reviewed and approved by the Committee annually and may include individual
performance targets for each executive officer. The corporate goals are prepared in an interactive process between management and the Board of Directors based on the Company&#146;s business plan and budget for the year. Cash incentive payments are
linked to the attainment of overall corporate goals and may include individual performance targets for each executive officer, or other factors the Committee determines appropriate.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Term Equity</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Incentives
(RSUs)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Motivates executive officers to achieve our business objectives by tying compensation to the performance of our common stock over the long term; creates an ownership culture; motivates our executive officers to remain with the
Company by mitigating swings in incentive values during periods when market volatility impacts our stock price; directly motivates an executive officer to maximize long-term stockholder value and serve as an</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RSUs generally vest on an annual basis, ratably over four years subject to executive officer&#146;s continued service; the ultimate value realized varies with our common stock
price.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">effective tool for incentivizing and retaining those executive officers who are most responsible for influencing stockholder value.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Term Equity</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Incentives (Stock
Options)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Motivates executive officers to achieve our business objectives by tying incentives to the appreciation of our common stock over the long-term and creates an ownership culture.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock options with an exercise price equal to the fair market value on the date of grant generally vesting monthly over four years subject to executive officer&#146;s continued service; the ultimate realizable value, if any, depends
on the appreciation of our common stock price from the date of grant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Term Equity</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Incentives
(PRSUs)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Creates a strong link to the Company&#146;s long-term performance, creates an ownership culture and closely aligns the interests of our executive officers with those of our stockholders because the value that the grants deliver are
directly dependent on our performance goal attainment.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PRSUs only vest upon achievement of objectively measurable performance goals tied to our business strategy that focus executive officers on achieving these long-term Company performance goals and increasing stockholder
value.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Other Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Provides benefits that promote employee health and welfare, which assists in attracting and retaining our executive officers; certain additional benefits reflect market standards and are reasonable and necessary to attract and/or
retain each of our executive officers and allow the executive officers to realize the full benefit of the other elements of compensation we provide.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive officers are eligible to participate in the Company&#146;s employee benefit plans on the same terms as all other full-time
employees. These plans include medical, dental and life insurance and eligibility to participate in the Company&#146;s employee stock purchase plan. Additional benefits include disability insurance premiums, an annual physical examination and
financial planning services.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The terms of the Company&#146;s 401(k) Savings Plan
(the &#147;401(k) Plan&#148;) provide for executive officer and broad-based employee participation on the same general terms. Under the 401(k) Plan, all Company employees are eligible to receive basic matching contributions from the Company that
vest annually over three years from date of hire.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Severance and Change in Control Benefits</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Serves our retention objectives by helping our NEOs maintain continued focus and dedication to their responsibilities to maximize</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Provides protection in the event of a termination of employment under specified circumstances, including following a change in control of the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">stockholder value, including in the event of a transaction that could result in a change in control of the Company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company as described below under &#147;Potential Payments Upon Termination or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control&#148;.</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation components for executive officers in
the event of a termination by the Company without cause or termination by the executive officer due to constructive termination within six months after the consummation of a change in control include payments for accrued annual base salary, a cash
compensation payment, cash compensation for the value of all outstanding stock awards, limited Company-paid health insurance benefits, and any accrued vacation and any accrued benefits under any plans of the Company in which the executive officer is
a participant. Eligibility for these benefits requires a signed release agreement by the executive officer.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Certain individuals whose offer letters were entered into in or before 2007, including Dr.&nbsp;Gorman, are entitled to tax
<FONT STYLE="white-space:nowrap">gross-ups</FONT> in the event of certain levels of payments they may receive upon a change in control. We have not entered into any new change in control <FONT STYLE="white-space:nowrap">gross-ups</FONT> for
executive officers since 2007, nor does the Company intend to enter into any new agreements containing such <FONT STYLE="white-space:nowrap">gross-ups.</FONT> Accordingly, Mr.&nbsp;Benevich&#146;s, Mr.&nbsp;Abernethy&#146;s, Dr.&nbsp;Gano&#146;s and
Dr.&nbsp;Roberts&#146; employment agreements do not provide for such tax <FONT STYLE="white-space:nowrap">gross-ups.</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Executive Officer Compensation Decisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, our
Committee reviewed and determined the 2018 base salaries for each of the NEOs as set forth in the table below, except for Mr.&nbsp;Abernethy&#146;s and Dr.&nbsp;Roberts&#146; base salary, which the Committee determined in connection with the
commencement with Mr.&nbsp;Abernethy&#146;s employment in the fourth quarter of 2017 and the commencement of Dr.&nbsp;Roberts&#146; employment in the first quarter of 2018, respectively. In making these 2018 decisions, the Committee considered the
market data for each individual NEO&#146;s position, as well as the individual&#146;s historical salary levels (if applicable), our then-current budget for employee salary adjustments, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anticipated role and responsibilities for the coming year, along with the other factors described under &#147;Compensation Philosophy and Overall Compensation Determination Process&#148; set
forth above. The changes also take into account the adjustments made to our peer group for 2018 as a result of our growth in revenue, market capitalization and headcount since late 2016 when our 2017 peer group was determined. Although the Committee
does not have a specific target compensation level for each NEO, the NEOs&#146; salaries are generally within the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> to 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles of
the market data. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018<BR>Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change<BR>from&nbsp;2017&nbsp;Base<BR>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">432,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">403,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">520,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Cash Incentives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the Committee approved the Company&#146;s executive officer cash incentive target percentages and performance goals for 2018,
with the exception of Dr.&nbsp;Roberts&#146; percentage, which the Committee determined in connection with her commencement of employment with us in January 2018. The table below sets forth the targets for our Chief Executive Officer and other NEOs
for 2018. No changes were made to the target percentages of our NEOs who were employed with us in 2017. The target percentage is paid as a percentage of such executive officer&#146;s base salary. For example, if 100% of the Company&#146;s
performance goals are achieved for 2018, this would yield our Chief Executive Officer a cash incentive award of 70% of his 2018 base salary. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<BR>Percentage&nbsp;of<BR>Base Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Executive Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In early 2018, the Committee established the corporate goals described below. Our objective corporate goals
are directly aligned with our specific strategic goals, including advancing our development programs, our research function, our clinical activities, commercialization activities and certain corporate and financial goals, which we believe will
create long-term value for stockholders. The Board of Directors and the Committee did not assign specific relative weightings to the goals for 2018. The maximum corporate achievement for 2018 was 120% of our 2018 corporate goals. In February 2019,
the Committee evaluated the accomplishments and performance of the Company against such corporate goals. After its consideration of the Company&#146;s performance, as more specifically described below, the Committee rated our 2018 corporate
achievement at 90% of our 2018 corporate goals. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Corporate Goal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Corporate Achievement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maximize the medical and economic impact of
INGREZZA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Partial&nbsp;Achievement</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enter into collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Achieved</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expand internal clinical pipeline</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Achieved</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepare for 2019 NDA for opicapone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Achieved</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, after making these determinations regarding level of corporate performance achieved against
the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, the Committee reviewed and approved corporate cash incentives as set forth in the table below. The Committee may, in its sole discretion, eliminate any individual cash
incentive or reduce or increase the amount of compensation payable with respect to any individual cash incentive. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee exercised its discretion to increase the amount of individual cash incentives with respect to Mr.&nbsp;Abernethy, Mr.&nbsp;Benevich and Dr.&nbsp;Gano for 2018 by paying their cash
incentives at the rates noted below, rather than 90%, due to their significant individual performances related to the achievement of the corporate goals and their individual goals. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018&nbsp;Target&nbsp;Annual&nbsp;Cash<BR>Incentive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018&nbsp;Actual&nbsp;Annual&nbsp;Cash Incentive&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Target&nbsp;Annual&nbsp;Cash<BR>Incentive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">425,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">245,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Roberts&#146; award was <FONT STYLE="white-space:nowrap">pro-rated</FONT> due to her commencement of
employment with us in January 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-Term Equity Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Size of Equity Awards</I>. In determining the size of the total equity compensation opportunity in 2018, the Committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aimed to have the aggregate target award value result in target total direct compensation at a level that is
competitive in the marketplaces in which we compete; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">focused a larger portion of total direct compensation in the form of long-term and performance-based equity
awards intended to drive long-term differentiated value relative to our peers and maximize long-term stockholder value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aimed to structure a substantial portion of equity opportunity in the form of awards that vest based on
achievement of performance goals to better align our executive officers&#146; long-term compensation opportunity with our stockholders&#146; interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considered the recommendations of Dr.&nbsp;Gorman for the other NEOs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Award Mix</I>. The Committee determined that the equity awards granted to the NEOs on February&nbsp;5, 2018 should consist of stock
options, time-vesting RSU grants and performance-vesting RSU grants, or PRSUs, as set forth in the table below. The Committee determined these three types of equity awards provided the appropriate balance of long-term incentives for our executive
officers. Specifically, PRSUs that vest based on objectively measurable performance goals focus executive officers on achieving longer-term Company performance goals that are key to our business strategy and increasing stockholder value and RSUs
that vest over time provide tangible value to executive officers and serve as an incentive and retention tool during a difficult operating or volatile business environment, while still being tied to our stockholder value. It is the Committee&#146;s
view that stock options are inherently performance oriented because the executive officer realizes no value from stock options unless and until the Company&#146;s stock price increases over the strike price. The Committee believes it is important to
evaluate the equity award mix each year to determine what types of equity awards should be granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In setting the mix of the three types
of equity awards for 2018, the Committee determined that a substantial portion of the equity grants should consist of awards that vest based on our performance (in the form of specific and measurable performance goals), in addition to continued
service over time. The mix between the three types of awards was determined based on market data of the equity award practices of peer group companies provided by the Committee&#146;s consultant. Accordingly, the Committee structured the mix of
equity such that the baseline award of options and RSUs would generally deliver value, as determined by the Black-Scholes value of stock options and the value of RSUs as if they were fully vested, to NEOs between approximately the 75th and 90th
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percentiles of the market data with PRSUs providing the opportunity for above-market compensation if earned. The opportunity for higher performance-based compensation opportunity reflects our
commitment to pay for performance, with compensation above the median of our peers for exceptional performance and compensation below this level if our performance goals are not reached. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSU&#151;Time&nbsp;Vesting</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PRSU&#151;Performance-<BR>based Vesting</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy (1) (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D. (2) (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Abernethy received grants in connection with his employment with us in fourth quarter 2017, and thus
was only awarded PRSUs in early 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Abernethy and Dr.&nbsp;Roberts received a grant of 12,250 and 18,400 PRSUs, respectively, in
February&nbsp;5, 2018 to align them with the PRSU grant that was made to the other executive officers in February 2016. The performance criteria for such PRSU grants remains the same as the February 2016 PRSU grant in that such PRSUs vest upon:
(i)&nbsp;obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine as determined by the Committee and (ii)&nbsp;the FDA&#146;s acceptance of our NDA submission of valbenazine for the treatment of Tourette
syndrome. Additionally, these PRSUs have a limited term until February&nbsp;5, 2020 for us to achieve the objectives required for vesting. The individual PRSUs either fully vest upon completion of the corporate objectives by February&nbsp;5, 2020 or
never vest. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Gano received a <FONT STYLE="white-space:nowrap">one-time</FONT> RSU award of 15,000 shares in
recognition of his contributions over time to us, including being the primary inventor of the valbenazine molecule. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Roberts received stock option and RSU grants in connection with her commencement of employment with
us, as further described under &#147;New Hire Awards&#148; below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2018 Award Vesting Criteria</I>. The Committee, in
consultation with the independent members of the Board of Directors, determined with respect to the February&nbsp;5, 2018 equity grants that the use of both stock options which vest monthly, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT>
basis, over a four-year period and RSUs which vest annually, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period were the appropriate time-vesting equity compensation vehicles to use in combination with the PRSU
awards. The Committee and Board of Directors believe that these long-term equity based compensation awards closely align stockholder and management interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee also carefully set the PRSU award goals to be rigorous and ultimately serve to align management and our stockholders&#146;
interests. A portion of the 2018 PRSUs will vest upon FDA approval of opicapone within a specified time period, and a portion of the 2018 PRSUs will vest upon achievement of specified revenue milestones within a specified time period. If the vesting
criteria are achieved, we believe significant stockholder value will be created. Additionally, these PRSUs have a limited term until March&nbsp;15, 2021 for us to achieve the objectives required for vesting. The individual PRSUs either fully vest
upon completion of the corporate objectives by March&nbsp;15, 2021 or never vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>New Hire Awards</I>. In connection with her
commencement of employment, on January&nbsp;8, 2018, Dr.&nbsp;Roberts was granted: (i)&nbsp;an initial stock option to purchase up to 70,000 shares of the Company&#146;s common stock, 25% of which will vest on the first anniversary of the grant
date, and the remainder of which will vest in equal monthly installments thereafter over three years and (ii)&nbsp;an RSU award covering 20,000 shares of the Company&#146;s common stock which vests in equal annual installments over four years, which
has generally been the vesting schedule for all new hire grants. The Committee and Board of Directors structures the vesting schedules for new hire awards in order to serve as an effective tool for incentivizing and retaining our NEOs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s matching contribution to the 401(k) Plan for 2018 was 50% of eligible participant contributions, subject to applicable
federal limits. Our NEOs are eligible for these benefits on the same basis as our other employees. The Company made no additional discretionary contributions to the 401(k) Plan in 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Ownership Guidelines </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
2014, we have maintained equity ownership guidelines for our executive officers. The Committee amended these guidelines in November 2018 to increase the guideline for our Chief Executive Officer from three to six times his base salary. The equity
ownership guidelines are designed to further align the interests of the executive officers with those of our stockholders by ensuring that our executive officers have a meaningful financial stake in the Company&#146;s long-term success. The equity
ownership guidelines establish a minimum equity ownership level by position, with such values determined based on the value of our common stock owned by such persons as of certain measurement dates. All shares directly or beneficially owned by the
executive officer, including the net exercisable value of outstanding vested stock options (where the market price of our common stock exceeds the strike price of such option) are included in determining the value of equity owned under our equity
ownership guidelines. The equity ownership requirements are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;times&nbsp;base&nbsp;salary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other executive officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;times&nbsp;base&nbsp;salary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New executive officers are granted a five-year period to reach the equity ownership requirements set forth in
the guidelines and are expected to make annual progress toward the equity ownership requirements during this five-year period. When an executive officer does not meet the equity ownership requirements set forth in the guidelines, he/she is
restricted from selling any held shares until such requirements are met. Additionally, should an executive officer who does not meet the equity ownership requirements choose to exercise a stock option or vest in any RSUs, he or she is required to
retain all shares acquired through those transactions, aside from any shares necessary to fulfill such transaction related tax obligations, until full compliance with the equity ownership guidelines is attained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual compliance with the equity ownership guidelines is assessed during the first quarter of each year. As of March&nbsp;1, 2019, each of
our executive officers is in compliance with the equity ownership guidelines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Trading Policies and Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has policies and procedures to prohibit direct or indirect participation by employees of the Company in transactions involving
trading activities in Company common stock which by their aggressive or speculative nature may give rise to an appearance of impropriety. Such prohibited activities would include the purchase of put or call options, or the writing of such options as
well as short sales, hedging transactions such as &#147;cashless&#148; collars, forward sales, equity swaps and other related arrangement which may indirectly involve short-sale and any other transactions designed for profit from short-term movement
in the Company&#146;s stock price. In addition, no officer, director or employee of the Company may margin, or make any offer to margin, any Company common stock, including without limitation, borrowing against such stock, at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the Company&#146;s knowledge, there were no transactions involving hedging, pledging or margining Company common stock during 2018, nor
were there any such transactions as of the Record Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also requires directors and executive officers to complete all equity
related open-market purchase and sale transactions via a <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan. The <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans typically cover, among other transactions, direct sales and purchases of Company
stock, as well as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">same-day-sales</FONT></FONT> related to option exercises and sales of stock for tax payments upon the vesting of restricted stock units. All <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plans are required to have a waiting period from the election date to the date of the first transaction. Additionally, Company policy restricts the executive officers from making certain changes to <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plan subsequent to adoption of the plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Recoupment Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, we adopted a clawback policy, even though the SEC has not yet issued final rules implementing the Dodd-Frank Wall Street
Reform and Consumer Protection Act requirement. Our policy currently provides that, in the event that (i)&nbsp;we are required to prepare an accounting restatement for any fiscal quarter or year due to our material noncompliance with any financial
reporting requirement and (ii)&nbsp;it is determined that misconduct contributed to the noncompliance that resulted in the obligation to restate our financial statements, we may take action to recover from any officer whose misconduct contributed to
the noncompliance which resulted in the obligation to restate our financial statements, the incentive compensation that was paid or vested to such officer during the twelve-month period preceding the restatement obligation. We will also comply with
the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and will modify our policy to the extent required by law once the SEC adopts final regulations on the subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Named Executive Officer Compensation Decisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, our
Committee reviewed and determined the 2019 base salaries and target cash bonus for each of the NEOs as set forth in the table below. In making these 2019 decisions, the Committee considered the market data for each individual NEO&#146;s position, as
well as the individual&#146;s historical salary levels, our then-current budget for employee salary adjustments, anticipated role and responsibilities for the coming year, along with the other factors described under &#147;Compensation Philosophy
and Overall Compensation Determination Process&#148; set forth above. Although the Committee does not have a specific target compensation level for each NEO, the NEOs&#146; salaries are generally within the 25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> to 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles of the market data. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019<BR>Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019&nbsp;Target<BR>Percentage&nbsp;of<BR>Base Salary</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">725,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">495,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">467,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">443,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">538,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-Term Equity Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, our Committee approved a grant of options and RSUs to each of the NEOs as set forth in the table below. The stock options
vest monthly, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period and the RSUs vest annually, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period.<B> </B>The Committee determined that
these two types of equity awards provided the appropriate balance of long-term incentives for our executive officers. The mix between the two types of awards was determined based on market data of the equity award practices of peer group companies
provided by the Committee&#146;s consultant. Accordingly, the Committee structured the mix of equity such that the baseline award of options and RSUs would generally deliver value, as determined by the Black-Scholes value of stock options and the
value of RSUs as if they were fully vested, to NEOs between approximately the 75th and 90th percentiles of our peer group. The opportunity for higher performance-based compensation opportunity reflects our commitment to pay for performance, with
compensation above the median of our peers for exceptional performance and compensation below this level if our performance goals are not reached. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Named Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSU&#151;Time&nbsp;Vesting</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Internal Revenue Code Section&nbsp;162(m) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;162(m) of the Internal Revenue Code (&#147;Section&nbsp;162(m)&#148;), compensation paid to any publicly held
corporation&#146;s &#147;covered employees&#148; that exceeds $1&nbsp;million per taxable year for any covered employee is generally <FONT STYLE="white-space:nowrap">non-deductible.</FONT> Prior to the enactment of the Tax Cuts and Jobs Act,
Section&nbsp;162(m) provided a performance-based compensation exception, pursuant to which the deduction limit under Section&nbsp;162(m) did not apply to any compensation that qualified as &#147;performance-based compensation&#148; under
Section&nbsp;162(m). Pursuant to the Tax Cuts and Jobs Act, the performance-based compensation exception under Section&nbsp;162(m) was repealed with respect to taxable years beginning after December 31, 2017, except that certain transition relief is
provided for compensation paid pursuant to a written binding contract which was in effect on November 2, 2017 and which is not modified in any material respect on or after such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation paid to each of the Company&#146;s &#147;covered employees&#148; in excess of $1&nbsp;million per taxable year generally will not
be deductible unless it qualifies for the performance-based compensation exception under Section&nbsp;162(m) pursuant to the transition relief described above. Because of certain ambiguities and uncertainties as to the application and interpretation
of Section&nbsp;162(m), as well as other factors beyond the control of the Committee, no assurance can be given that any compensation paid by the Company will be eligible for such transition relief and be deductible by the Company in the future.
Although the Committee will continue to consider tax implications as one factor in determining executive officer compensation, the Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for
the Company&#146;s NEOs in a manner consistent with the goals of the Company&#146;s executive officer compensation program and the best interests of the Company and its stockholders, which may include providing for compensation that is not
deductible by the Company due to the deduction limit under Section&nbsp;162(m). The Committee also retains the flexibility to modify compensation that was initially intended to be exempt from the deduction limit under Section&nbsp;162(m) if it
determines that such modifications are consistent with the Company&#146;s business needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Internal Revenue Code Section&nbsp;409A </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;409A governs deferred compensation arrangements. The Committee structures our deferred compensation programs with the assistance
of our external counsel to be exempt from, or compliant with, Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for equity compensation paid to our employees under the FASB ASC Topic 718, which requires us to estimate and record an
expense over the service period of the equity award. Our cash compensation is recorded as an expense at the time the obligation is incurred. The accounting impact of our compensation programs are one of many factors that the Committee considers in
determining the structure and size of our executive officer compensation programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risk Analysis of Our Compensation Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage
excessive or inappropriate risk taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on the Company. As part of its assessment, the Committee considered, among other factors, the
allocation of compensation among base salary and short- and long-term compensation, our approach to establishing Company-wide and individual financial, operational and other performance targets, our bonus structure of payouts at multiple levels of
performance (including maximum payout caps and payments for performance below target levels) and the nature of our key performance metrics. We believe these practices encourage our employees to focus on sustained, long-term Company growth, which we
believe will ultimately contribute to the creation of stockholder value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE COMPENSATION AND OTHER INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Summary Compensation Table</I></B>&nbsp;The following table sets forth the compensation paid by the Company for the fiscal years ended
December&nbsp;31, 2016, 2017 and 2018 to the NEOs named below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All<BR>Other<BR>Compensation<BR>($)&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">592,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">337,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,202,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,114,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,289,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">515,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,929,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,556,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">675,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">425,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,486,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,632,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">920,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">394,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,789,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,996,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,685,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">376,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">831,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,490,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,977,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">432,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,496,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,672,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">345,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">734,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,014,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,254,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Business Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">328,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,350,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">403,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,656,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,568,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">490,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">220,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,863,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,053,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">671,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,300,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The titles and capacities set forth in the table above are as of March&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Salary and bonus figures represent amounts earned during each respective fiscal year, regardless of whether
part or all of such amounts were paid in subsequent fiscal year(s). Bonuses are awarded pursuant to a bonus program. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown are the full grant date fair value in accordance with Accounting Standards Codification <FONT
STYLE="white-space:nowrap">718-10,</FONT> Compensation&#151;Stock Compensation (ASC 718). The assumptions used to calculate the grant date fair value of stock awards are set forth under Note 8 of the Notes to the Consolidated Financial Statements
included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 filed with the SEC on February&nbsp;8, 2019. The grant date fair values of option awards for 2016, 2017 and
2018 (other than Mr.&nbsp;Abernethy&#146;s 2017 option award and Dr.&nbsp;Roberts&#146; new hire award) are based on per share Black-Scholes values of $20.19, $23.77 and $43.06, respectively. Mr.&nbsp;Abernethy&#146;s 2017 option awards are based on
per share Black-Scholes value of $40.28 and Dr.&nbsp;Roberts&#146; new hire option awards are based on per share Black-Scholes value of $40.91. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown are the full grant date fair value in accordance with Accounting Standards Codification <FONT
STYLE="white-space:nowrap">718-10,</FONT> Compensation&#151;Stock Compensation (ASC 718). The assumptions used to calculate the grant date fair value of stock awards are set forth under Note 8 of the Notes to the Consolidated Financial Statements
included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 filed with the SEC on February&nbsp;8, 2019. The fair values of restricted stock units granted in 2016, 2017
and 2018 are based on the Company&#146;s closing market price per share on the grant date, which was $35.99 for all 2016 grants, which was $43.24 for all 2017 grants (other than Mr.&nbsp;Abernethy&#146;s grant, for which it was $73.60) and which was
$81.49 for all 2018 grants (other than Dr.&nbsp;Roberts&#146; new hire grant, for which it was $77.81). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes all other compensation as described in the table below. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>All Other Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>401(k)<BR>Employer<BR>Match</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Insurance<BR>Premiums&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Inducement<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Relocation<BR>Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Other</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">394,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 26,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle. W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">402,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">671,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the costs for medical insurance for Company-wide plans, as well as
disability insurance premiums and related tax <FONT STYLE="white-space:nowrap">gross-up</FONT> amounts. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Plan-Based
Awards During the Fiscal Year Ended December&nbsp;31, 2018 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding plan based-awards granted
by the Company during the year ended December&nbsp;31, 2018 to the NEOs below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future<BR>Payouts Under<BR>Equity Incentive<BR>Plan Awards<BR>Target(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Stock&nbsp;Awards:<BR>Number&nbsp;of<BR>Shares of</B><br><B>Stock or&nbsp;Units<BR>(#) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Option<BR>Awards:&nbsp;Number<BR>of Securities<BR>Underlying<BR>Options (#) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;or&nbsp;Base<BR>Price&nbsp;of&nbsp;Awards<BR>($/Sh) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair&nbsp;Value&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,486,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Matthew C. Abernethy.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,496,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,309,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Eiry W. Roberts, M.D..</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,556,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">998,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,863,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents the target number of shares that may be earned under the PRSUs granted to NEOs in 2018 under the
Company&#146;s 2011 Plan. The PRSUs did not include threshold or maximum award amounts. The PRSUs vest upon the following: (i)&nbsp;a portion of each grant shall vest automatically on the date the FDA approves the NDA for opicapone within a
specified period of time; and (ii)&nbsp;a portion of each grant shall vest upon the achievement of specified revenue </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
milestones within a specified time period. These PRSUs either fully vest upon the completion of the above criteria by March&nbsp;15, 2021 or never vest. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">All options and restricted stock units were granted and approved on the same date with option awards having an
exercise price equal to the closing market price of the Company&#146;s common stock on the date of grant. All option awards are time-based awards, which vest monthly, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over four years and
have an option term of ten years. These restricted stock units vest annually, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Reflects the grant date per share Black-Scholes value of $43.06 for option awards and the grant date per share
value of $81.49 for restricted stock units, each granted on February&nbsp;5, 2018 (other than with respect to Dr.&nbsp;Roberts&#146; new hire equity awards) which was calculated in accordance with ASC 718. The grant date per share Black-Scholes
value for Dr.&nbsp;Roberts&#146; new hire option awards and restricted stock units was $40.91 and $77.81, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents additional PRSU grant made to Mr.&nbsp;Abernethy and Dr.&nbsp;Roberts, which grant was made on
February&nbsp;5, 2018 and was made to align with the PRSU grant that was made to the other executive officers in February 2016. The performance criteria for such grant remains the same as the February 2016 PRSU grant in that such PRSUs vest upon:
(i)&nbsp;obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine as determined by the Committee and (ii)&nbsp;the FDA&#146;s acceptance of our NDA submission of valbenazine for the treatment of Tourette
syndrome. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kevin C. Gorman,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B> has an employment contract that provides that: (i)&nbsp;Dr.&nbsp;Gorman
will serve as the Company&#146;s Executive Vice President and Chief Operating Officer commencing on August&nbsp;1, 2007 at an initial annual salary of $400,000, subject to annual adjustment by the Board of Directors (subsequent to entering into the
employment contract, Dr.&nbsp;Gorman became Chief Executive Officer and his annual base salary for 2018 is $675,000); (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive
termination or voluntary resignation; (iii)&nbsp;Dr.&nbsp;Gorman is eligible for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;each year starting in 2007 and
continuing for the term of the agreement, Dr.&nbsp;Gorman will be eligible to receive equity awards with the number of&nbsp;shares, vesting terms, and exercise price as shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew C. Abernethy</I></B> has an employment contract that provides that: (i)&nbsp;Mr.&nbsp;Abernethy will be entitled to receive an
initial base salary of $420,000 per year, which was his base salary for 2018, subject to future adjustments; (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive termination or
voluntary resignation; (iii)&nbsp;Mr.&nbsp;Abernethy is eligible for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; (iv)&nbsp;Mr.&nbsp;Abernethy is eligible to receive equity
awards with the number of&nbsp;shares, vesting terms, and exercise price as shall be determined by the Board of Directors; (v)&nbsp;Mr.&nbsp;Abernethy received a <FONT STYLE="white-space:nowrap">one-time</FONT> cash inducement advance in the amount
of $180,000, which will be deemed earned when Mr.&nbsp;Abernethy completes two full years of employment with the Company; and (vi)&nbsp;Mr.&nbsp;Abernethy received relocation benefits, including a <FONT STYLE="white-space:nowrap">one-time</FONT>
cash relocation advance in the amount of $140,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eric Benevich</I></B> has an employment contract that provides that:
(i)&nbsp;Mr.&nbsp;Benevich will serve as the Company&#146;s Chief Commercial Officer commencing on May&nbsp;26, 2015 at an initial annual salary of $365,000, subject to annual adjustment by the Board of Directors (Mr.&nbsp;Benevich&#146;s annual
base salary for 2018 is $432,600); (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation; (iii)&nbsp;Mr.&nbsp;Benevich is eligible for a
discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;Mr.&nbsp;Benevich is eligible to receive stock option awards with the equity awards with the number of&nbsp;shares,
vesting terms, and exercise price as shall be determined by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kyle W. Gano, Ph.D.</I></B> has an employment
contract that provides that: (i)&nbsp;Dr.&nbsp;Gano will serve as the Company&#146;s Chief Business Development Officer commencing on November&nbsp;12, 2014 at an initial annual salary of $310,000, subject to annual adjustment by the Board of
Directors (Dr.&nbsp;Gano&#146;s annual base salary for 2018 is $403,100); (ii) the agreement terminates upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation;
(iii)&nbsp;Dr.&nbsp;Gano is eligible for a discretionary annual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;Dr.&nbsp;Gano is eligible to receive stock option awards with the equity awards
with the number of shares, vesting terms, and exercise price as shall be determined by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eiry W. Roberts,
M.D. </I></B>has an employment contract that provides that: (i)&nbsp;Dr.&nbsp;Roberts will serve as the Company&#146;s Chief Medical Officer commencing on January&nbsp;8, 2018 at an initial annual salary of $520,000, subject to annual adjustment by
the Board of Directors; (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation; (iii)&nbsp;Dr.&nbsp;Roberts is eligible for a discretionary
annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; (iv)&nbsp;Dr.&nbsp;Roberts is eligible to receive stock option awards with the equity awards with the number of shares, vesting terms, and
exercise price as shall be determined by the Board of Directors, (v)&nbsp;Dr.&nbsp;Roberts received a <FONT STYLE="white-space:nowrap">one-time</FONT> cash inducement advance in the amount of $225,000, which will be deemed earned when
Dr.&nbsp;Roberts completes two full years of employment with the Company; and (vi)&nbsp;Dr.&nbsp;Roberts received relocation benefits, including a <FONT STYLE="white-space:nowrap">one-time</FONT> cash relocation advance in the amount of $220,000.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End.</FONT></I></B>&nbsp;The following table sets forth the outstanding
equity awards held by the NEOs at December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Award<BR>Grant and<BR>Commencement<BR>of Vesting Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Shares<BR>or&nbsp;Units<BR>of<BR>Stock<BR>That<BR>Have<BR>Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares<BR>or Units<BR>of&nbsp;Stock<BR>That<BR>Have&nbsp;Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market&nbsp;or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other<BR>Rights<BR>That<BR>Have
Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/12/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/12/2022&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/10/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/10/2023&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2024&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2025&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,552,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,767,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2028&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2027&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">669,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,749,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2025&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2028&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/12/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/12/2022&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2024&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2025&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2028&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,453,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Eiry W. Roberts, M.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2028&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,428,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,188,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Vests monthly over four years, subject to an initial <FONT STYLE="white-space:nowrap">one-year</FONT>
&#147;cliff.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Vests monthly over four years. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 35,750 Performance Restricted Stock Units (PRSUs) for Dr.&nbsp;Gorman, 20,500 PRSUs for
Mr.&nbsp;Benevich and Dr.&nbsp;Gano. These PRSUs vest upon the Company obtaining positive pivotal data in Tourette syndrome and filing of a NDA for valbenazine in Tourette syndrome. The
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
PRSUs have a limited term of four years to file the NDA. Additionally, Dr.&nbsp;Gorman has 11,500 restricted stock unit (RSU) awards, Mr.&nbsp;Benevich has 4,350 RSUs and Dr.&nbsp;Gano has 3,850
RSUs. These RSUs are time-based and vest annually, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis over four years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Vests annually over four years. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 18,400 Performance Restricted Stock Units (PRSUs) for Dr.&nbsp;Gorman, 12,250 PRSUs foreach of
Mr.&nbsp;Abernethy, Mr.&nbsp;Benevich, Dr.&nbsp;Gano and Dr.&nbsp;Roberts.&nbsp;A portion of portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of
specified revenue milestones within a specified time period. These PRSUs have a limited term of 23 months to achieve the objectives. Mr.&nbsp;Abernethy and Dr.&nbsp;Roberts also have 12,250 PRSUs and 18,400 PRSUs, respectively, that were granted to
align them with the PRSU grant that was made to the other executive officers in February 2016. These PRSUs vest upon the Company obtaining positive pivotal data in Tourette syndrome and filing of a NDA for valbenazine in Tourette syndrome.
Additionally, Dr.&nbsp;Gorman has 18,400 restricted stock unit (RSU) awards, Mr.&nbsp;Benevich has 6,150 RSUs and Dr.&nbsp;Gano has 20,350 RSUs. These RSUs are time-based and vest annually, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis
over four years. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Exercises and Stock Vested During the Year.</I></B> The following table sets forth the options exercised
and stock awards that vested during fiscal 2018 along with their respective values at December&nbsp;31, 2018 for the NEOs: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Option
Exercises and Stock Vested Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Exercise (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized on<BR>Exercise&nbsp;($)&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Vesting (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized&nbsp;on<BR>Vesting&nbsp;($)&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,039,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,271,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">281,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,861,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,929,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">801,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information relates to stock option exercises during 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information relates to restricted stock units that vested during 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated by multiplying the number of shares acquired upon exercise of stock options by the difference
between the exercise price and the market price of the Company&#146;s common stock at the time of exercise. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calculated by multiplying the number of shares acquired upon vesting of restricted stock units by the average
price of shares sold for purposes of satisfying federal and state income tax liabilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Payments Upon Termination or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control.</FONT></FONT></I></B>&nbsp;The following tables set forth the potential severance benefits payable to the NEOs in the event of a termination prior to or following a
change in control, assuming such event occurred on December&nbsp;31, 2018: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon Termination Table* </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Medical&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">843,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">590,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,295,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,833,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">906,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">432,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,582,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">403,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,681,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,337,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">520,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">357,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects a termination without cause or due to a constructive termination, or deemed termination, prior to a
change in control. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on salary as of December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on bonus targets established by the Board of Directors for 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the intrinsic value of
<FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2018 that would vest in accordance with the executive officers&#146; employment agreements. Values were derived
using the closing price of the Company&#146;s common stock on December&nbsp;31, 2018 of $71.41. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Medical is comprised primarily of health insurance premiums for the period specified in each executive
officer&#146;s employment contract. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Table* </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Severance&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Medical&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">945,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,747,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,173,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,419,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,431,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">648,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">324,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,475,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,542,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">604,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,065,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,025,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">780,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">390,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,616,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,855,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects benefits to be provided upon a termination without cause, or due to a constructive termination, within
a specified time following a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control.</FONT></FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on salary as of December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on bonus targets established by the Board of Directors for 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the intrinsic value of
<FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2018 that would vest in accordance with the executive officers&#146; employment agreements. Values were derived
using the closing price of the Company&#146;s common stock on December&nbsp;31, 2018 of $71.41. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Medical is comprised primarily of health insurance premiums for the period specified in each executive
officer&#146;s employment contract. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon Termination by Disability Table* </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Medical&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">843,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">590,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,295,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,833,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">906,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">432,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,582,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">403,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,681,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,337,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">520,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">357,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects a termination due to disability. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on salary as of December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on bonus targets established by the Board of Directors for 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the intrinsic value of
<FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2018 that would vest in accordance with the executive officers&#146; employment agreements. Values were derived
using the closing price of the Company&#146;s common stock on December&nbsp;31, 2018 of $71.41. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Medical is comprised primarily of health insurance premiums for the period specified in each executive
officer&#146;s employment contract. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon Termination by Death Table* </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,295,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,826,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,582,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,681,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,931,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">357,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects a termination due to death. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on bonus targets established by the Board of Directors for 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent the intrinsic value of
<FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2018 that would vest in accordance with the executive officers&#146; employment agreements. Values were derived
using the closing price of the Company&#146;s common stock on December&nbsp;31, 2018 of $71.41. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a
description of the arrangements under which the NEOs may be entitled to potential payments upon a termination without cause or resignation due to a constructive termination (including following a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control)</FONT></FONT> or upon disability or death. Resignation due to constructive termination may include an executive&#146;s resignation following one or more of the following material adverse changes in the
nature of such executive&#146;s employment, as specified in the agreement, which is not cured following notification: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a significant reduction in the executive or the executive supervisor&#146;s duties or responsibilities,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a material reduction in base salary, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material relocation, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material breach of the executive&#146;s employment agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Gorman</I></B> is entitled to 1.25 times the amount of his annual base salary and target annual
bonus to be paid equally over 15&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 15 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of
15&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months after the consummation of a change of
control, Dr.&nbsp;Gorman is entitled to 2 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all vested and outstanding stock awards, and
payment of COBRA benefits to continue then-current coverage for a period of 24&nbsp;months following termination. In addition, the Company has agreed to reimburse Dr.&nbsp;Gorman for the increase in federal and state income taxes payable by him by
reason of the benefits provided in connection with such a termination in connection with a change in control if the total payment exceeds 2.99 times his base amount by more than 15%. In the event of termination due to disability, Dr.&nbsp;Gorman is
entitled to 15&nbsp;months of base salary paid semi-monthly over 15&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Gorman in the
fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 15&nbsp;continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a
period of 15&nbsp;months following termination. In the event of a termination due to Dr.&nbsp;Gorman&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 15
continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Gorman in the fiscal year and the denominator
of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mr.</I></B><B><I></I></B><B><I>&nbsp;Abernethy </I></B>is entitled to 1.0 times the
amount of his annual base salary and target annual bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA
benefits to continue then-current coverage for a period of 12&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination
within six months after the consummation of a change of control, Mr.&nbsp;Abernethy is entitled to 1.5 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested
stock awards and all vested and outstanding stock awards, and payment of COBRA benefits to continue then-current coverage for a period of 18&nbsp;months following termination; provided, however, in the event such payment to Mr.&nbsp;Abernethy after
a change of control is subject to a <FONT STYLE="white-space:nowrap">&#147;best-after-tax&#148;</FONT> provision. The <FONT STYLE="white-space:nowrap">best-after-tax</FONT> provision provides that if the change of control payment due to
Mr.&nbsp;Abernethy would be subject to the excise tax provisions of Section&nbsp;280G of the Internal Revenue Code, the Company may reduce the change of control payments to Mr.&nbsp;Abernethy if, after all applicable taxes, the final payments would
be larger than if the change of control payments were not reduced and therefor subject to an excise tax. In the event of termination due to disability, Mr.&nbsp;Abernethy is entitled to 12&nbsp;months of base salary paid semi-monthly over
12&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Abernethy in the fiscal year and the denominator of which is 12, an
acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of 12&nbsp;months following termination. In the
event of a termination due to Mr.&nbsp;Abernethy&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, a lump sum
amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Abernethy in the fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on
the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mr.</I></B><B><I></I></B><B><I>&nbsp;Benevich</I></B> is entitled to 1.0 times the amount of his annual
base salary and target annual bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue
then-current coverage for a period of 12&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months
after the consummation of a change of control, Mr.&nbsp;Benevich is entitled to 1.5 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all
vested and outstanding stock awards, and payment of COBRA benefits to continue then-current coverage for a period of 18&nbsp;months following termination; provided, however, in the event such payment to Mr.&nbsp;Benevich after a change of control is
subject to a <FONT STYLE="white-space:nowrap">&#147;best-after-tax&#148;</FONT> provision. The <FONT STYLE="white-space:nowrap">best-after-tax</FONT> provision provides that if the change of control payment due to Mr.&nbsp;Benevich would be subject
to the excise tax provisions of Section&nbsp;280G of the Internal Revenue Code, the Company may reduce the change of control payments to Mr.&nbsp;Benevich if, after all applicable taxes, the final payments would be larger than if the change of
control payments were not reduced and therefor subject to an excise tax. In the event of termination due to disability, Mr.&nbsp;Benevich is entitled to 12&nbsp;months of base salary paid semi-monthly over 12&nbsp;months, a lump sum amount equal to
his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Benevich in the fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have
vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of 12&nbsp;months following termination. In the event of a termination due to Mr.&nbsp;Benevich&#146;s
death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a
fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Benevich in the fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Gano</I></B> is entitled to 1.0 times the amount of his annual base salary and target annual bonus
to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of 12&nbsp;months following termination in the event that the Company terminates
his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months after the consummation of a change of control, Dr.&nbsp;Gano is entitled to 1.5 times the amount of his annual base
salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all vested and outstanding stock awards, and payment of COBRA benefits to continue then-current coverage for a period of
18&nbsp;months following termination; provided, however, in the event such payment to Dr.&nbsp;Gano after a change of control is subject to a <FONT STYLE="white-space:nowrap">&#147;best-after-tax&#148;</FONT> provision. The <FONT
STYLE="white-space:nowrap">best-after-tax</FONT> provision provides that if the change of control payment due to Dr.&nbsp;Gano would be subject to the excise tax provisions of Section&nbsp;280G of the Internal Revenue Code, the Company may reduce
the change of control payments to Dr.&nbsp;Gano if, after all applicable taxes, the final payments would be larger than if the change of control payments were not reduced and therefor subject to an excise tax. In the event of termination due to
disability, Dr.&nbsp;Gano is entitled to 12&nbsp;months of base salary paid semi-monthly over 12&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of
employment by Dr.&nbsp;Gano in the fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue
then-current coverage for a period of 12&nbsp;months following termination. In the event of a termination due to Dr.&nbsp;Gano&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have
vested over the 12 continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Gano in the fiscal year and
the denominator of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Roberts</I></B> is entitled to 1.0 times the amount of her annual base salary and target annual
bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of
12&nbsp;months following termination in the event that the Company terminates her employment without cause, or she resigns due to a constructive termination. In the event of such termination within six months after the consummation of a change of
control, Dr.&nbsp;Roberts is entitled to 1.5 times the amount of her annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all vested and outstanding stock awards,
and payment of COBRA benefits to continue then-current coverage for a period of 18&nbsp;months following termination; provided, however, in the event such payment to Dr.&nbsp;Roberts after a change of control is subject to a <FONT
STYLE="white-space:nowrap">&#147;best-after-tax&#148;</FONT> provision. The <FONT STYLE="white-space:nowrap">best-after-tax</FONT> provision provides that if the change of control payment due to Dr.&nbsp;Roberts would be subject to the excise tax
provisions of Section&nbsp;280G of the Internal Revenue Code, the Company may reduce the change of control payments to Dr.&nbsp;Roberts if, after all applicable taxes, the final payments would be larger than if the change of control payments were
not reduced and therefor subject to an excise tax. In the event of termination due to disability, Dr.&nbsp;Roberts is entitled to 12&nbsp;months of base salary paid semi-monthly over 12&nbsp;months, a lump sum amount equal to her target annual bonus
multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Roberts in the fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 12
continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of 12&nbsp;months following termination. In the event of a termination due to Dr.&nbsp;Roberts&#146;s death, her
beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, a lump sum amount equal to her target annual bonus multiplied by a fraction the
numerator of which is the number of full months of employment by Dr.&nbsp;Roberts in the fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CEO PAY RATIO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to reflect our employee compensation practices, we have calculated the annual base salary of our median employee while taking only
annual base salary into account, as well as the ratio of the base salary of our CEO as compared to the annual base salary of such median employee. In calculating the annual base salary of our median employee we used the applicable methodology listed
above. For fiscal 2018, the median of the annual base salary of our employees (other than our CEO) was $133,120, and the annual base salary of our CEO, Kevin C. Gorman, Ph.D., as reported in the Summary Compensation Table included in this Proxy
Statement, was $675,000. Based on this information, the ratio of the annual base salary of our CEO to the median of the annual base salary of all employees (other than the CEO) was approximately 5 to 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the information above, under SEC rules, we are required to calculate and disclose the annual total compensation of our median
employee, as well as the ratio of the annual total compensation of our median employee as compared to the annual total compensation of our CEO (&#147;CEO Pay Ratio&#148;). To identify our median employee, we used the following methodology: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To determine our total population of employees, we included all full-time and part-time as of December&nbsp;31,
2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To identify our median employee from our employee population, we calculated the aggregate amount of each
employee&#146;s fiscal 2018 base salary (using a reasonable estimate of the hours worked and overtime actually paid during fiscal 2018 for hourly employees and actual salary paid for our remaining employees) and bonuses attributable to fiscal 2018
performance and the grant date fair value of equity awards granted in fiscal 2018 using the same methodology we use for estimating the value of the equity awards granted to our named executive officers and reported in our Summary Compensation Table.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In making this determination, we annualized the base salary and target bonus compensation of employees who were
employed by us for less than the entire fiscal year. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal 2018, the median of the annual total compensation of
our employees (other than our CEO) was $259,000 and the annual total compensation of our CEO, Kevin C. Gorman, Ph.D., as reported in the Summary Compensation Table included in this Proxy Statement, was $8,632,979. Based on this information, the
ratio of the annual total compensation of our CEO to the median of the annual total compensation of all employees was approximately 33 to 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CEO Pay Ratio above represents our reasonable estimate calculated in a manner consistent with SEC rules and applicable guidance. SEC rules
and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions particular to that company. As a result, and as explained by the SEC when it
adopted these rules, in considering the pay ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios among different companies, even companies within the same industry, but rather to
allow stockholders to better understand and assess each particular company&#146;s compensation practices and pay ratio disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making compensation decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS COMPENSATION SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Philosophy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation philosophy is based on the following guiding principles: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aligning the long-term interests of stockholders and directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensating directors appropriately and adequately for their time, effort and experience. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The elements of director compensation consist of annual cash retainers and equity awards, as well as customary and usual expense reimbursement
in attending Board or Committee meetings. In an effort to align the long-term interests of our stockholders and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, the mix of cash and equity compensation has historically been, and is
currently, weighted more heavily to equity. The equity compensation has historically taken the form of stock options, which we believe motivates the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors to help us achieve our business
objectives by tying incentives to the appreciation of our common stock over the long term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board and the Company&#146;s stockholders
approved certain annual limits on compensation to be paid to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, beginning with our 2016 annual meeting of stockholders. The aggregate value of all compensation granted
or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director will not exceed $1,250,000 in total value during any year, measured from our annual meeting of stockholders for a particular
year and ending on the date of our annual meeting of stockholders for the subsequent year. In addition, the aggregate value of the initial option grant or other similar stock awards granted under the 2011 Plan or otherwise to any individual for
service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon or in connection with his or her initial election or appointment to the Board will not exceed $2,000,000 in total value. These limits are further described in our 2011
Plan. The Board has the authority to make exceptions to these limits in extraordinary circumstances, in its discretion, provided that any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is granted or paid such additional
compensation may not participate in the decision to grant or pay such additional compensation. No exceptions were made in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Compensation Committee regularly assesses our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program in consultation with its independent compensation consultant, who provides analysis and input on prevailing market
practices, and recommends any changes to the program to our Board, who ultimately approves <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation. On at least an annual basis, qualified experts in the field of <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation also deliver a presentation to the Compensation Committee about recent developments and best practices related to <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 compensation for the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was recommended
by the Compensation Committee to the Board following the review of a report from Radford, its independent compensation consultant during 2018, which contained an analysis of prevailing market practices regarding levels and types of <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation, including the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation practices of our peer group, which is described in the &#147;Compensation Discussion and
Analysis&#148; section of this proxy statement, and a comparative assessment of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation to such peers and market practices. In 2018, the Compensation Committee also received a
presentation from Radford about recent developments and best practices related to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors to inform its analysis of, and recommendations regarding,
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation. In 2018 the Board approved certain adjustments to cash compensation of certain committee Chairs and members based primarily on an increase in the number of meetings that
certain committees had as compared to prior years. In addition, the Board approved a decrease in the number of shares subject to the annual option granted to each <FONT STYLE="white-space:nowrap">non-employee</FONT> director at the 2018 Annual
Meeting of Stockholders and the initial option granted each <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon his or her initial election or appointment to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In formulating its recommendations to the Board for 2018, the Compensation Committee did not engage in benchmarking or targeting compensation
to a specific level of the peer group data provided by Radford, but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rather used the peer data as a reference point in making <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation recommendations. The Compensation Committee determined that the
equity awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors should consist of stock options rather than time-vesting RSU grants. It is the Compensation Committee&#146;s view that stock options are inherently performance
oriented and align the interest of the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors with those of our stockholders, as the <FONT STYLE="white-space:nowrap">non-employee</FONT> director realizes no value from stock options unless
and until the Company&#146;s stock price increases. Ultimately, the Board set 2018 <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation in the forms and amounts it determined to be appropriate using its professional experience
and judgment, after careful review of the Radford analysis and the Compensation Committee&#146;s recommendations. Our director compensation for fiscal 2018 is described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation for Fiscal 2018 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are reimbursed for expenses incurred in connection with performing their duties
as directors of the Company. For 2018, directors who are not employees of the Company received a $50,000 annual retainer. The Company provided the Chair of the Board, William H. Rastetter, an additional $30,000, making his total annual cash retainer
$80,000. In addition to the cash compensation set forth above, the Chairs of the Audit Committee and Compensation Committee each received an additional $20,000 annual cash retainer. The Chair of the Nominating/Corporate Governance Committee received
an additional $10,000 annual cash retainer, and the Chair of the Science and Medical Technology Committee received an additional $15,000 annual cash retainer. Each other director who was a member of the Audit Committee, the Compensation Committee,
the Nominating/Corporate Governance Committee or the Science and Medical Technology Committee received an additional annual cash retainer of $12,000, $12,000, $5,000 and $7,500, respectively, for each Committee on which she or he served. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, for 2018, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director received a grant of a nonstatutory stock option to
purchase 12,500 shares of the Company&#146;s common stock (except that the Chair of the Board received an option to purchase 15,000 shares) on the date of the 2018 Annual Meeting of Stockholders. The options granted to
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors have exercise prices equal to the closing price of the Company&#146;s common stock on the date of the grant, are subject to a <FONT STYLE="white-space:nowrap">ten-year</FONT> term and
vest monthly over the <FONT STYLE="white-space:nowrap">one-year</FONT> period following the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we did not have any
new <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during 2018, any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is first elected or appointed to the Board would receive a grant of a nonstatutory stock option to
purchase shares of the Company&#146;s common stock. The initial option would be granted upon such director&#146;s initial election or appointment to the Board, have an exercise price equal to the closing price of the Company&#146;s common stock on
the date of grant, a <FONT STYLE="white-space:nowrap">ten-year</FONT> maximum term and vest monthly over the three-year period following the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation paid by the Company for the fiscal year
ended December&nbsp;31, 2018 to the directors of the Company named below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Director Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">786,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">873,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. Lyons (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">712,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">730,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinne H. Nevinny (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">737,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">737,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr., M.D. Ph.D. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">733,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin,&nbsp;M.D. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">732,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column reflect compensation earned in 2018, all of which was paid during 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown represent the full grant date fair value of option awards granted in 2018 as determined
pursuant to ASC 718. The assumptions used to calculate the value of such awards are set forth under Note 8 of the Notes to the Consolidated Financial Statements included in the Company&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018. The grant date fair values of all option awards are based on a per share Black-Scholes value of $52.42. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During 2018, Dr.&nbsp;Gorman was an employee of the Company, and as such, did not receive any compensation for
service on the Board of Directors. As of December&nbsp;31, 2018, Dr.&nbsp;Gorman had outstanding options to purchase 1,125,944 shares of common stock, and 115,050 outstanding restricted stock units. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Dr.&nbsp;Rastetter had outstanding options to purchase 141,000 shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Mr.&nbsp;Lyons had outstanding options to purchase 112,500 shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Mr.&nbsp;Morrow had outstanding options to purchase 82,500 shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Nevinny resigned from the Board of Directors in September 2018. As of December&nbsp;31, 2018,
Ms.&nbsp;Nevinny had outstanding options to purchase 88,125 shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Mr.&nbsp;Pops had outstanding options to purchase 112,500 shares of common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Dr.&nbsp;Sandrock had outstanding options to acquire 82,500 shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Dr.&nbsp;Sherwin had outstanding options to purchase 112,500 shares of common
stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Ownership Guidelines </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Board of Directors implemented equity ownership guidelines for our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors. The equity ownership guidelines are designed to further align the interests of the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors with those of our stockholders by ensuring that our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors have a significant financial stake in the Company&#146;s long-term success. The equity ownership guidelines establish a minimum equity ownership equal to one times the cash retainer paid
to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director, with such values determined based on the value of our common stock owned by such persons as of certain measurement dates. All shares directly or beneficially owned by the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, including the net exercisable value of outstanding vested stock options (where the market price of our common stock exceeds the strike price of such option) are included in determining the
value of equity owned under our equity ownership guidelines. New <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are granted a five-year period to reach the equity ownership requirements set forth in the guidelines and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are expected to make annual progress toward the equity ownership requirements during this five-year period. When a <FONT STYLE="white-space:nowrap">non-employee</FONT> director does not meet the
equity ownership requirements set forth in the guidelines, he/she is restricted from selling any held shares until such requirements are met. Additionally, should <FONT STYLE="white-space:nowrap">non-employee</FONT> director who does not meet the
equity ownership requirements choose to exercise a stock option or vest in any RSUs, he or she is required to retain all shares acquired through those transactions, aside from any shares necessary to fulfill such transaction related tax obligations,
until full compliance with the equity ownership guidelines is attained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual compliance with the equity ownership guidelines is
assessed during the first quarter of each year. As of March&nbsp;1, 2019, each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors is in compliance with the equity ownership guidelines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive
officers of the Company serve at the discretion of the Board of Directors. There are no family relationships among any of the directors, executive officers or key employees of the Company. None of our directors or executive officers has been
involved in any of the legal proceedings specified in Item&nbsp;401(f) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in the past 10 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review, Approval or Ratification of Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Company&#146;s Audit Committee Charter, the Company&#146;s Audit Committee is responsible for reviewing and approving
the terms and conditions of all related person transactions. In connection with its review, approval or ratification of related person transactions, the Company&#146;s Audit Committee takes into account all relevant available facts and circumstances
in determining whether such transaction is in the best interests of the Company and its stockholders. Any transaction that would disqualify a director from meeting the &#147;independent director&#148; standard as defined under the Nasdaq Stock
Market rules requires review by the Company&#146;s Audit Committee prior to entering into such transaction. For all other related person transactions, the Company reviews all agreements and payments for related person transactions and based on this
review, a report is made to the Company&#146;s Audit Committee quarterly disclosing all related person transactions during that quarter, if any. All related person transactions shall be disclosed in the Company&#146;s applicable filings with the SEC
as required under SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transactions During Fiscal 2018 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no related person transactions during fiscal 2018. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the
date of this proxy statement, the Company knows of no other matters to be submitted to the stockholders at the Annual Meeting. If any other matters properly come before the Annual Meeting, it is the intention of the persons named in the proxy to
vote the&nbsp;shares they represent as the Board of Directors may recommend. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Householding&#148; of Proxy Materials.</I></B> The SEC has adopted rules that permit companies and intermediaries such as brokers
to satisfy delivery requirements for proxy statements with respect to two or more stockholders sharing the same address by delivering a single set of proxy materials addressed to those stockholders. This process, which is commonly referred to as
&#147;householding,&#148; potentially provides extra convenience for stockholders and cost savings for companies. The Company, as well as certain brokers, household proxy materials, unless contrary instructions have been received from the affected
stockholders. Once you have received notice from your broker or us that they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no
longer wish to participate in householding and would prefer to receive a separate set of proxy materials, please notify your broker if your&nbsp;shares are held in a brokerage account or us if you hold registered&nbsp;shares. If you hold
registered&nbsp;shares, you may direct your written request to the Company&#146;s Corporate Secretary at 12780 El Camino Real, San&nbsp;Diego, California 92130 or contact the Company&#146;s Corporate Secretary at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">858-617-7600.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Procedures.</I></B> To be considered for inclusion in next
year&#146;s proxy materials, a stockholder must submit his, her or its proposal in writing by December&nbsp;24, 2019, which is the date that is 120&nbsp;days prior to the first anniversary of the mailing date of this proxy statement, to the
Company&#146;s Corporate Secretary at 12780 El Camino Real, San&nbsp;Diego, California 92130. Any proposal must comply with the requirements as to form and substance established by the SEC for such proposal to be included in our proxy statement.
Stockholders are also advised to review our bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2011 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY&nbsp;21, 2011 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVED BY THE STOCKHOLDERS: MAY&nbsp;25, 2011 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;23, 2013 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;22, 2014 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;28, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;20, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;22, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;24, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION DATE: FEBRUARY&nbsp;20, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
Successor to and Continuation of Prior Plans</B>. The Plan is intended as the successor to and continuation of the Neurocrine Biosciences, Inc. 2003 Incentive Stock Plan, 2001 Stock Option Plan, 1997 Incentive Stock Plan, 1996 Director Stock Option
Plan and 1992 Incentive Stock Plan (together the &#147;<B><I>Prior Plans</I></B>&#148;). On the Effective Date, awards will automatically be granted to the Company&#146;s Directors pursuant to the terms of Section&nbsp;10 of the Neurocrine
Biosciences, Inc. 2003 Incentive Stock Plan (the &#147;<B><I>2011 Automatic Director Awards</I></B>&#148;). From and following the Effective Date, no additional stock awards shall be granted under the Prior Plans except for the 2011 Automatic
Director Awards. From and after the Effective Date, all outstanding stock awards granted under the Prior Plans shall remain subject to the terms of the Prior Plans; provided, however, any shares subject to outstanding stock awards granted under the
Prior Plans that expire or terminate for any reason prior to exercise or settlement or are otherwise forfeited prior to issuance of the shares because of the failure to meet a contingency or condition required to vest such shares shall not again
become available for issuance under either the Prior Plans or this Plan. Except with respect to the 2011 Automatic Director Awards, all Awards granted on or after the Effective Date of this Plan shall be subject to the terms of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Eligible Award Recipients</B>. The persons eligible to receive discretionary Awards are Employees, Directors and Consultants. The
persons eligible to receive Stock Awards under the Director Grant Program are Eligible Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Available Awards</B>. The Plan
provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options, (ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights (iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted Stock Unit Awards,
(vi)&nbsp;Performance Stock Awards, and (vii)&nbsp;Other Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Purpose</B>. The Company, by means of the Plan, seeks to
secure and retain the services of the group of persons eligible to receive Awards as set forth in Section&nbsp;1(b), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a
means by which such eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Section</B><B></B><B>&nbsp;162(m) Transition Relief.</B> Notwithstanding anything in the Plan to the contrary: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any provision in the Plan that refers to &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code will only
apply to any Award that is intended to qualify, and is eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act (the
&#147;<B><I>TCJA</I></B>&#148;) for remuneration provided pursuant to a written binding contract which was in effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on November&nbsp;2, 2017 and which was not modified in any material respect on or after such date (the &#147;<B><I>Transition Relief</I></B>&#148;), as determined by the Board, in its sole
discretion, in accordance with the TCJA and any applicable guidance, rulings or regulations issued by the U.S. Department of the Treasury, the Internal Revenue Service or any other governmental authority (collectively, the &#147;<B><I>TCJA
Guidance</I></B>&#148;) (each such Award, a &#147;<B><I>162(m) Award</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>any Award (including any 162(m) Award)
that was granted prior to May&nbsp;22, 2019 will be subject to and governed by the terms of the Plan, as in effect on the date of grant of such Award (or as in effect on the date of any subsequent amendment of the Plan, to the extent applicable, but
no later than November&nbsp;2, 2017 with respect to any 162(m) Award and no later than May&nbsp;23, 2018 with respect to any Award that is not a 162(m) Award); <I>provided, however</I>, that any such terms which refer to a subsection of
Section&nbsp;162(m) of the Code (or any regulations thereunder) will mean such subsection (or any regulations thereunder) as in effect on December&nbsp;31, 2017 (or with respect to any Award that is not a 162(m) Award, as amended by the TCJA or any
TCJA Guidance and as in effect on January&nbsp;1, 2018 (or as subsequently amended thereafter), to the extent applicable); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)
</B>any Award (including any 162(m) Award) that is granted on or after May&nbsp;22, 2019 will be subject to and governed by the terms of the Plan, as in effect on May&nbsp;22, 2019 (or as in effect on the date of any subsequent amendment of the
Plan, to the extent applicable, provided that with respect to any 162(m) Award, no such subsequent amendment will be effective if it would result in such 162(m) Award not being able to qualify for the Transition Relief); <I>provided, however</I>,
that (a)&nbsp;with respect to any 162(m) Award, any such terms which refer to a subsection of Section&nbsp;162(m) of the Code (or any regulations thereunder) will mean such subsection (or any regulations thereunder) as in effect on December&nbsp;31,
2017, and (b)&nbsp;with respect to any Award that is not a 162(m) Award, any such terms which refer to a subsection of Section&nbsp;162(m) of the Code (or any regulations thereunder) will mean such subsection (or any regulations thereunder), as
amended by the TCJA or any TCJA Guidance and as in effect on January&nbsp;1, 2018 (or as subsequently amended thereafter), to the extent applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. A<SMALL>DMINISTRATION</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
Administration by Board</B>. The Board shall administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(d). However, the Board may not delegate administration of
the Director Grant Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Powers of Board</B>. Except with respect to the Director Grant Program, the Board shall have the
power, subject to, and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to
time (A)&nbsp;which of the persons eligible under the Plan shall be granted Awards; (B)&nbsp;when and how each Award shall be granted; (C)&nbsp;what type or combination of types of Award shall be granted; (D)&nbsp;the provisions of each Award
granted (which need not be identical), including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to an Award; (E)&nbsp;the number of shares of Common Stock with respect to which a Stock Award shall be
granted to each such person; and (F)&nbsp;the Fair Market Value applicable to a Stock Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and
interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock
Award Agreement in a manner and to the extent it shall deem necessary or expedient to make the Plan or Award fully effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all controversies regarding the Plan and Awards granted under it. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>To accelerate the time at which an Award may first be exercised or the time during which an Award or any part
thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time. Suspension or termination of the Plan shall not impair rights and
obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan in any respect the Board deems necessary or
advisable. However, except as provided in Section&nbsp;10(a) relating to Capitalization Adjustments, to the extent required by applicable law or listing requirements, stockholder approval shall be required for any amendment of the Plan that either
(A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the benefits
accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (D)&nbsp;materially extends the term of the Plan, or (E)&nbsp;expands the types of Awards available
for issuance under the Plan. Except as provided above, rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected Participant, and
(2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vii) </B>To submit any amendment to the Plan for stockholder approval,
including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of
compensation paid to Covered Employees, (B)&nbsp;Section&nbsp;422 of the Code regarding incentive stock options or <FONT STYLE="white-space:nowrap">(C)&nbsp;Rule&nbsp;16b-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards,
including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however,
that except with respect to amendments that disqualify or impair the status of an Incentive Stock Option, a Participant&#146;s rights under any Award shall not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the
affected Participant, and (B)&nbsp;such Participant consents in writing. Notwithstanding the foregoing, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected
Participant&#146;s consent if necessary to maintain the qualified status of the Award as an Incentive Stock Option or to bring the Award into compliance with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ix) </B>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote
the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> To
adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Administration of Director Grant Program</B>. The Board shall have the power, subject to and within the limitations of, the
express provisions of the Director Grant Program: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine the provisions of each Stock Award to the extent
not specified in the Director Grant Program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>To construe and interpret the Director Grant Program and the
Stock Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Director Grant Program or in any Stock
Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Director Grant Program fully effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To amend the terms of the Director Grant Program or a Stock Award granted thereunder, except that rights under any
such Stock Award granted before amendment of the Director Grant Program shall not be impaired by any amendment of the Director Grant Program unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant
consents in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Generally, to exercise such powers and to perform such acts as the Board deems necessary
or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Director Grant Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Delegation to Committee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) General</B>. The Board may delegate some or all of the administration of the Plan (except the Director Grant Program) to a Committee or
Committees. If administration of the Plan is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including
the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to
such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.
The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Section</B><B></B><B>&nbsp;162(m) and Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance</B>. The Committee may consist
solely of two or more Outside Directors, in accordance with Section&nbsp;162(m) of the Code, or solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, in accordance with Rule
<FONT STYLE="white-space:nowrap">16b-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Delegation to an Officer</B>. The Board may delegate to one (1)&nbsp;or more
Officers the authority to do one or both of the following (i)&nbsp;designate Employees who are providing Continuous Service to the Company or any of its Subsidiaries who are not Officers to be recipients of Options and SARs (and, to the extent
permitted by applicable law, other Stock Awards) and the terms thereof, and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions
regarding such delegation shall specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Notwithstanding the
foregoing, the Board may not delegate authority to an Officer to determine the Fair Market Value pursuant to Section&nbsp;14(z)(iii) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Effect of Board&#146;s Decision</B>. All determinations, interpretations and constructions made by the Board in good faith shall not be
subject to review by any person and shall be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Cancellation and <FONT
STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</B>. Except in connection with a Corporate Transaction, as provided in Section&nbsp;10(a) relating to Capitalization Adjustments, or unless the stockholders of the Company have approved such
an action within twelve (12)&nbsp;months prior to such an event, neither the Board nor any Committee shall have the authority to: (i)&nbsp;reduce the exercise price of any outstanding Options or SARs under the Plan, or (ii)&nbsp;cancel any
outstanding Options or SARs that have an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash, Full Value Awards, or Options or SARs with an exercise price less than the original exercise
price of the Options or SARs that are cancelled. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Share Reserve</B>. Subject to Section&nbsp;10(a) relating to Capitalization Adjustments, the aggregate
number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date shall not exceed <FONT STYLE="white-space:nowrap">twenty-one</FONT> million (21,000,000)&nbsp;shares. For clarity, the Share Reserve in
this Section&nbsp;3(a) is a limitation on the number of shares of the Common Stock that may be issued pursuant to the Plan and does not limit the granting of Stock Awards except as provided in Section&nbsp;8(a). Shares may be issued in connection
with a merger or acquisition as permitted by, as applicable, NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance shall not
reduce the number of shares available for issuance under the Plan. Furthermore, if a Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued, such expiration or
termination shall not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Reversion of Shares to the Share Reserve</B>. If any shares of common stock issued
pursuant to a Stock Award are forfeited back to the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited shall revert to and again become available for
issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Limitation on Full Value Awards</B>. The aggregate number of shares of Common Stock that may be issued
pursuant to grants of Full Value Awards shall not exceed fifty percent (50%)&nbsp;of the aggregate number of shares of Common Stock available for issuance under this Plan as set forth in Section&nbsp;3(a), subject to adjustment as provided in
Sections 3(b) and 10(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Shares Not Available For Subsequent Issuance</B>. If any shares subject to a Stock Award are not
delivered to a Participant because the Stock Award is exercised through a reduction of shares subject to the Stock Award (i.e., &#147;<B><I>net exercised</I></B>&#148;), the number of shares that are not delivered to the Participant shall no longer
be available for issuance under the Plan. Also, any shares used to pay the exercise price of a Stock Award or that are withheld in satisfaction of applicable tax withholding obligations shall no longer be available for issuance under the Plan. Any
shares repurchased on the open market with the proceeds of the exercise price of a Stock Award shall not again be available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Incentive Stock Option Limit</B>. Notwithstanding anything to the contrary in this Section&nbsp;3 and, subject to the provisions of
Section&nbsp;10(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options shall be <FONT STYLE="white-space:nowrap">twenty-one]</FONT>
million (21,000,000)&nbsp;shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Section</B><B></B><B>&nbsp;162(m) Limitation on Annual Grants</B>. Subject to
the provisions of Section&nbsp;10(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section&nbsp;162(m) of the Code, a maximum of five hundred thousand (500,000)&nbsp;shares of
Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least one hundred percent (100%)&nbsp;of the Fair Market Value on the date any such Stock Award
is granted may be granted to any Participant during any calendar year; provided, however that in connection with his or her initial employment, an Employee may be granted such forms of Stock Awards for up to an additional five hundred thousand
(500,000)&nbsp;shares of Common Stock which shall not count against such annual limit. Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to an increase over an exercise or
strike price of at least one hundred percent (100%)&nbsp;of the Fair Market Value on the date the Stock Award are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards shall
not satisfy the requirements to be considered &#147;qualified performance-based compensation&#148; under Section&nbsp;162(m) of the Code unless such additional Stock Awards are approved by the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit.</B> The aggregate value of all compensation granted
or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any period commencing on the date of the Company&#146;s regular Annual Meeting for a particular year and ending
on the date of the Company&#146;s regular Annual Meeting for the next subsequent year (the &#147;<B><I>Annual Period</I></B>&#148;), including Awards granted and cash fees paid by the Company to such
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed one million two hundred fifty thousand dollars ($1,250,000) in total value. In addition, the aggregate value of the Initial Award(s) (or other similar stock award(s)
granted under the Plan or otherwise to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director upon or in connection with his or her initial election or appointment to the Board) will not exceed two million
dollars ($2,000,000) in total value; for the avoidance of doubt, the aggregate compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to an Annual
Period in which such individual is first appointed or elected to the Board shall not exceed the sum of the two preceding limitations in this Section&nbsp;3(g). The value of any stock awards, for purposes of the limitations described in this
Section&nbsp;3(g), shall be calculated based on the grant date fair value of such stock awards for financial reporting purposes.&nbsp;The limitations in this Section&nbsp;3(g) shall apply beginning with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Annual period in which the Company&#146;s 2016 Annual Meeting occurs. The Board may make an exception to the applicable limit in this Section&nbsp;3(g) for any
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director in extraordinary circumstances, as the Board may determine in its discretion, provided that any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is granted or paid such
additional compensation may not participate in the decision to grant or pay such additional compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) Source of Shares</B>.
The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise; provided, however that the Company may not repurchase shares to be
used under this Plan to the extent such repurchased shares would exceed the limitation in Section&nbsp;3(a). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Eligibility for Specific Stock Awards</B>. Incentive Stock Options may be granted only to employees of the Company or a &#147;parent
corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants;
provided, however, Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405 promulgated
under the Securities Act, unless the stock underlying such Stock Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code because the Stock Awards are granted pursuant to a corporate transaction (such as a spin
off transaction) or unless such Stock Awards comply with the distribution requirements of Section&nbsp;409A of the Code. Stock Awards granted under the Director Grant Program in Section&nbsp;7 may be granted only to Eligible Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Ten Percent Stockholders</B>. A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of
such Option is at least one hundred ten percent (110%)&nbsp;of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five (5)&nbsp;years from the date of grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> T<SMALL>O</SMALL> O<SMALL>PTIONS</SMALL> A<SMALL>ND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option or SAR shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates shall be
issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be a Nonstatutory Stock Option. The provisions of separate Options or
SARs need not be identical; provided, however, that each Option Agreement or SAR Agreement shall conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the
following provisions: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Term</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, no Option or SAR
shall be exercisable after the expiration of ten (10)&nbsp;years from the date of its grant or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Exercise Price</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the exercise price (or strike
price) of each Option or SAR shall be not less than one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Option or SAR is granted. Notwithstanding the foregoing, an Option or SAR
may be granted with an exercise price (or strike price) lower than one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the Option or SAR if such Option or SAR is granted pursuant to an assumption of or
substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. Each SAR will be denominated in shares of Common
Stock equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Purchase Price for Options</B>. The purchase price of Common Stock acquired pursuant
to the exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant
Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The permitted
methods of payment are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash, check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the
issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>if the option is a Nonstatutory Stock Option, by a &#147;<B><I>net exercise</I></B>&#148; arrangement pursuant to
which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company shall
accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; provided, further, that shares of Common Stock
will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#147;<B><I>net exercise,</I></B>&#148; (B)&nbsp;shares are
delivered to the Participant as a result of such exercise, and (C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of legal consideration that may be acceptable to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Exercise and Payment of a SAR</B>. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the
Company in compliance with the provisions of the SAR Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on
the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such
date, over (B)&nbsp;the strike price that will be determined by the Board at the time of grant of the SAR. The appreciation distribution in respect to a SAR may be paid in Common Stock, in cash, in any combination of the two or in any other form of
consideration, as determined by the Board and contained in the SAR Agreement evidencing such SAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Transferability of Options and
SARs</B>. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board shall determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the
transferability of Options and SARs shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Restrictions on Transfer</B>. An Option or SAR shall not be
transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Participant only by the Participant. Except as explicitly provided herein, neither an Option nor a SAR may be transferred.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Domestic Relations Orders</B>. Notwithstanding the foregoing, an Option or SAR may be transferred pursuant to a
domestic relations order; provided, however, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) Beneficiary Designation</B>. Notwithstanding the foregoing, the Participant may, by delivering written notice to the
Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect Option exercises, designate a third party who, in the event of the death of the Participant, shall thereafter be entitled to
exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant&#146;s estate shall be entitled to exercise the
Option or SAR and receive the Common Stock or other consideration resulting from such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Vesting Generally</B>. The total number of shares of Common Stock subject to an
Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be
based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f) are subject to any Option or SAR provisions
governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Termination of Continuous
Service</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause or upon the Participant&#146;s death
or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) but only within such period of time ending on the
earlier of (i)&nbsp;the date three (3)&nbsp;months following the termination of the Participant&#146;s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement), or (ii)&nbsp;the expiration of the term of the
Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the time specified herein or in the Award Agreement (as applicable), the Option or SAR
shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) Extension of Termination Date</B>. If the exercise of an Option or SAR following the termination of the
Participant&#146;s Continuous Service (other than for Cause or upon the Participant&#146;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under
the Securities Act, then the Option or SAR shall terminate on the earlier of (i)&nbsp;the expiration of a total period of three (3)&nbsp;months (that need not be consecutive) after the termination of the Participant&#146;s Continuous Service during
which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided
in a Participant&#146;s Award Agreement, if the immediate sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause) would violate the
Company&#146;s insider trading policy, then the Option or SAR shall terminate on the earlier of (i)&nbsp;the expiration of a period equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous
Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the
applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Disability of Participant</B>. Except as otherwise provided in the applicable Award Agreement or other
agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was
entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date twelve (12)&nbsp;months following such termination of Continuous Service (or
such longer or shorter period specified in the Award Agreement), or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or
her Option or SAR within the time specified herein or in the Award Agreement (as applicable), the Option or SAR (as applicable) shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) Death of Participant</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and
the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or (ii)&nbsp;the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the
termination of the Participant&#146;s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the
Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant&#146;s death, but only within the period ending on the earlier of (i)&nbsp;the date eighteen (18)&nbsp;months following the date of death (or such longer or shorter period specified
in the Award Agreement), or (ii)&nbsp;the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the time specified herein or in the Award
Agreement (as applicable), the Option or SAR shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) Termination for Cause</B>. Except as explicitly provided otherwise
in a Participant&#146;s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR shall terminate immediately
upon such Participant&#146;s termination of Continuous Service, and the Participant shall be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. No Option or SAR, whether or not vested, granted to an Employee who
is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common Stock until at least six months following the date of grant of the
Option or SAR. Notwithstanding the foregoing, consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;in the event of the Participant&#146;s death or Disability, (ii)&nbsp;upon a Corporate Transaction in which such Option or
SAR is not assumed, continued, or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the Participant&#146;s Award Agreement or in another applicable agreement or in
accordance with the Company&#146;s then current employment policies and guidelines), any such vested Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any
income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>ROVISIONS</SMALL> O<SMALL>F</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL>
A<SMALL>ND</SMALL> S<SMALL>ARS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Restricted Stock Awards</B>. Each Restricted Stock Award Agreement shall be in such
form and shall contain such terms and conditions as the Board shall deem appropriate. To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election, shares of Common Stock may be (i)&nbsp;held in book entry form subject to
the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&nbsp;evidenced by a certificate, which certificate shall be held in such form and manner as determined by the Board. The terms and
conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical; provided, however, that each Restricted Stock Award Agreement shall
conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Consideration</B>. A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash, check, bank draft or
money order payable to the Company, (B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible
under applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Vesting</B>. Shares of Common Stock awarded under the Restricted Stock Award Agreement may
be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)
Termination of Participant&#146;s Continuous Service</B>. If a Participant&#146;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the
Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) Transferability</B>. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement shall be
transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award
Agreement remains subject to the terms of the Restricted Stock Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) Dividends</B>. A Restricted Stock Award Agreement may provide that
any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Restricted Stock Unit Awards</B>. Each Restricted Stock Unit Award Agreement shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical;
provided, however, that each Restricted Stock Unit Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Consideration</B>. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if
any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit
Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Vesting.</B> At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or
conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)
Payment</B>. A Restricted Stock Unit Award will be settled by the delivery of shares of Common Stock as determined by the Board and contained in the Restricted Stock Unit Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) Additional Restrictions</B>. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems
appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) Dividend Equivalents</B>. Dividend equivalents may be credited in respect of shares of Common Stock covered by a
Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the
Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the
underlying Restricted Stock Unit Award Agreement to which they relate, including any vesting restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vi)
Termination of Participant&#146;s Continuous Service</B>. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the
Participant&#146;s termination of Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Performance Awards. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Performance Stock Awards</B>. A Performance Stock Award is a Stock Award that may vest or may be exercised contingent
upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period, the Performance
Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion. The maximum number of shares
covered by an Award that may be granted to any Participant in a calendar year attributable to Stock Awards described in this Section&nbsp;6(c)(i) (whether the grant, vesting or exercise is contingent upon the attainment during a Performance Period
of the Performance Goals) shall not exceed five hundred thousand (500,000)&nbsp;shares of Common Stock; provided, however that in connection with his or her initial employment, an Employee may be granted Performance Stock Awards for up to an
additional five hundred thousand (500,000)&nbsp;shares of Common Stock which shall not count against such annual limit. The Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
may provide for or, subject to such terms and conditions as the Board may specify, may permit a Participant to elect for, the payment of any Performance Stock Award to be deferred to a specified
date or event. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Performance Stock Award, as determined
by the Board and contained in the Performance Stock Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Performance Stock Award in such manner as
determined by the Board. Any additional shares covered by the Performance Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Performance Stock Award Agreement to which they
relate, including any vesting contingent upon the attainment during a Performance Period of certain Performance Goals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Board Discretion</B>. The Board retains the discretion to reduce or eliminate the compensation or economic benefit due
upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) Section</B><B></B><B>&nbsp;162(m) Compliance</B>. Unless otherwise permitted in compliance with the requirements of
Section&nbsp;162(m) of the Code with respect to an Award intended to qualify as &#147;performance-based compensation&#148; thereunder, the Committee shall establish the Performance Goals applicable to, and the formula for calculating the amount
payable under, the Award no later than the earlier of (a)&nbsp;the date ninety (90)&nbsp;days after the commencement of the applicable Performance Period, or (b)&nbsp;the date on which twenty-five percent (25%)&nbsp;of the Performance Period has
elapsed, and in either event at a time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior to the payment of any compensation under an Award intended to qualify as &#147;performance-based
compensation&#148; under Section&nbsp;162(m) of the Code, the Committee shall certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where such relate solely to the
increase in the value of the Common Stock). Notwithstanding satisfaction of any completion of any Performance Goals, to the extent specified at the time of grant of an Award to &#147;covered employees&#148; within the meaning of Section&nbsp;162(m)
of the Code, the number of shares of Common Stock, Options, or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further
considerations as the Committee, in its sole discretion, shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Other Stock Awards</B>. Other forms of Stock Awards
valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof may be granted either alone or in addition to Stock Awards provided for under Section&nbsp;5 and the preceding provisions of
this Section&nbsp;6. Subject to the provisions of the Plan, the Board shall have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common
Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. I<SMALL>NITIAL</SMALL> A<SMALL>ND</SMALL> A<SMALL>NNUAL</SMALL> G<SMALL>RANTS</SMALL> T<SMALL>O</SMALL> E<SMALL>LIGIBLE</SMALL>
D<SMALL>IRECTORS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) General</B>. The Director Grant Program in this Section&nbsp;7 provides that Eligible Directors shall
receive certain Stock Awards at designated intervals over their period of Continuous Service on the Board. For the avoidance of doubt, all Stock Awards granted the Plan, including any Stock Awards granted under this Section&nbsp;7, are subject to
all the terms and conditions of the Plan, including but not limited to the share reserve limitations of Section&nbsp;3 and the cancellation and regrant restrictions set forth in Section&nbsp;2(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Eligibility</B>. Stock Awards shall be granted under this Section&nbsp;7 to all
Eligible Directors who meet the criteria specified below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Director Grants. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Initial Award</B>. At the time a person is first elected or appointed to serve on the Board, provided such person is an
Eligible Director, he or she automatically shall, upon the date of his or her initial election or appointment as an Eligible Director, be granted an Option to purchase a number of shares of Common Stock as determined by the Board in its sole
discretion, on the terms and conditions set forth in Section&nbsp;7(d) (each such Option is an &#147;<B><I>Initial Award</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Annual Awards</B>. On the date of each Annual Meeting, commencing with the Annual Meeting in 2012, each person who is
then a Eligible Director and who has served as an Eligible Director on the Board for a period of at least six (6)&nbsp;months shall be granted an Option to purchase a number of shares of Common Stock as determined by the Board, in its sole
discretion on the terms and conditions set forth in Section&nbsp;7(d) (each such Option is an &#147;<B><I>Annual Award</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Director Option Grant Provisions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Option Type</B>. Each Option automatically granted under this Section&nbsp;7 shall be a Nonstatutory Stock Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Term</B>. No Option shall be exercisable after the expiration of ten (10)&nbsp;years from the date it was granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) Exercise Price</B>. The exercise price of each Option shall be one hundred percent (100%)&nbsp;of the Fair Market
Value of the Common Stock subject to the Option on the date the Option is granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Vesting</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Initial Awards granted pursuant to this Section&nbsp;7 shall vest monthly with respect to 1/36th of the shares over
the three (3)&nbsp;year period following the date of grant, subject to the Eligible Director&#146;s Continuous Service through the applicable vesting dates, so that the Option will be fully vested on the third anniversary of the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> Annual Awards granted pursuant to this Section&nbsp;7 shall vest monthly with respect to 1/12th of the shares over
the one (1)&nbsp;year period following the date of grant, subject to the Eligible Director&#146;s Continuous Service through the applicable vesting dates, so that the Option will be fully vested on the first anniversary of the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> Each Option granted pursuant to this Section shall automatically fully accelerate vesting upon a Corporate
Transaction, subject to the Eligible Director&#146;s Continuous Service through the date of the Corporate Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) Remaining Terms</B>. The remaining terms and conditions of each Option shall be as set forth in an Option Agreement in
the form adopted from time to time by the Board; provided, however, that the terms of such Option Agreement shall be consistent with the terms of the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. C<SMALL>OVENANTS</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Availability of Shares</B>. During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of
Common Stock reasonably required to satisfy such Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Securities Law Compliance</B>. The Company shall seek to obtain
from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this
undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any
such regulatory commission or agency the authority that counsel for the Company deems </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock
Awards unless and until such authority is obtained. A Participant shall not be eligible for the grant of a Stock Award or the subsequent issuance of Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any
applicable securities law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) No Obligation to Notify or Minimize Taxes</B>. The Company shall have no duty or obligation to any
Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a
possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. M<SMALL>ISCELLANEOUS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
Use of Proceeds from Sales of Common Stock</B>. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Corporate Action Constituting Grant of Stock Awards</B>. Corporate action constituting a grant by the Company of a Stock Award to any
Participant shall be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or
accepted by, the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Stockholder Rights</B>. No Participant shall be deemed to be the holder of, or to have any of the
rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms, if applicable, and
(ii)&nbsp;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)
No Employment or Other Service Rights</B>. Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto shall confer upon any Participant any right to continue to
serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or
without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any
applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)
Incentive Stock Option $100,000 Limitation</B>. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder
during any calendar year (under all plans of the Company and any Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated
as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Investment
Assurances</B>. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and
experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone
or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award
for the Participant&#146;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (A)&nbsp;the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act,
or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the
Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Withholding Obligations</B>. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole
discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares
of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to
be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from
any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)
Electronic Delivery</B>. Any reference herein to a &#147;written&#148; agreement or document shall include any agreement or document delivered electronically or posted on the Company&#146;s intranet (or other shared electronic medium controlled by
the Company to which the Participant has access). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Deferrals</B>. To the extent permitted by applicable law, the Board, in its sole
discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made
by Participants. Deferrals by Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise
providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#146;s termination
of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) Compliance with Section</B><B></B><B>&nbsp;409A</B>. To the extent that the Board determines that any Award granted hereunder is
subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code. To the extent applicable, the Plan
and Award Agreements shall be interpreted in accordance with Section&nbsp;409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are
publicly traded and a Participant holding an Award that constitutes &#147;<B><I>deferred compensation</I></B>&#148; under Section&nbsp;409A of the Code is a &#147;<B><I>specified employee</I></B>&#148; for purposes of Section&nbsp;409A of the Code,
no distribution or payment of any amount shall be made upon a &#147;<B><I>separation from service</I></B>&#148; before a date that is six (6)&nbsp;months following the date of such Participant&#146;s &#147;<B><I>separation from service</I></B>&#148;
(as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) Minimum Vesting</B>. After the Effective Date of the Plan, generally (i)&nbsp;no Full Value Award that vests on the basis of the
Participant&#146;s Continuous Service with the Company shall vest at a rate that is any more rapid than ratably over a three (3)-year period and (ii)&nbsp;no Full Value Award that vests based on the satisfaction of Performance Goals shall provide
for a Performance Period of less than twelve (12)&nbsp;months. Notwithstanding the foregoing, Full Value Awards may be granted by the Committee after the Effective Date that do not meet the foregoing minimum vesting guidelines, provided that such
Awards shall be limited to no more than 5% of the total number of shares reserved for issuance under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. A<SMALL>DJUSTMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGES</SMALL> I<SMALL>N</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Capitalization
Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii)&nbsp;the
class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(e), (iii)&nbsp;the class(es) and maximum number of securities that may be awarded to any person pursuant to
Sections 3(f) and 6(c)(i) , and (iv)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Dissolution or Liquidation</B>. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or
liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) shall terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject
to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Corporate Transaction</B>. The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Stock Awards May Be Assumed. In the event of a Corporate Transaction, any surviving corporation or acquiring
corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but
not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to
Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#146;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose
to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants. The terms of any assumption,
continuation or substitution shall be set by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Stock Awards Held by Current Employee and Director
Participants. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such
outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants that are Employees or Directors and whose Continuous Service has not terminated prior to the effective
time of the Corporate Transaction (referred to as the &#147;<B><I>Current Employee and Director Participants</I></B>&#148;), the vesting of such Stock Awards (and, with respect to Options and SARs, the time when such Stock Awards may be exercised)
shall be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board shall determine (or, if the Board shall not determine such a date, to the
date that is fifteen (15)&nbsp;days prior to the effective time of the Corporate Transaction), and such Stock Awards shall terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any
reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall lapse (contingent upon the effectiveness of the Corporate Transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Stock Awards Held by Persons other than Current Employee and Director
Participants</B>. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such
outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Employee and Director Participants, such Stock Awards shall terminate if not exercised
(if applicable) prior to the effective time of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall not terminate and may continue to be exercised
notwithstanding the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Payment for Stock Awards in Lieu of Exercise</B>. Notwithstanding the foregoing, in the
event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but will receive a
payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of the Stock Award (including, at the
discretion of the Board, any unvested portion of such Stock Award), over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Change in Control</B>. A Stock Award may be subject to acceleration of vesting and exercisability upon or after a Change in Control as
may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration shall occur.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Plan Term</B>. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan shall
automatically terminate on the day before the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the earlier of (i)&nbsp;the date the Plan is adopted by the Board, or (ii)&nbsp;the date the Plan is approved by the
stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) No
Impairment of Rights</B>. Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.&nbsp;</B>T<SMALL>HIS</SMALL> P<SMALL>LAN</SMALL>
<SMALL>SHALL</SMALL> <SMALL>BECOME</SMALL> <SMALL>EFFECTIVE</SMALL> <SMALL>ON</SMALL> <SMALL>THE</SMALL> E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL>.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B>T<SMALL>HE</SMALL> L<SMALL>AWS</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> S<SMALL>TATE</SMALL> <SMALL>OF</SMALL> C<SMALL>ALIFORNIA</SMALL> <SMALL>SHALL</SMALL> <SMALL>GOVERN</SMALL> <SMALL>ALL</SMALL> <SMALL>QUESTIONS</SMALL> <SMALL>CONCERNING</SMALL> <SMALL>THE</SMALL> <SMALL>CONSTRUCTION</SMALL>,
<SMALL>VALIDITY</SMALL> <SMALL>AND</SMALL> <SMALL>INTERPRETATION</SMALL> <SMALL>OF</SMALL> <SMALL>THIS</SMALL> P<SMALL>LAN</SMALL>, <SMALL>WITHOUT</SMALL> <SMALL>REGARD</SMALL> <SMALL>TO</SMALL> <SMALL>THAT</SMALL>
<SMALL>STATE</SMALL>&#146;<SMALL>S</SMALL> <SMALL>CONFLICT</SMALL> <SMALL>OF</SMALL> <SMALL>LAWS</SMALL> <SMALL>RULES</SMALL>.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14. D<SMALL>EFINITIONS</SMALL>. </B>A<SMALL>S</SMALL> <SMALL>USED</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>,
<SMALL>THE</SMALL> <SMALL>FOLLOWING</SMALL> <SMALL>DEFINITIONS</SMALL> <SMALL>SHALL</SMALL> <SMALL>APPLY</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>CAPITALIZED</SMALL> <SMALL>TERMS</SMALL> <SMALL>INDICATED</SMALL> <SMALL>BELOW</SMALL>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or &#147;subsidiary&#148; of the
Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board shall have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing
definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Annual Meeting</I></B>&#148; means the first meeting of the Company&#146;s stockholders held each
calendar year at which Directors of the Company are selected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#147;<B><I>Award</I></B>&#148; means a Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>&#147;<B><I>Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms and
conditions of an Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to,
the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend,
dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used
in Statement of Financial Accounting Standards No.&nbsp;123 (revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a Capitalization Adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Cause</I></B>&#148; shall mean, with respect to a Participant, the occurrence of any of the following events:
(i)&nbsp;such Participant&#146;s commission of any crime involving fraud, dishonesty or moral turpitude; (ii)&nbsp;such Participant&#146;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in
(or might have reasonably resulted in) material harm to the business of the Company; (iii)&nbsp;such Participant&#146;s intentional, material violation of any contract or agreement between Participant and the Company or any statutory duty
Participant owes to the Company; or (iv)&nbsp;such Participant&#146;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business
of the Company; provided, however, that the action or conduct described in clauses (iii)&nbsp;and (iv)&nbsp;above will constitute &#147;<B><I>Cause</I></B>&#148; only if such action or conduct continues after the Company has provided such
Participant with written notice thereof and not less than five business days to cure the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Change in
Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more
than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be
deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person
that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level of
Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the
Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the
Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the
designated percentage threshold, then a Change in Control shall be deemed to occur; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>there is consummated a
merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do
not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more than fifty percent (50%)&nbsp;of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or
(B)&nbsp;more than fifty percent (50%)&nbsp;of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of
the outstanding voting securities of the Company immediately prior to such transaction; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>the stockholders of the Company approve or the Board approves a
plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent
(50%)&nbsp;of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> individuals who, on the date the Plan is adopted by the Board,
are members of the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any
new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, the term Change in Control shall not include a sale of assets, merger or
other transaction effected exclusively for the purpose of changing the domicile of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Code</I></B>&#148;
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>
&#147;<B><I>Committee</I></B>&#148; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section&nbsp;2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Company</I></B>&#148; means Neurocrine Biosciences, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, shall not cause a Director to be considered a &#147;<B><I>Consultant</I></B>&#148; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, shall not terminate a Participant&#146;s Continuous Service; provided, however, if the Entity
for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s Continuous Service shall be considered to have terminated on the date such Entity ceases to
qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of
(i)&nbsp;any leave of absence approved by the Board or Chief Executive Officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the
foregoing, a leave of absence shall be treated as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence
agreement or policy applicable to the Participant, or as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Corporate
Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the
consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>a sale or other disposition of at least ninety
percent (90%)&nbsp;of the outstanding securities of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>a merger, consolidation or
similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>
&#147;<B><I>Covered Employee</I></B>&#148; shall have the meaning provided in Section&nbsp;162(m)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>
&#147;<B><I>Director</I></B>&#148; means a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Director Grant Program</I></B>&#148; means the
grant program in effect under Section&nbsp;7 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a
Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to
last for a continuous period of not less than twelve (12)&nbsp;months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under
the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan document, which is the date
of the annual meeting of stockholders of the Company held in 2011 provided this Plan is approved by the Company&#146;s stockholders at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Eligible Director</I></B>&#148; means a Director who is not an Employee and is eligible to participate in the Director
Grant Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service
solely as a Director, or payment of a fee for such services, shall not cause a Director to be considered an &#147;<B><I>Employee</I></B>&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Exchange Act Person</I></B>&#148; means any natural person, Entity or &#147;group&#148;
(within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;<B><I>Exchange Act Person</I></B>&#148; shall not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the
Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the
Company; or (v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company
representing more than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s then outstanding securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market
Value of a share of Common Stock shall be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a
source the Board deems reliable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Unless otherwise provided by the Board, if there is no closing sales price
for the Common Stock on the date of determination, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in
good faith and in a manner that complies with Sections 409A and 422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Full Value Award</I></B>&#148;
generally means any Award granted under the Plan, but does not include any Option or a SAR granted pursuant to Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan that is intended
to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B>
&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or
indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item&nbsp;404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be
required under Item&nbsp;404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation
<FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;5 of the Plan that does not
qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option
or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><I>Option
Agreement</I></B>&#148; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#147;<B><I>Other Stock Award Agreement</I></B>&#148; means a written agreement
between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><I>Outside Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee of the Company or an
&#147;affiliated corporation&#148; (within the meaning of Treasury Regulations promulgated under Section&nbsp;162(m) of the Code), is not a former employee of the Company or an &#147;affiliated corporation&#148; who receives compensation for prior
services (other than benefits under a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan) during the taxable year, has not been an officer of the Company or an &#147;affiliated corporation,&#148; and does not receive remuneration
from the Company or an &#147;affiliated corporation,&#148; either directly or indirectly, in any capacity other than as a Director, or (ii)&nbsp;is otherwise considered an &#147;outside director&#148; for purposes of Section&nbsp;162(m) of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#147;<B><I>Own,</I></B>&#148; &#147;<B><I>Owned,</I></B>&#148; &#147;<B><I>Owner,</I></B>&#148;
&#147;<B><I>Ownership</I></B>&#148; A person or Entity shall be deemed to &#147;<B><I>Own,</I></B>&#148; to have &#147;<B><I>Owned,</I></B>&#148; to be the &#147;<B><I>Owner</I></B>&#148; of, or to have acquired &#147;<B><I>Ownership</I></B>&#148;
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#147;<B><I>Participant</I></B>&#148; means a person to whom an Award is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><I>Performance Criteria</I></B>&#148; means the
one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination
of, the following as determined by the Board: (i)&nbsp;earnings (including earnings per share and net earnings, in either case before or after any or all of: interest, taxes, depreciation and amortization, legal settlements or other income
(expense), or stock-based compensation, other <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses and changes in deferred revenue); (ii)&nbsp;total stockholder return; (iii)&nbsp;return on equity or average stockholder&#146;s equity;
(iv)&nbsp;return on assets, investment, or capital employed; (v)&nbsp;stock price; (vi)&nbsp;margin (including gross margin); (vii)&nbsp;income (before or after taxes); (viii)&nbsp;operating income; (ix)&nbsp;operating income after taxes; <FONT
STYLE="white-space:nowrap">(x)&nbsp;pre-tax</FONT> profit; (xi)&nbsp;operating cash flow; (xii)&nbsp;sales or revenue targets; (xiii)&nbsp;increases in revenue or product revenue; (xiv)&nbsp;expenses and cost reduction goals; (xv)&nbsp;improvement
in or attainment of working capital levels; (xvi)&nbsp;economic value added (or an equivalent metric); (xvii)&nbsp;market share; (xviii)&nbsp;cash flow; (xix)&nbsp;cash flow per share; (xx)&nbsp;cash burn; (xxi)&nbsp;share price performance;
(xxii)&nbsp;debt reduction; (xxiii)&nbsp;implementation or completion of projects or processes (including, without limitation, discovery of a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> drug candidate, recommendation of a drug candidate to
enter a clinical trial, clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals,
presentation of studies and launch of commercial plans, compliance programs or education campaigns); (xxiv)&nbsp;customer satisfaction; (xxv)&nbsp;stockholders&#146; equity; (xxvi)&nbsp;capital expenditures; (xxvii)&nbsp;debt levels;
(xxviii)&nbsp;financings; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii)&nbsp;employee hiring; (xxxiv)&nbsp;funds from
operations; (xxxv)&nbsp;budget management; (xxxvi)&nbsp;strategic partnerships or transactions (including acquisitions, joint ventures or licensing transactions); (xxxvii)&nbsp;engagement of thought leaders and patient advocacy groups;
(xxxviii)&nbsp;enhancement of intellectual property portfolio, filing of patent applications and granting of patents; (xxxix)&nbsp;litigation preparation and management; and (xl)&nbsp;to the extent that an Award is not intended to comply with
Section&nbsp;162(m) of the Code, other measures of performance selected by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#147;<B><I>Performance
Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Performance Goals are established, the Board shall appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to
exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated Performance Goals; (3)&nbsp;to exclude the effects of changes
to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels
during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed
under generally accepted accounting principles; (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; and (12)&nbsp;to exclude the effects of the
timing of acceptance for review and/or approval of submissions to the U.S. Food and Drug Administration or any other regulatory body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or
more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a Stock Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><I>Performance Stock Award</I></B>&#148; means a Stock Award granted under the terms and conditions of
Section&nbsp;6(c)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#147;<B><I>Plan</I></B>&#148; means this Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common Stock which is granted pursuant to the terms
and conditions of Section&nbsp;6(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#147;<B><I>Restricted Stock Award Agreement</I></B>&#148; means a written agreement
between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#147;<B><I>Restricted Stock Unit Award</I></B>&#148; means a right to receive shares of Common Stock which is granted pursuant to
the terms and conditions of Section&nbsp;6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#147;<B><I>Restricted Stock Unit Award Agreement</I></B>&#148; means a
written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement shall be subject to the terms and conditions
of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right to receive the appreciation on
Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#147;<B><I>Stock Appreciation Right
Agreement</I></B>&#148; or &#147;<B><I>SAR Agreement</I></B>&#148;) means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock
Appreciation Right Agreement shall be subject to the terms and conditions of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#147;<B><I>Stock Award</I></B>&#148; means any right to receive Common Stock
granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a SAR, a Performance Stock Award or any Other Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> &#147;<B><I>Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than fifty
percent (50%)&nbsp;of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall
have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct
or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd)</B> &#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of
the Code) stock possessing more than ten percent (10%)&nbsp;of the total combined voting power of all classes of stock of the Company or any Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:</B> The proxy
statement and annual report to stockholders are available at www.proxyvote.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.50pt;background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>This Proxy is solicited on behalf of the Board of
Directors</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 ANNUAL MEETING OF STOCKHOLDERS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD MAY&nbsp;22, 2019</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned stockholder of NEUROCRINE BIOSCIENCES, INC., a Delaware corporation, hereby acknowledges receipt of the Notice of Annual Meeting of
Stockholders and Proxy Statement, each dated April&nbsp;17, 2019, and hereby appoints Kevin C. Gorman and Matthew C. Abernethy, and each of them, proxies and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> with full power to each of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the 2019 Annual Meeting of
Stockholders of NEUROCRINE BIOSCIENCES, INC. to be held on May&nbsp;22, 2019 at 10:30 a.m. local time, at the Company&#146;s corporate headquarters located at 12780 El Camino Real, San Diego, California 92130, and at any adjournment or adjournments
thereof, and to vote all&nbsp;shares of Common Stock which the undersigned would be entitled to vote, if then and there personally present, on the matters set forth on the reverse side.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION IS INDICATED, WILL BE
VOTED FOR THE ELECTION OF THE TWO NOMINEES FOR DIRECTOR NAMED IN THE PROXY STATEMENT, FOR THE ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY&#146;S NAMED EXECUTIVE OFFICERS, FOR THE APPROVAL OF THE AMENDMENT TO THE COMPANY&#146;S 2011 EQUITY
INCENTIVE PLAN, FOR RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG LLP AS THE COMPANY&#146;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AND TO TRANSACT SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE ANNUAL MEETING OR ANY
CONTINUATION, ADJOURNMENT OR POSTPONEMENT THEREOF.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(This Proxy should be marked,
dated and signed by the stockholder(s) exactly as his or her name appears hereon, and returned promptly in the enclosed envelope. Persons signing in a fiduciary capacity should so indicate. If&nbsp;shares are held by joint tenants or as community
property, both should sign.)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Continued and to be signed on reverse
side</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> </div>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g695930g23y78.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Neurocrine Biosciences, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>12780 EL CAMINO REAL</I></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>SAN DIEGO, CA
92130</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTE BY INTERNET - www.proxyvote.com</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the meeting
date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Delivery of Future PROXY MATERIALS</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you would like to reduce the costs incurred by Neurocrine Biosciences, Inc. in mailing stockholder communications, you can consent to receiving all future
proxy statements, proxy cards and annual reports electronically via <FONT STYLE="white-space:nowrap">e-mail</FONT> or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when
prompted, indicate that you agree to receive or access stockholder communications electronically in future years.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTE BY PHONE -
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in
hand when you call and then follow the instructions.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTE BY MAIL</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark, sign and date your proxy card and return it in the postage-paid envelope we have
provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">KEEP&nbsp;THIS&nbsp;PORTION&nbsp;FOR&nbsp;YOUR&nbsp;RECORDS</TD></TR>
</TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;&nbsp;-&nbsp;-&nbsp;- </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">DETACH&nbsp;AND&nbsp;RETURN&nbsp;THIS&nbsp;PORTION&nbsp;ONLY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.00pt;background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="5" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Withhold</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For&nbsp;All</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Except</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">To withhold authority to vote for any<BR>individual nominee(s), mark &#147;For All<BR>Except&#148; and write the number(s)&nbsp;of&nbsp;the<BR>nominee(s) on the line below.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.70em; font-size:8pt; font-family:Times New Roman"><B>The Board of Directors recommends that you vote FOR ALL of the following Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>1.&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Election of Directors</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Nominees</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13">(01) Richard F. Pops&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(02) Stephen A. Sherwin, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; font-size:8pt; font-family:Times New Roman"><B>&nbsp;The Board of Directors recommends you vote FOR proposals 2, 3 and 4:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>For</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Against</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Abstain</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>2.</B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13"><FONT STYLE="font-size:8pt">Advisory vote to approve the compensation paid to the Company&#146;s named executive officers.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:8pt"><B>3.</B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13"><FONT STYLE="font-size:8pt">To approve an amendment to the Company&#146;s 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 19,000,000 to
21,000,000.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:8pt"><B>4.&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"><FONT STYLE="font-size:8pt">To ratify the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.70em; font-size:8pt; font-family:Times New Roman"><B>NOTE: </B>Company to transact such other business as may properly come before the Annual Meeting or
any continuation, adjournment or postponement thereof.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.70em; font-size:8pt; font-family:Times New Roman">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator,
or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership,&nbsp;please sign in full corporate or partnership name, by authorized officer.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD></TR>

<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;Signature [PLEASE
SIGN&nbsp;WITHIN&nbsp;BOX]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;Signature (Joint
Owners)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> </div>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g695930g23y78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g695930g23y78.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M5&(7L: /7/&WQ"TSP3IRRW3>9<R#Y(5/)H \5O/CWXGOKH_V;:(D8_A"9.*
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M0!W'Q?\  VA^"M,LCI$<L<TK8=V?.10!S/PH\$VWC3Q(T-ZQ%I N]U4X+>U
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M0!\=Z]8ZO\.O&%Q;6\TEN\3YC93@,O:@#Z.^'_C&_P!<^'4VKWBJUS;HW/\
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M *X&@#U'XX^%KK7O"RW5E&9);0[RHZD4 ?/G@GQC>>!]=^W6Z;@1LDC;C(H
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M(AG0HV#@XH \\L?@3X8L;V"ZC><O"P9<OW% %C7/@OX<UW5IM0NGF$TO4*U
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@ B#"CH* (A96PN?M/E#SO[U $] !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g695930g59p42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g695930g59p42.jpg
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M 0$! 0$! 0'_P  1"  [ (4# 1$  A$! Q$!_\0 '0 !  (" P$!
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M*7,$U8'#>.+)=31ZBP-S3TO'LCIUFK-UQ_%-];+*O$5J/,;P0'TJW]9BE\F
M92JTEFZ%1CZ7O=A-93L4D<[V59>QY"R[B[-;Z:6_-6;N.3R9:/=WADE52_:
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M=,% ]?!WLY_2^5?0C3[M]@J)OE.Z/=6&K^8J3DISN)GFMV?.$]B*YUZ^(5+
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M,@ 4H!P2//=^I!N:N.NU&VKI*"A^Y]=<#OC"!O3]S].=9&C0,/Q\^G[8E_\
MG..N7OS1>%7!43=)/TB>A]SI J^TU]^R_JL<L-W?E+^6]!8YC%^KX]U^FL,:
MR:GV_/\ D!?XRD?/I_VW/_LI@X*O^%??T9:"X)#@$!/9;JOE[67*+[MTZ_8I
M ,\XZK@EVXP(B5=O4]N<#0B2+B>5D6# AS%RE1XA@63B)QJV7EY".B6QV9)"
M9@H^"LHI!I]R6#K1TO%OH\R3W1_=+#F_.MM&V8PL_7_;%J0<LIZO2IT"V+']
MTAP23L]'M**!SIH3$$Y53.1=,?:2\.[BK#&'6B9=@X5&)1<71XD.5@^I(P]<
MY:VQ.F.D.\&ZC6F2B\3*W3%^)WK;'ZRZ9S W<-9.-2N%L9M'R12N6O[CI%??
M*-U"*>Q\#\#?9/YI1B]C:K[]V,=A>X;MTR^)F^%>AW--<,J/H92N<LHR] 9+
M>K_K75:W_$V)6J:(_ B)+ JB(?D#H"B @.ZD%CI%X)OS\/3:C(0MOU069E2E
MC\5]>&HD>KX%(+78IR_3K,AOD2R#^KV3-L,\73\B &80+5$P@ "4W^8CG])9
MS;VJB7G=&10^IOU'$M*-GUK[5]8*:S!4AW4/2M7:!<8[T>?)T2'L^&:U+K)^
M/)0$)=FL8 #_ )4S#Y *Z/Z)?]$^6.HFZP5!ID+DBWQ^0,@1-8A(ZZWF)K"=
M*C+?:&<<W0G+(PJ",I-HUEK,R*;A^C!HR\BC&$7!HD[6(D4XB9F? ' *=>'=
ME\4])>WO>E1[G(1+&C"WQ;MAK/BY20;Q07*S9.;3ZW[ I48!RN3M26W(M2ID
MLK'-7*E>JU+<SKA,T7$+K +-.:T>V\6[Y85\+^)*GT::=7;"FOMMVRV,!>6W
M&WYL@[!YLFY9L*,O7X"S+/9S'N/"(*@"L.A%14VXL4K!@DU-#35C7JZR1VE4
MB00&)M-ZJ^&-EU?BR2O)2&S,/E5GD*DV.F3V *;B:YR%AP%%T(SC-V6,K-F<
MRZK<?5\HSM]A:55XAR!(-E',)&O(^J8*_+,V (N5;N:X,VIOVUM3A2OGX%'K
MLTU)WE[G]S[;L)K)IAL)BFDX[Q;BW$LQ'[45)E@RS/K9%.+K-3:,&QL$JZCY
MYM"N9<T=(.8.5D4VX@P=.!01EX_[HM'4C%*4JU;?=OL5^1Z#?! K,]J*L#IG
MV\]7/9+;?,;B*S(W;3?-UG,F*454QM,+=28ZL,ZZ /0FV3/DNU3\@X$#KD@<
M</" 10$T"E%8=Z$X+&TEOR?3WC9FX)#@'R<A%"&34*4Z9RF(<AR@8AR& 2F*
M8I@$IBF*(@8H@(" B AXX!4R^F;!.&SGW$TC&RHK:R5C:V*#"_LS"-=(FI<,
M[1 JP I_TJ@N\?P&-/?F1^2L6M?'_K43X+:3X='MU57DJ=2US#0,'7&8QU>A
MHF!CS.73TS"&CF<6S%X^7.Z?.Q:L44$!<O'*BCATN)/NN%U#K+'.H8QA$3EN
M . . . . . 44<U4W%?9Y]49"8\".C[MAS75C$1N4C%(F^A;(ZUSJDC99^&E
M4/R1>P_\SRT7BVPM7/\ 3O6S600$%FZZ9%A=5CH<;R=MU?TFR]< >/@/@ ^
M /\ 7! < < < Z2V)Q#@G-^(+C1-DJ#4<D8>4CE)ZV5VZQ!9F'3;5LAY@LRF
MB5,[UG(P_M3O6,C%'0E6:J8G8KD5-\CJ;3JG1\C$=/-K<5;LZ\T393"3:U-L
M87]2T-JL%SKY:S-K)4VVSE(DESQ*;V0229GF*Y(%CU$G:I5FA$CF*BJ*B"0-
M.+H\5U53K#8#LWZ_=70D4<X[=8/ITS$_="0I[6Z,+AD%L9#U H0V.:.-DO0G
M Y3)E*6O&$RI12+Y4 2@.J,GA%O?2W/ A S'VD[:]LC.Q:O].>%,A5O'-L]W
M3LL[_P"8(MYCRC4:LORF93R6-A]+Q\VGWD>N9-&0_J<F,&ZKL]?QW%R";2WP
MXVH*%YM5^A7;XY4]?(FYZX] \4];NL%4USQ@X6GG+=XZM>2,@2#-)A+Y)R1,
MMF3>>M;YDBJNG&LP;1\="5V%(Y=_HM:B(F/</Y1^B]EGXQ*3DVV;X<&1P!P!
MP!P!P#7W:Y+/CC6O.+75I."4V)>XTM3##IK)(H140UO3Z+79PL@L_=IJ,4'4
M8NL,C%A)@2)6E&K)"56;QRKI=,=5*JN%;\"!?Z?3IRS)U_N,S[';;?HR>R&8
M6"5(AZY&61E='E+H(3*-FM+JQVV-7>Q4K9\@6IA!OWJ$5)2K:/CZQ'.%Y=U(
MS4@PB132:12HE\*\W^BS5P2' ' ' /P<MFSULX9O$$731V@JV=-7"9%F[ELN
MF9)=!=%0#)JHK)',FJF<IB*$,8I@$HB' /*$GBR^/=OME]5Z)=\HTW76%SOD
M6M,<.UG+63H2CC"LK0_CF[-]$1UM;IRPE8HI-E'4J9Z\<)D#W#A4WSSF;X+J
M>I7@I-)O5BZM)NM6MFY%SWK(Z:>L=WB>M9?GM1:!=+V=P03O<C3-]R7 G%%%
M!=,3T>_VZR48Y@54,83&K8F-\%.)BE*!>D9:2;MK.E%A19;J<BQ? P$%5H:-
MKM8A8FN5^&:),(>"@8YG$0T4P;E]"#*-C(]%NR8M$2_BDV:H)(IE^"$ ."9R
5W ' ' ' ' ' ' ' ' ' ' ' /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g695930g68x09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g695930g68x09.jpg
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M4G2S8I/4X?#_Q  = 0$  00# 0               04&!P@" P0)_\0 6!$
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M]0(W6P<V%3 \+N%FK4;G]/OPJX5'DAUT45L/.;*U<HH,1>@)4O B%1!95DB
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M8.!J[  "*?JM<DBP;/\ A]_M_P"IC*?&/.?+>!AKX-YN)FC2W5+Q9.G=/NI
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MZ!^FWC]U/09A8)TH: $V&FVZ.)B#HMQH\.%6 FJI5+(T2#TN5";(U2.((_\
M6]!&SUKPZ=.GAO\ O/Y?$2_P(# !@ P 8 , & # !@ P 8 , & # !@ P 8
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M0)(S+6C[B,B^0][^TQ=E_P##7"NPP>ACNV-7?L<7I%<J59)M7J[F5-UJ+2+
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M77#I%GZ[9Z'SA!"/-CUJOF.BW U8GF],3)D5**\#'3(5;IE+#U\(V9EK?O\
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MA>C0.1]>$E3?00EVO/H"L=/8@P:7, #+1S.J09)@O)#HD1Y8=FR,RV1%HO\
M926NO<9EW&1;+Y_,9@K]-[7>?'_CJW5O^)7GWB_$5^LYGK#DO0O2'4K5TF-U
M6A%[Y0JQ.L/:QTZ;TGLO+>=]<"WRZC@ FQL3+W!;Y,P$'2Q ]F' "#,B,^Y6
M]:,B(BUW]VM$>NAEKH>_$2L^'UW]-TLW7>>_M3JDJ:'ZOT.LV^_=)Z+/N[T3
MIO-15&B7#D]5BV,_9+-*IW#A%@IW.;C?VIX^J6?N?[W(UP$W$LOY[H<3\/D^
MWS]Y_9H8Z^,9V_O/,N.M'/,I&VMWOS;*H_L+H0.L5*Y'H-YYQS'H Y^5R2YG
M*T&)#ZG5.B5(1UBS3R9B1%:F)Y*H K;;!QZ5'"4$1GU\=D7N,R[_ )CUT[_$
M=0=[QN5Y]\<V>Y];';9Y!-_";L7MX3SVE<W*V_I?1"EDZS2P8:* C!K-N>:O
M[(J-!&T^NP <U_\ ,-VJG["D#MA'&P$;ZZ]Q&'+HNO?S<ON+S$.OB%^FSLWU
M]\+#K].XWZ>-5.]\>^)98[[Y4((NO!>J]1A\1X]!(U<99^;&RM?DHL%=):.W
M+GR241X\^S.@%*BU*)$P[#\CD1%RJZEWHZ^!;WXZW\HL7S)Z5Z?4.3?!AL$[
MKS_M>]=&XK\1>^0+X0[%T2F,3K-SWB9WH@7EO129VSPJW>9M36V/X\6M'=*\
M5(48W7BERA2ALM3KB8\2]_3ZM_P!1=5=-:Y>FM]^NI?;HO/0HG=OBBWB5T;P
MMWVR".G5:P<8ZW[4J_>?/('E?6>=WH*2IW@2#TS5-[#R G;3O[P@5BV'%7\5
M8P5DL=4?YLV#NXJ6-.,FH4"0)/Y1=/R2,CV7YY%T/KK9=/EZ&/3KQJYHZ-R?
MG-_:M]*O\>[4VOVN)=.<1)\&AV>%8!K!6$8J48J8/$FP<R)*9<@*GEI4MUG:
M7G]1W'%16 ZQDO !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@!AGT#QL/W_ )-:.2V*Y7^A5ZU. 5'++RZX$^?W
MJ,, V,399,$)=0SK!>N-FM!TAC,\:\Q.6 GE(D:1%=DIE, (]=?MZ_4/,K7X
MUXYM!\%U*G=$[F7\P^U>V?$C[7((]'[!T6_6&1R[E_DJ_.^-Q$Z_6<],/)"6
MROU=GTB*K[9!J#&NLF.3B(?DUJ!,:#M[^;H1&1)+H6M'S$1]"[^\R]Y=!)3D
M)#V1WWR+\/SU#V&^7210&/%S^[C7ZITNV<RZ/=_2_0;%1*=R/J9./5Y 2;TN
MSVOG<@GKDE8=-0Q+_=KQ6BY5H<-F(L 0.*N4C422W[70^_1%O>O[_(OG&PWX
M<W?XG5:24$CP=W(C7;9V.6QURW74G<$=.LU Z2FA],*5IJSDS%V#\C"WMTES
M7@DVX$WK%:*-R\E(*C SP9IXV'$RUW]^B/IW=2V7=[A%WXL?J[K/G6U\1[KS
M(I=E<F\9=KYE=_6%;K=+NARN7SF781MDYO=PIFU!0[]5$6#CU$MX3I,2L68F
MA!)[H5.L[+#$RMBG9(2DB/9'WGW'Y'WE\N^[Z/$QD<7[.Z:.]_\ LH,1+ENG
M>;N)>5_*O1><<NXGRD]T7H]JG]G*= D$+!5(U9L4XE=C4Q EB;(V. 28>Z3
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MS4N&S(T7!,;*GMM!R6G-3!K?ZV7^F&\SK]3G:_ZRX'6*U@ P 8 , & # !@
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M0*KU*IA1M<K-<!C6$1AP8"!#QH8L0*@1FT1X0\?%CQ(K"$-,,MMITG00+BP
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !
M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M !@ P 8 , & # !@!^;WI.MJ5O6M:UO>][W\M:UK^>][WO\ EK6M?SWO?]F
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M/IOP[_D+^._E$I," P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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M!:I5W3JV?NF$B/8&;!K]5CDFIGS=SS>JZ7^TT7]V6O\ AAZ/6=Q_9Z5U[_\
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M/$^H_7WHR@76J=+)69JIR^[7KN1^A"+Q&Z?RJS >SUJ?5.RSZ%W"H7BJRT&
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MRVV^^<EY)&2WS;0R;A\QF1FVW["=$9)TGH>M]YB\,Z!W!@ P 8 , & # !@
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MV+UH0[5U>N]LK0,/RVLQ ;?/#PR&/E(NR"G/N0$W3$8S *,NP)PCI$KO-8/
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MOQ]]FP@V\6917\-N=!6S;5BEUT]QA+AQ);T):HRI3+BXZG(RV'7)29V"W P
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MY'X&)31F1D?KF]/1D>E3DF1Z/>C+L.I'W&7D)JY0!70P 8 , & # !@ P 8
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MT.LNH,VWX[R'&)#2E-/MN-J4D_(K\8[FOJ/S<;F5>-.%-^0NL65[5#+4>OJ
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MK">QLB?-ZXQ"3$D2'5.*C0HU)V'8H7,FS'3]C689&2@P 8 , & # !@ P 8
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M*2X:&2=:YH[KC:FG.W;;<-]EM"G'66R+0]CW#&[DU5SF&+&K+^&E1E5ABO\
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MV!5QER8&+1;"U5*6W8U%I&:;OXD<HC)PYR'$I/HXY*]"66H+7# !@ P 8 ,
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M,R!AMN#.<3ILI"8EU\B%,% X]PSM@ P 8 , & # !@ P 8 , & # !@ P 8
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MIR:HH_*K9Q%RU/<VO9T3S:4<N_RMGO7<)-92150P 8 , & # !@ P 8 , &
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MIT,R/*N>3/37*.5\/[7*$5P;'.%XI_F5DF78P I[\(#;6[,RZ!#QTZ":CO\
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M6XT@]*@UQTQ7CI"O].K,&R$180E:.?A1\TN'U)05AU<8W+^'W_N^L8YOU/\
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M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@!Y-?54#GE?\
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M;BN87BM-)D1YL"\=BE727$Y)+GPI<*)+5*8TE;[9(<+7LHS# R2& # !@ P
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M2WK:6M@3OW?<RT?W]Y_-%[I/PZ5,\/N%-YO=RQJU?L:6%I\,['##(4L^UY&
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M)D:%8+5-AL/E#D\KK"R&\K)&,@P 8 , & # !@ P 8 , & # !@ P 8 , &
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MP/B?C$3+:!^XLRM;V+9MF4#+*N[FJ2V[*LHE^U(?D2C90RM4WT=M;CD1\TW
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M:\Y_W(\S_P ,8]>W?QS:_O"7_6#U+3?%-9^P1?Z0_-^._(ZM;TKRSYR5K?\
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MB?A2>6JG)!@O=5GKUZ$=,Z?1)=8I5<O20R1]/YRY89LF%9JC!A-KGQ7.DB&
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M)33C<@I9>2C#\Z7 E-7:)SI\BP'9M4!,'<.!/TER'%A3)D50R1%><BN8.MN
MV+?]K3,4<DXW8SXJTQHS;SDG'HTXW4.%,]4+/V%*2E;/9L/MQVFW#-J.1I)*
MML8GPN,RR-&(4W&.OK^(M#CUO&DS[GT6+5<1[*C9BRHRJ%>9,M&X]#4Y(;FN
M+EQ79\N3%;](L>97;-[$>1_%W[55Z/<G_2O# =VME?\ VLW37O/4U^(U>6)I
M)V):9!81>"BW:[/!B]1R\=$-^9#.2URAS+(9IMF0O$TKACQ+IX%G*G5E5>+@
MKAE#9QR6^N5:-ON+1(<9BS665-+AH)#KS;BT=ISFF-VO*9EE5>7_  <LNR/&
M*["LWR?"(%XW=+O7^*=7#1!Q21"B-/U<=RUQ]Z0W.8N)2GX3#S;"U0D-(?GK
M2;A(.3%?^,KYA(\[,7VRT+T30I(6P"JZ]1[)RQ,BXDW2D63*V9 PZ[8#8\E7
M8'XVV)Q)PE#>:?>CH3!7]Q7T6LN#DC%8_:3<,RZ"S&ELPULR:204M;KS:G$K
MCQD&MZ1&223)<II*F4+TA2R49$+C5@-._E5=BE)Q<X-9&_:4\V[8M:G/(9TD
M:-!?9CN1;.QF1XK-?:NJ>2MBM>_TAUI*W4D:$\PY"?QE/++',M]) 4OT-<7M
MW55);Y^!Y2IGH&WD@DG-69T2=.AQS--_KI%*-;+J>28^J)H>I"?O9Q:B9#)J
MO6T/#LOFL>L?5GH\>BE*GE(]'*3VJH2^20F&2#)*IIH]'2Z9,J<)PR2<N</J
MV'F'X&W/%C@U0R2QG\*3NK//X"<:.%ZS.J]7HNHK,F,N^-Y)R$4Q:EKA?Z6E
M/9$I11XZ5\87I%BY\!(>=/.^J_>BYD]"+Q_1)/\  %54-#1&_032A-()/%#L
M@RMV5N2+:(#?TK\5I/Y1'4E2H]S0N'/$FZK8DROHH5.])E/L.Q\HENPWX3#:
M4&W,?BQ67W5M/FHTH;:6I]*D*YVR3I1V^[D'P?,0RFWJ<VXE6F655955TV%.
MX2U3%LS>V$IQ],ZGAVMV[$A1'J]+3:U2I3/HLA#Y&TZE:#;/7;Z Z5V+UZ*H
M</TI=73$2IP)31BA\[F6"E\IMY9PP^3'G;+4$EY23!8+'6R,'RWGHZ/QF-J7
M%TI]_3F4ZK@'0R(]0[F<N5>6$-#RI\&'*>@X[.D+D&Y&6N$@D2UIB-$AHB7*
M2F0OM%O-]FM+",9R/A;W>&6.8L\#Z&NPZIO7XB*+(\BKJ_(.(]!7-5R8EC%A
M7KJ5UT0K>4IZ8\EFO=7#2;#461VS)RW;6A0H@V'$'CXK$*! C,0X4.*TAB-$
MB1FDLQXT=AM*6V6&&4(:::;2E#;:4I3K6M:UF>8T:/#CL1(C#4:+%9:C1HS#
M:6F(\=A"6V666D$E#;33:4H;;01)0A))21$1$-2+*RL+BQGV]M-E65I:3)-C
M96,Y]R5-GSYKRY,N9+DO*6](DR9#CCS[[JU..NK4M:C4HS'9SN'B'RM:&D+<
M<6EMMM*EN.+5I"$(3K:E+6I6])2E.M;VI6]ZUK6M[WOY9Q6M+:5+6I*$(2:U
MK69)2A*2,U*4HS(DI21&9F9D1$1F9Z'8TTZ^ZVRPVX\\ZM+;332%..NN+,DH
M;;;01J6M:C)*4I(U*,R(B,S$NO#'D&_^C.Q64]W3CL.!Y0I(TA7WZYUJJDV"
M?:;H1APYP<S5!LB2,>CT^K-NPC4*U2&IPHR\_'9%1Y\QQ<^I:D<2L_M,HNKK
M$(\!AC#:Y3E99G8PVW9-]:1I3#_;PS69G%A0'XR"CO(]J0:G%JV:FBB;_P##
MG <2X08%AW$2'EDV=QTR4XV2T#^(W:F*WAUBLR#-@O5UXIA*D6-_?1IK[5C5
MN\BJTFVFE&RVR\5YZ8V&&(K#,6*RU&C1FFV(\=AM#+###*--LLLLMZ2VTTTV
ME*&VT)2A"$Z2G6DZUK,?D1$1$1$1$6B(NA$1=Q$7@1"C+6MQ:G'%*6XM2EK6
MM1J6M:C-2E*4HS4I2E&9J49F9F9F9['+DCB& # !@ P 8 , & # !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 , & 'PZTV\VXR\VAYEY"VG6G4)<;=;<3M"V
MW$+UM*T+3O:5H5K:5)WO6];UO>L&1&1D9;(^AD?4C(^\C(2E2D*2I*C2I)DI
M*DF9*2HCV2DF6C(R,MD9=2/J0\OGMGQ.!\&[M_:Z8=(J\U7KH@2/ YN/JI4D
MGA)BW?JCYP@]88KCL 7RMTTS#BBHTMAAX80.#P\1$IW2I)*\N&6<P.&:;"OO
M9\PL3L9\156PW".2SCTR8ZX4]UZ03Z5Q:AQ1M.J;0P\3;REK;2AQ;GI-Z<3L
M1OOA5JQUW&Z*H/C+C.,VY9)=2KQFME\3:>BCQ3H8<2K<B*39YLQ&]*95)7,C
M>DPHQ'(=5':8161?CR(\R.Q+B/LRHLEEN1&DQW4/,2&'D:<9>8>;4IMUIUM2
M5MN(4I"T*TI.]ZWK>;A,O-2&FGV'6WV'VT/,O,K2XT\TXDEMNM.(-2'&W$*)
M:%H,TK29*29D9&/G5+B2Z^7)@3XLB%.A2'HDR'+9<C2HDJ.XIF1&DQWDH=8D
M,.H6T\RZA+C;B5(6E*DF1<V=@\XZ\N)%(1)4"='9F0IL=Z),B26D/1Y462VI
MF1'D,N:4VZR^TM;3K2TJ0XVI25:VG>]9TR([$N._%E,M2(TEEV/(CO(2ZR^P
M\A3;S+K:R-#C3K:E(<0HC2M"C2HC(S(>ROL)U3/A6E9,DU]E6RXT^OGPWG(T
MR#.AO(D1)<60TI#K$F,^VV\P\TI+C3J$K0HE)(Q<GG[HW8/(4&]M>;;O)$0[
M6)1&$<]Z#./W'DE3-;,1"DVQUZGJ*QDB3!-B.^,ERV7GV_Q);GTQ=[;8TU@:
MTX!4,=FW?PV9,HYTQILZ^OERG9N.0912$NO.HAK2Y,;3):[1I26Y2DLJ-"V6
MR;0;*MN6/A<W>9S,.B\;J"KS&JHYC_KW)\?K8-#Q)OJI5:]#@P)5XUV5;*36
MRCCS&NWKVG)1-NMR9!O/>E(V+\N^,)TH!0;-/](>>$&[J#GUN, :\[%/U(;<
MQ\YV6W92>@MX)1B5<>!-MPI,. \3*_K/Y,AG[PS<1M<K%LOASQ*IZZ=+L:*#
M;.Q)$=IAC&9CDQ^Q:=Y^VDQHDIEAUMN,24FMM]2'EFLB;;41&8R5^$/P>LLR
MBAJL&XDVV+U=Q!M95C,XL5#%2QC<N(3!UU;.MJ5V9"FNVAN/(3(AQSBQ28YW
MGC-PD%(<5\9/RS*YH_T<_3?0M,>C7"-37*!8>4K=O[CT@,Z9_<,42!.FATBI
MMI96.<,?J[;FB>VXWX/TKT[ELN1,ACU:[:9A^70V$6":U4>112DSCD*8.03B
M(2>>0N(:$FDIA(]'-S\5S]I[(N%/#ZME9>SAU/Q7X-7TE_''<G1<U6?P%XVF
M"U9(K%0GKF4S%C,W7;.(>]4*_P!,]$W)Y.R(U#'9GX]7A@76KD7::[-*LE3<
M ,Q.>R><+#VRU.G9#[3NPGZH8CA(C ".R@D>=L9<$M,"3&V$9-S'-PD\:6/>
M9'&OGZ'%LDLWL;76MVE>Q6FBS:<MG%HB(;@/.MRGCY4*??)II1QXO^E.DE@C
M63,.'L'AW<\/JS/^)O"O%('$MK*)&-Y/89:E[%E,8C%8DVKDV\API$&+VRY#
M<"K[1WDL;4_5K*REF39P1Z[_ )1A+*44O'X+P!^J]#4=C1PI7K!*-9ZO^U'(
M$G<XI*%58I7B<2SM$=Q40!>YA,/J,AV3+G/K7J"G(%)P>XI9'5ORD4T#$I12
MX[,5G*I9FN1#<0M4F9Z-5)EOQUQE$A"8\I+:GE++E]A*U)Q+DW&7X+?#C+ZZ
MLNN(U[Q=H54=E-MI'!^G3'.!?QI$9%72)L\O.!76,.S97(=?LJU2RB(9Y5$E
MU31.:._3'N;U#[!%5X'Z"Z.FWA:L;-'P@4;70%4$Q9QO41M>I$2N#Q^BC0V+
M"9AB/U9<UR RJ6XA:I9$C)EYPQ?X.F+1:^ 6=J;S:XAV#M@4A;4FLJM.--H:
M@.5+,U<:=&B.)6XA<Q)G)->I#/9D;1ZUYO\ #MS>'D>1O?!WKY' _%+['(.-
MO14SX>5Y6OT.5+>D7T;*[*J;L:"TMFI#34EFF=0W )A!P91/(:D-Q*2G2=:2
MG6DI3K6M)3K6M:UK^6M:UK^6M:_T:UFP<>/'B,,Q8C#,6-';0S'C1VD,,,--
MD24-,LMI2VTVA)$E"$)2E)$1$1$-&K&RL;B?,M;:?-M+2PD.RY]E8RGYT^=+
M?6;C\J9,DN.R),AYQ1K=>><6XXLS4M1F9F/W.X>(?*E)0E2UJTE*=;VI2M_+
M6M:_MWO>_P"S/%8V,"H@2[2TF1X%= 8<DS)DIU+,>,PTDU..NN+,DI2DB\3V
M9Z2DC49$=:QW';W+KVIQC&*BPOLAO9T>LIZ:KC.S+"QGREDVQ&BQF4J<<<6H
M_ N5*24M9I0E2B](7P>/A50^CN\L]K=NFM3:1 ES;+R[D\H*:'3"=FKQQ<:M
MW>U2"L.'#)5EER$NPUN"&40'FW-B)4XAN&T3"3-"N*N>,<5;>FDU-A.5@]2U
MZ5#JI4!RN5.OFY$EGUK*2MYQ4N*W%)HZTG&V3;)Y[F90I;W;?8;@O@%A\$[$
ML_PJYQ^E8XZY9(;I<ESBIR&)D35%P_EU==,=PVE5'B,E37,BS<E1LJ4T_*[0
MX<?LI+I-5[L'UH99(\X8 , & # !@ P 8 , & # !@ P 8 , & $?.L^6N(=
MPL,&T]+K!LV<&AF $.4-Z+TNH,-BHTV>19CK'4RX5\8^ZF63FN;FR(;LYQ#J
M&')*H\>,TU4X5O85[2F8CS;;:G#=4E<6*^9K-*4F?,^PZLBY4)+E)1)Z;(MF
M9G3IE3 GN)=E-.+<2@FTFB3*9(D$I2B+E8>;09[4KVC2:CWHST1$6+O\WIY,
M_P#0"V?WX=Z_^IN>O\)KG])9_=]=_A!Y/P<I_P!'>_;[#_%!_F]/)G_H!;/[
M\.]?_4W'X37/Z2S^[Z[_  @?@Y3_ *.]^WV'^*#_ #>GDS_T MG]^'>O_J;C
M\)KG])9_=]=_A _!RG_1WOV^P_Q0_-_#S\EJUM*N?6M25:WI2=]O[SO6];U\
MMZWK?3?EO6]?RWK?\MZQ^$US^DL_N^N_P@%CE074H[Q&74C*?8=/_P"4-)?N
M[X% &6<N?6^)G[),Y*V&-] N7$Y1B_7"_1;%7(KQ;\/B\E2K+)L,BZ)_-'N5
M^TH?F09DA7Z48<3-@(KM3QSB#D='>JEW5K(M<4<BR%SJM,!A^PB/1X[BXRZ7
MT8HAK4^Z267F)*W4$TI1MI4LFNRN^TP[AMG&"P,3K\3AXOQ79N:J#CV=)OGJ
M[&K.OL)[$6>C/T6KT]F*S61%NRH]E4LQW''4-G))I*99V,*N<W*F6^NQ%4LA
MI^&'8CBI J4Y(2< NPFM14C#L.>XX3BSX^F%-.*G*<7)4TM]$B2A7WU[/8EF
M6-YM5HM,;L6IK!$A,AC?9S8#QIV<:PB+/MHSZ=*+3A&ATDFXPXZT:7%:H<4^
M$/$'@WD3F.<0,?DU$M?:.UU@DO2*2^AI,N6QH;9HO0[.$XE;:C4PLGHQN)8F
ML19*5L(H]V3:M68)+$OG'J_!$G=V$,&A/-392)0@LJ%-#E_U!B!(-,DX(T4T
M$(0GE(0;0:A31ZA\E[*G.*7Z2PME3ZHS;+_I+#*%)<42V7C0XP\3B6UO)=0T
MT3#C:C(GB?;6V;:S%DP3B>BOI>3'*0X\QZ.\\M)H0:7F26AYGLU.)8-I;KQO
M-N)(S8-EQ#A.(2+2!Q^KCYM,=?FF; -D.QVC*"K<(6\,@_H,IEALFVVWM\HX
M@U DR)1-&X)':389Z=$F('/#)'D83;-KA*4MZ0VHTD\3I(:4TWZ.LDDZ1;4Z
M9/MJ4MW\6Y_I#"G$.=DII7L?54.-S22AF,ZE*C8-HUNDZYZ0A1FT>]-$;+B4
MI:/G:(V'DMJ1VA.ID'EPBW0P 8 , & # "V[7;JW1PDNQ6LM%#!X>M:=E2E;
M^;CJM*VW&BL-I7(F3'OI5IB)%:>DO;2K[;:OI5\J+D&14N+5<BZO["/65L8O
MQDA]1^VLR,T,,-()3TF2[RF34=A#CSID?(@]'J\<"X?YCQ.R:!A^"4$[(\AL
M3,V(,%"=-,(4A+TV;)=4W%KZ^-SH.5/G/,0XY*3VKR>9)'.7R]\-PS[&K'->
MM]PG7GF/#)I,X2,<)*U^35;OU,2,F#7*42+V!!+1$'0[.TJ?-F#&A\$Q+@QH
MC@Z8IHL./"=3.(&?2.)D2!#KE7%%BIJDKM*N4TU%FWQM22]7JD.L/NN-UJV$
MI?7#4:#4\K2R=)N/(1O?PZQBM^"Y=91VC&'Y[Q:;8JX^-YQ5SGKF@X?KEU[A
M9(Q @3(#$67E,&8OT)BV2N2PTR2O9C*.PK)/I3'CX0D?!%#8S4(<,AQA\"&P
MGZ&(D*&RB-%C,HU_)#3##;;3:?\ R4(UK_1EII2E"4I21$E)$E)%W$DBT1%[
MB(M"RWGG9#SLA]:G7GW%O/.+/:G'75&MQ:C\5+6HU&?B9F.YDCK# !@ P 8
M, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P HMDK=?N-?-
M52V!1=DK-C&3 QX ;@QR0@P)(L+BSAQ(?+;=C3(<N.XME^.^VMMQM6TJ3O6\
MX.M-O-K:>0AUIQ*D.-N))2%H46E)4E1&2DF1Z,C+1CUP)\VKFQ;*MER(%A!D
M-2H4V(\Y'E19+"R<9?COM*2XTZTM*5H6A1*2HB,C'G6]A_#UZ_Q"[U,[Y%Y1
M!O/G"; J],F\@ICI%WHW,S:Y>X+UPC2;0;(O7*NF),QJ6??42BN@M)7-EQ(8
MR*5/R+SP[B1D.%2::E]7Q[7"&VX]8B%$0U&M*13LMQ2K%$AU:43V.:2?I3<E
MQ'(TVAQ+K'9ONR*_DV!<-^-E-F&1Y/E<_$N.KDJURD\IO'')F(YS'CUL<F\;
M?@5T1*L=L66J_DJ%U\1],E]]R-V4U;]=7P8*0R8X@Z28@SHDM\,5( R[$=]I
MUX69%27(9(40:0K;D,A!E-.,R8DA+;S2T_)2-:WK>]MJNYJ;MAR33V<&TCLR
M'HKKT"4S+;;DL+-#S#BV%K)#B%%U2HR,TFE9;0I*CT-R+$\GQ&3$A93CUSCL
MN?7P[:%'NJV76O2ZRP93(A3XS<MII3T60TLE-O-DI',2FS,G$+2GO94A;X8
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MS<L"E/..H)YUQ;OMB7N5(8\# !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !
M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
M P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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MGY@0& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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B P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
